### **PCT**

### WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



#### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61K 9/14, 9/48, 9/127, 38/16, 39/00, 39/02, 39/118, 39/395, 39/40, C07H 21/04, C07K 14/00, 14/195, 14/295, 16/00, 16/12, C12N 5/00, 15/63, C12Q 1/68, G01N 33/53, 33/563, 33/571

(11) International Publication Number:

WO 99/17741

(43) International Publication Date:

15 April 1999 (15.04.99)

(21) International Application Number:

PCT/US98/20737

A1

(22) International Filing Date:

1 October 1998 (01.10.98)

(30) Priority Data:

08/942,596

2 October 1997 (02.10.97)

US

(71) Applicant (for all designated States except US): ANTEX BIO-LOGICS INC. [US/US]; 300 Professional Drive, Gaithersburg, MD 20879 (US).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): JACKSON, James, W. [US/US]; 1687 Armistice Way, Marriotsville, MD 21104 (US). PACE, John, L. [US/US]; 20408 Afternoon Lane, Germantown, MD 20874 (US).
- (74) Agents: BALDWIN, Geraldine, F. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: CHLAMYDIA PROTEIN, GENE SEQUENCE AND USES THEREOF

#### (57) Abstract

A high molecular weight ("HMW") protein of Chlamydia, the amino acid sequence thereof, and antibodies that specifically bind the HMW protein are disclosed as well as the nucleic acid sequence encoding the same. Also disclosed are prophylactic and therapeutic compositions, comprising the HMW protein, a fragment thereof, or an antibody that specifically binds the HMW protein or a portion thereof, or the nucleotide sequence encoding the HMW protein or a fragment thereof, including vaccines.

# FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

Codes used to identity  Albania Armenia Austria Austria Azerbaijan Bosnia and Herzegovina Barbados Belgium Burkina Faso Bulgaria Benin Berazil Belarus A Canada Central African Republic Congo H Switzerland Cote d'Ivoire M Cameroon China UU Cuba	ES FI FR GA GB GB GR GN GR HU IE IL IS IT JP KE KG KP KZ	Spain Finland France Gabon United Kingdom Georgia Ghana Guinea Greece Hungary Ireland Israel Iceland Italy Japan Kenya Kyrgyzstan Democratic People's Republic of Korea Republic of Korea Kazakstan	LS LT LU LV MC MD MG MK MI MN NN NE NI NO NZ PL PT RO	Lesotho Lithuania Luxembourg Latvia Monaco Republic of Moldova Madagascar The former Yugoslav Republic of Macedonia Mali Mongolia Mauritania Malawi Mexico Niger Netherlands Norway New Zealand Poland Portugal Romania	SI SK SN SZ TD TG TJ TM TR TT UA UG US UZ VN YU ZW	Slovenia Slovakia Senegal Swaziland Chad Togo Tajikistan Turkmenistan Turkey Trinidad and Tobago Ukraine Uganda United States of America Uzbekistan Viet Nam Yugoslavia Zimbabwe
Z Czech Republic	LC	Saint Lucia	RU	Russian Federation Sudan		
E Germany	LI	Liechtenstein	SD SE	Sugan Sweden		
DK Denmark EE Estonia	LK LR	Sri Lanka Liberia	SG	Singapore		

### CHLAMYDIA PROTEIN, GENE SEQUENCE AND USES THEREOF

#### 1. FIELD OF THE INVENTION

ď,

The present invention generally relates to a high 5 molecular weight ("HMW") protein of Chlamydia, the amino acid sequence thereof, and antibodies, including cytotoxic antibodies, that specifically bind the HMW protein. The invention further encompasses prophylactic and therapeutic compositions comprising the HMW protein, a fragment thereof, 10 or an antibody that specifically binds the HMW protein or a portion thereof or the nucleotide sequence encoding the HMW protein or a fragment thereof, including vaccines. invention additionally provides methods of preventing, treating or ameliorating disorders in mammals and birds 15 related to Chlamydia infections and for inducing immune responses to Chlamydia. The invention further provides isolated nucleotide sequences and degenerate sequences encoding the HMW protein, vectors having said sequences, and host cells containing said vectors. Diagnostic methods and 20 kits are also included.

#### 2. BACKGROUND OF THE INVENTION

Chlamydia are prevalent human pathogens causing disorders such as sexually transmitted diseases, respiratory 25 diseases including pneumonia, neonatal conjunctivitis, and blindness. Chlamydia are obligate intracellular bacteria that infect the epithelial lining of the lung, conjunctivae or genital tract. The most common species of Chlamydia include Chlamydia trachomatis, Chlamydia psittaci, Chlamydia pecorum and Chlamydia pneumoniae. Recently, the newly designated species of Chlamydia, C. pneumoniae (formerly C. trachomatis TWAR), has been implicated as a major cause of epidemic human pneumonitis and perhaps may play a role in atherosclerosis.

35 There are currently 18 recognized *C. trachomatis* serovars, causing trachoma and a broad spectrum of sexually transmitted diseases: with the A, B and C serovars being most

frequently associated with trachoma, while the D-K serovars are the most common cause of genital infections.

C. trachomatis is the major cause of sexually transmitted disease in many industrialized countries, 5 including the United States. While the exact incidence of C. trachomatis infection in the U.S. is not known, current epidemiological studies indicate that more than 4 million chlamydial infections occur each year, compared to an estimated 2 million gonococcal infections. While all racial, 10 ethnic and socioeconomic groups are affected, the greatest prevalence of chlamydial infections occur among young, 12 to 20 year-old, sexually active individuals. Most genitourinary chlamydial infections are clinically asymptomatic. Prolonged carriage in both men and women is common. As many as 25% of 15 men and 75% of women diagnosed as having chlamydial infections have no overt signs of infection. As a consequence, these asymptomatic individuals constitute a large reservoir that can sustain transmission of the agent

Far from being benign, serious disease can develop from these infections including: urethritis, lymphogranuloma venereum (LGV), cervicitis, and epididymitis in males.

Ascending infections from the endocervix commonly gives rise to endometritis, pelvic inflammatory disease (PID) and salpingitis which can cause tubal occlusion and lead ultimately to infertility.

C. trachomatis infection of neonates results from perinatal exposure to the mother's infected cervix. Nearly 70% of neonates born vaginally to mothers with chlamydial cervicitis become infected during delivery. The mucus membranes of the eye, oropharynx, urogenital tract and rectum are the primary sites of infection. Chlamydial conjunctivitis has become the most common form of ophthalmia neonatorum. Approximately 20-30% of exposed infants develop inclusion conjunctivitis within 14 days of delivery even after receiving prophylaxis with either silver nitrate or antibiotic ointment. C.trachomatis is also the leading cause

of infant pneumonia in the United States. Nearly 10-20% of neonates delivered through an infected cervix will develop chlamydial pneumonia and require some type of medical intervention.

In developing countries, ocular infections of C.trachomatis cause trachoma, a chronic follicular conjunctivitis where repeated scar formation leads to distortion of the eyelids and eventual loss of sight. Trachoma is the world's leading cause of preventable

•

10 blindness. The World Health Organization estimates that over 500 million people worldwide, including about 150 million children, currently suffer from active trachoma and over 6 million people have been blinded by this disease.

In industrialized countries, the costs associated

15 with treating chlamydial infections are enormous. In the
U.S., the annual cost of treating these diseases was
estimated at \$2.5-3 billion in 1992 and has been projected to
exceed \$8 billion by the year 2000.

One potential solution to this health crisis would 20 be an effective chlamydial vaccine. Several lines of evidence suggest that developing an effective vaccine is feasible.

Studies in both humans and primates have shown that short-term protective immunity to *C. trachomatis* can be

25 produced by vaccinating with whole *Chlamydia*. However, protection was characterized as short lived, serovar specific, and due to mucosal antibody. Additionally, in some vaccinees disease was exacerbated when these individuals became naturally infected with a serovar different from that 30 used for immunization. This adverse reaction was ultimately demonstrated to be due to a delayed-type hypersensitivity response. Thus, the need exists to develop a subunit-based chlamydial vaccine capable of producing an efficacious but nonsensitizing immune response. Such a subunit vaccine may 35 need to elicit both mucosal neutralizing secretory IgA antibody and/or cellular immune response to be efficacious.

Subunit vaccine development efforts to date have focused almost exclusively on the major outer membrane protein (MOMP). MOMP is an integral membrane protein of approximately 40 kDa in size and comprises up to about 60% of the infectious elementary body (EB) membrane protein (Caldwell, H.D., J.Kromhout, and L.Schachter. 1981. Infect. Immun., 31:1161-1176). MOMP imparts structural integrity to the extracellular EB and is thought to function as a porinlike molecule when the organism is growing intracellularly and is metabolically active. With the exception of four surface exposed variable domains (VDI-VDIV), MOMP is highly conserved among all 18 serovars. MOMP is highly immunogenic and can elicit a local neutralizing anti-Chlamydia antibody. However, problems exists with this approach.

- that have been mapped are located within the VD regions and thus give rise only to serovar-specific antibody. Attempts to combine serovar-specific epitopes in various vaccine vectors (e.g. poliovirus) to generate broadly cross-reactive neutralizing antibodies have been only marginally successful (Murdin, A.D., H. Su, D.S. Manning, M.H. Klein, M.J. Parnell, and H.D. Caldwell. 1993. <a href="Infect. Immun.">Infect. Immun.</a>, 61:4406-4414; Murdin, A.D., H. Su, M.H. Klein, and H.D. Caldwell. 1995.
- 25 Two other major outer membrane proteins in C.

  trachomatis, the 60 kDa and 12 kDa cysteine-rich proteins, as
  well as the surface-exposed lipopolysaccharide, are highly
  immunogenic but, unlike MOMP, have not been shown to induce a
  neutralizing antibody (Cerrone et al., 1991, Infect. Immun.,
- 30 <u>59</u>:79-90). Therefore, there remains a need for a novel subunit-based chlamydial vaccine.

## 3. SUMMARY OF THE INVENTION

An object of the present invention is to provide an 35 isolated and substantially purified high molecular weight protein of a *Chlamydia* sp. ("HMW protein"), wherein the HMW protein has an apparent molecular weight of about 105-115

kDa, as determined by SDS-PAGE, or a fragment or analogue thereof. Preferably the HMW protein has substantially the amino acid sequence of any of SEQ ID Nos.: 2, 15 and 16. Preferred fragments of the HMW protein include SEQ ID Nos: 3, 5 17, and 25-37. As used herein, "substantially the sequence" is intended to mean that the sequence is at least 80%, more preferably at least 90% and most preferably at least 95% identical to the referenced sequence. Preferably, the HMW protein is an outer membrane protein. More preferably, the 10 outer membrane HMW protein is surface localized. Preferably, the HMW protein has a heparin binding domain. Preferably, the HMW Protein has a porin-like domain. It is intended that all species of Chlamydia are included in this invention, however preferred species include Chlamydia trachomatis, 15 Chlamydia psittaci, Chlamydia percorum and Chlamydia pneumoniae. The substantially purified HMW protein is at least 70 wt% pure, preferably at least about 90 wt% pure, and

Also included in this invention are recombinant

20 forms of the HMW protein, wherein in transformed E. coli
cells, the expressed recombinant form of the HMW protein has
an apparent molecular weight of about 105-115 kDa, as
determined by SDS-PAGE, or a fragment or analogue thereof.
The term HMW-derived polypeptide is intended to include

25 fragments of the HMW protein; variants of wild-type HMW
protein or fragment thereof, containing one or more amino
acid deletions, insertions or substitutions; and chimeric
proteins comprising a heterologous polypeptide fused to the
C-terminal or N-terminal or internal segment of a whole or a

may be in the form of an aqueous solution thereof.

30 portion of the HMW protein.

As used herein and in the claims, the term "HMW protein" refers to a native purified or recombinant purified high molecular weight protein of a species of *Chlamydia* wherein the apparent molecular weight (as determined by SDS-35 PAGE) is about 105-115 kDa. As used herein and in the claims, the term "rHMW protein" refers to recombinant HMW protein.

Another object of the present invention is to provide an isolated substantially pure nucleic acid molecule encoding a HMW protein or a fragment or an analogue thereof. Preferred is the nucleic acid sequence wherein the encoded 5 HMW protein comprises the amino acid sequence of any of SEQ ID Nos.: 2, 15 and 16, or a fragment thereof, particularly SEQ ID Nos.: 3, 17, 25-37. Also included is an isolated nucleic acid molecule comprising a DNA sequence of any of SEQ ID Nos.: 1, 23-24 or a complementary sequence thereof; a 10 fragment of the HMW DNA sequence having the nucleic acid sequence of any of SEQ ID Nos.: 4-14, 18-22 or the complimentary sequence thereto; and a nucleic acid sequence which hybridizes under stringent conditions to any one of the sequences described above. The nucleic acid that hybridizes 15 under stringent condition preferably has a sequence identity of about 70 % with any of the sequences identified above, more preferably about 90 %.

The production and use of derivatives and analogues of the HMW protein are within the scope of the present

- 20 invention. In a specific embodiment, the derivative or analogue is functionally active, i.e., capable of exhibiting one or more functional activities associated with a fulllength, wild-type HMW protein. As one example, such derivatives or analogues which have the desired
- 25 immunogenicity or antigenicity can be used, for example, in immunoassays, for immunization, etc. A specific embodiment relates to a HMW fragment that can be bound by an anti-HMW antibody. Derivatives or analogues of HMW can be tested for the desired activity by procedures known in the art.
- In particular, HMW derivatives can be made by altering HMW sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid
- 35 sequence as a HMW gene may be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or portions of genes

which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change. Likewise, the HMW derivatives of the invention include, but 5 are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of a HMW protein including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change. 10 example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class 15 to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and 20 glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively

charged (acidic) amino acids include aspartic acid and glutamic acid.

In a specific embodiment of the invention, proteins 25 consisting of or comprising a fragment of a HMW protein consisting of at least 6 (continuous) amino acids of the HMW protein is provided. In other embodiments, the fragment consists of at least 7 to 50 amino acids of the HMW protein. In specific embodiments, such fragments are not larger than 30 35, 100 or 200 amino acids. Derivatives or analogues of HMW include but are not limited to those molecules comprising regions that are substantially homologous to HMW or fragments thereof (e.g., in various embodiments, at least 60% or 70% or 80% or 90% or 95% identity over an amino acid sequence of 35 identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art) or whose encoding nucleic acid is capable

of hybridizing to a coding HMW sequence, under stringent, moderately stringent, or nonstringent conditions.

By way of example and not limitation, useful computer homology programs include the following: Basic

5 Local Alignment Search Tool (BLAST) (www.ncbi.nlm.nih.gov)

(Altschul et al., 1990, J. of Molec. Biol., 215:403-410, "The BLAST Algorithm; Altschul et al., 1997, Nuc. Acids Res. 25:3389-3402) a heuristic search algorithm tailored to searching for sequence similarity which ascribes significance using the statistical methods of Karlin and Altschul 1990, Proc. Nat'l Acad. Sci. USA, 87:2264-68; 1993, Proc. Nat'l Acad. Sci. USA 90:5873-77. Five specific BLAST programs perform the following tasks:

- The BLASTP program compares an amino acid query
   sequence against a protein sequence database.
  - 2) The BLASTN program compares a nucleotide query sequence against a nucleotide sequence database.
  - 3) The BLASTX program compares the six-frame conceptual translation products of a nucleotide query
- 20 sequence (both strands) against a protein sequence database.
  4) The TBLASTN program compares a protein query
  - 4) The TBLASTN program compares a protein query sequence against a nucleotide sequence database translated in all six reading frames (both strands).
- 5) The TBLASTX program compares the six-frame
  25 translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

Smith-Waterman (database: European Bioinformatics Institute wwwz.ebi.ac.uk/bic\_sw/) (Smith-Waterman, 1981, J. of Molec. Biol., 147:195-197) is a mathematically rigorous algorithm for sequence alignments.

FASTA (see Pearson et al., 1988, Proc. Nat'l Acad. Sci. USA, 85:2444-2448) is a heuristic approximation to the Smith-Waterman algorithm. For a general discussion of the procedure and benefits of the BLAST, Smith-Waterman and FASTA

35 algorithms see Nicholas et al., 1998, "A Tutorial on Searching Sequence Databases and Sequence Scoring Methods" (www.psc.edu) and references cited therein.

The HMW derivatives and analogues of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned HMW gene 5 sequence can be modified by any of numerous strategies known in the art (Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York). The sequence can be cleaved at appropriate sites with restriction

- 10 endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated in vitro. In the production of the gene encoding a derivative or analogue of HMW, care should be taken to ensure that the modified gene remains within the same translational reading frame as HMW,
- 15 uninterrupted by translational stop signals, in the gene region where the desired HMW activity is encoded.

Additionally, the HMW-encoding nucleic acid sequence can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination

- 20 sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification. Any technique for mutagenesis known in the art can be used, including but not limited to, chemical
- 25 mutagenesis, in vitro site-directed mutagenesis (Hutchinson,
   C., et al., 1978, J. Biol. Chem 253:6551), use of TAB®
   linkers (Pharmacia), etc.

Manipulations of the HMW sequence may also be made at the protein level. Included within the scope of the 30 invention are HMW protein fragments or other derivatives or

- analogues which are differentially modified during or after translation, e.g., by glycosylation, lipidation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to
- 35 an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited to specific chemical

cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH<sub>4</sub>; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

- In addition, analogues and derivatives of HMW can be chemically synthesized. For example, a peptide corresponding to a portion of a HMW protein which comprises the desired domain, or which mediates the desired activity in vitro, can be synthesized by use of a peptide synthesizer.
- 10 Furthermore, if desired, nonclassical amino acids or chemical amino acid analogues can be introduced as a substitution or addition into the HMW sequence. Non-classical amino acids include but are not limited to the D-isomers of the common amino acids,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid,
- 15 Abu, 2-amino butyric acid,  $\gamma$ -Abu,  $\epsilon$ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, fluoro-amino
- 20 acids, designer amino acids such as  $\beta$ -methyl amino acids,  $C\alpha$ -methyl amino acids,  $N\alpha$ -methyl amino acids, and amino acid analogues in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

Another object of the invention is to provide a

25 recombinant expression vector adapted for transformation of a
host or for delivery of a HMW protein to a host comprising
the nucleic acid molecule of SEQ ID No.: 1, 23 or 24 or any
fragment thereof. Preferably, the recombinant expression
vector is adapted for transformation of a host and comprises

- 30 an expression means operatively coupled to the nucleic acid molecule for expression by the host of said HMW protein or the fragment or analogue thereof. More preferred is the expression vector wherein the expression means includes a nucleic acid portion encoding a leader sequence for secretion
- 35 from the host or an affinity domain coupled to either the Nor C-terminus of the protein or the fragment or analogue thereof.

A further aspect of the invention includes a transformed host cell containing an expression vector described above and the recombinant HMW protein or fragment or analogue thereof producible by the transformed host cell.

- Still a further aspect of the invention is directed to a HMW protein recognizable by an antibody preparation that specifically binds to a peptide having the amino acid sequence of SEQ ID No. 2, 15-16 or a fragment or conservatively substituted analogue thereof.
- Antigenic and/or immunogenic compositions are another aspect of the invention wherein the compositions comprise at least one component selected from the following group:

15

20

25

30

35

- a) a HMW protein, wherein the molecular weight is about 105-115 kDa, as determined by SDS-PAGE, or a fragment or analogue thereof;
  - b) an isolated nucleic acid molecule encoding a HMW protein, or a fragment or analogue thereof;
  - an isolated nucleic acid molecule having the sequence of SEQ ID Nos. 1, 22, 23 or 24, the complimentary sequence thereto or a nucleic acid sequence which hybridizes under stringent conditions thereto or fragment thereof;
  - d) an isolated recombinant HMW protein, or fragment or analogue thereof, producible in a transformed host comprising an expression vector comprising a nucleic acid molecule as defined in b) or c) and expression means operatively coupled to the nucleic acid molecule for expression by the host of said HMW protein or the fragment or analogue thereof;
  - e) a recombinant vector comprising a nucleic acid encoding a HMW protein or fragment or analogue thereof;

> f) a transformed cell comprising the vector of e) and optionally an adjuvant, and a pharmaceutically acceptable carrier or diluent therefor, said composition producing an immune response when administered to a host.

Preferred adjuvants include cholera holotoxin or subunits, E. coli heat labile holotoxin, subunits and mutant forms thereof, alum, QS21, and MPL. Particularly, preferred are alum, LTR192G, mLT and QS21.

5

30

Also included are methods for producing an immune response in a mammal or a bird comprising administering to said mammal, an effective amount of the antigenic or the immunogenic composition described above.

Another aspect of the invention is directed to

15 antisera raised against the antigenic or immunogenic
composition of the invention, and antibodies present in the
antisera that specifically bind a HMW protein or a fragment
or analogue thereof. Preferably the antibodies bind a HMW
protein having the amino acid sequence of SEQ ID Nos.: 2, 15-

20 16 or fragment or a conservatively substituted analogue thereof. Also included are monoclonal antibodies that specifically bind a HMW protein or a fragment or analogue thereof.

A further aspect of the invention includes

25 pharmaceutical and vaccine compositions comprising an
effective amount of at least one component selected from the
following group:

- a) a HMW protein, wherein the isolated protein molecular weight is about 105-115 kDa, as determined by SDS-PAGE, or a fragment or analogue thereof;
  - b) an isolated nucleic acid molecule encoding a HMW protein, or a fragment or analogue thereof;
- 35 c) an isolated nucleic acid molecule having the sequence of SEQ ID Nos.: 1, 22, 23 or 24 the complimentary sequence thereto or a nucleic

5

10

15

35

acid sequence which hybridizes under stringent conditions thereto or a fragment thereof;

- d) an isolated recombinant HMW protein, or fragment or analogue thereof producible in a transformed host comprising an expression vector comprising a nucleic acid molecule as defined in b) or c) and expression means operatively coupled to the nucleic acid molecule for expression by the host of said HMW protein of a Chlamydia species or the fragment or analogue thereof;
- e) a recombinant vector, comprising a nucleic acid encoding a HMW protein or fragment or analogue thereof;
- f) a transformed cell comprising the vector ofe),
- g) antibodies that specifically bind the component of a), b), c), d) or e), and a pharmaceutically acceptable carrier or diluent therefor.
   20 Preferred are vaccine compositions which are effective at the mucosal level.

The invention also includes a diagnostic reagent which may include any one or more of the above mentioned aspects, such as the native HMW protein, the recombinant HMW 25 protein, the nucleic acid molecule, the immunogenic composition, the antigenic composition, the antisera, the antibodies, the vector comprising the nucleic acid, and the transformed cell comprising the vector.

Methods and diagnostic kits for detecting Chlamydia 30 or anti-Chlamydia antibodies in a test sample are also included, wherein the methods comprise the steps of:

a) contacting said sample with an antigenic composition comprising Chlamydia HMW protein or a fragment or analogue thereof or immunogenic composition or antibodies thereto to form Chlamydia antigen: anti-Chlamydia antibody immunocomplexes, and further,

b) detecting the presence of or measuring the amount of said immunocomplexes formed during step a) as an indication of the presence of said *Chlamydia* or anti-*Chlamydia* antibodies in the test sample.

The diagnostic kits for detecting Chlamydia or antibodies thereto comprise antibodies, or an antigenic or immunogenic composition comprising Chlamydia HMW protein or a fragment or analogue thereof, a container means for contacting said antibodies or composition with a test sample suspected of having anti-Chlamydia antibodies or Chlamydia and reagent means for detecting or measuring Chlamydia antigen: anti-Chlamydia antibody immunocomplexes formed between said antigenic or immunogenic composition or said antibodies and said test sample.

5

35

A further aspect of the present invention provides methods for determining the presence of nucleic acids encoding a HMW protein or a fragment or analogue thereof in a test sample, comprising the steps of:

20 a) contacting the test sample with the nucleic acid molecule provided herein to produce duplexes comprising the nucleic acid molecule and any said nucleic acid molecule encoding the HMW protein in the test sample and specifically hybridizable therewith; and

determining the production of duplexes.

The present invention also provides a diagnostic kit and reagents therefor, for determining the presence of nucleic acid encoding a HMW protein or fragment or analogue 30 thereof in a sample, comprising:

- a) the nucleic acid molecule as provided herein;
- b) means for contacting the nucleic acid with the test sample to produce duplexes comprising the nucleic acid molecule and any said nucleic acid molecule encoding the HMW protein in the test sample and specifically hybridizable therewith; and

c) means for determining the production of duplexes.

Also included in this invention are methods of preventing, treating or ameliorating disorders related to

- 5 Chlamydia in an animal including mammals and birds in need of such treatment comprising administering an effective amount of the pharmaceutical or vaccine composition of the invention. Preferred disorders include a Chlamydia bacterial infection, trachoma, conjunctivitis, urethritis,
- 10 lymphogranuloma venereum (LGV), cervicitis, epididymitis, or endometritis, pelvic inflammatory disease (PID), salpingitis, tubal occlusion, infertility, cervical cancer, and artherosclerosis. Preferred vaccine or pharmaceutical compositions include those formulated for in vivo
- 15 administration to a host to confer protection against disease or treatment therefor caused by a species of *Chlamydia*. Also preferred are compositions formulated as a microparticle, capsule, liposome preparation or emulsion.

#### 20 4. ABBREVIATIONS

SDS

anti-HMW HMW polypeptide antibody or antiserum ATCC American Type Culture Collection immuno-reactive = capable of provoking a cellular or 25 humoral immune response kDa kilodaltons OG n-octyl  $\beta$ -D-glucopyranoside or octyl = glucoside OMP outer membrane protein 30 OMPs outer membrane proteins PBS phosphate buffered saline PAGE polyacrylamide gel electrophoresis polypeptide a peptide of any length, preferably 35 one having ten or more amino acid residues

sodium dodecylsulfate

SDS-PAGE = sodium dodecylsulfate polyacrylamide gel electrophoresis

Nucleotide or nucleic acid sequences defined herein are represented by one-letter symbols for the bases as

```
5 follows:
  A (adenine)
  C (cytosine)
  G (guanine)
  T (thymine)
10 U (uracil)
   M (A or C)
   R (A or G)
   W (A or T/U)
   s (C or G)
15 Y (C or T/U)
   K (G or T/U)
   V (A or C or G; not T/U)
   H (A or C or T/U; not G)
   D (A or G or T/U; not C)
20 B (C or G or T/U; not A)
   N (A or C or G or T/U) or (unknown)
```

Peptide and polypeptide sequences defined herein are represented by one-letter symbols for amino acid residues

```
as follows:
A (alanine)
R (arginine)
N (asparagine)
D (aspartic acid)
C (cysteine)
Q (glutamine)
E (glutamic acid)
G (glycine)
H (histidine)
I (isoleucine)
L (leucine)
```

- K (lysine)
- M (methionine)
- F (phenylalanine)
- P (proline)
- 5 S (serine)
  - T (threonine)
  - W (tryptophan)
  - Y (tyrosine)
  - V (valine)
- 10 X (unknown)

The present invention may be more fully understood by reference to the following detailed description of the invention, non-limiting examples of specific embodiments of 15 the invention and the appended figures.

#### 5. BRIEF DESCRIPTION OF THE FIGURES

Figure 1: Western blot analysis of C. trachomatis L, elementary bodies (EBs). 20 Gradient purified EBs were solubilized in standard Laemmli SDS-PAGE sample buffer containing 2-mercaptoethanol, boiled for ~3 minutes and loaded onto a 4-12% Tris-qlycine 25 gradient gel containing SDS and electrophoresed at 100V. Immediately following electrophoresis, proteins were electroblotted onto PVDF membranes at 4°C for ~2.5 hours at ~50V. The blocked membrane was 30 probed using a 1/5,000 dilution of anti-rHMWP' antibody (K196) for 1.5 hours at room temperature. Following washing, the membrane was treated with a 1/5,000 dilution of a goat anti-rabbit IgG antibody conjugated to HRP for 35 1 hour at room temperature. The blot was developed using a standard TMB substrate system.

Three immunoreactive bands detected in EBs and RBs. Dot indicates HMW Protein of about 105-115 kDa.

- Figure 2. Consensus Nucleic Acid Sequence encoding the open reading frame of the HMW protein from C. trachomatis LGV L<sub>2</sub>.
  - Figure 3. Deduced Amino Acid Sequence of the HMW protein from the PCR open reading frame from C. trachomatis LGV  $L_2$ .
- SDS-PAGE of partially purified recombinant HMW protein from C. trachomatis LGVL2 expressed in 10 Figure 4. E. coli. Counterstained and prestained SDS-PAGE standards were used as molecular weight The positions of the molecular markers. weight markers in the gel are noted on the left and right side of the figure by lines to 15 the molecular weights (kDa) of some of the markers. See Text Example 10 for details. Lane A: Mark 12 Wide Range Molecular Weight Markers (Novex); myosin, 200 Kdal; Bgalactosidase, 116.3 Kdal; phosphorylase B, 20 97.4 Kdal; bovine serum albumin, 66.3 Kdal. Lane B: C. trachomatis L2 recombinant HMWP. Lane C: SeeBlue Prestained Molecular Weight markers (Novex); myosin, 250 Kdal; bovine serum albumin, 98 Kdal; glutamic 25 dehydrogenase, 64 Kdal.
  - Figure 5. Map of plasmids pAH306, pAH310, pAH312, pAH316 and the PCR open reading frame.
  - for C. trachomatis L<sub>2</sub>, B, and F.

    The C. trachomatis L<sub>2</sub> sequence is given in the top line and begins with the first residue of the mature protein, E. Potential eucaryotic N-glycosylation sequences are underlined. A hydrophobic helical region flanked by prolinerich segments and of suitable length to span

the lipid bilayer is underlined and enclosed in brackets. Amino acid differences identified in the B and F serovars are designated below the  $L_2$  HMWP protein sequence.

5 Figure 7

10

Indirect florescence antibody staining of *C*. trachomatis N11 (serovar F) inclusion bodies using anti-rHMWP' antibody.

Panel A: Post-immunization sera from rabbit K196. Chlamydia inclusion bodies are stained yellow.

Panel B: Pre-immunization sera from rabbit
K196.

#### 6. <u>DETAILED DESCRIPTION OF THE INVENTION</u>

The term "antigens" and its related term "antigenic" as used herein and in the claims refers to a substance that binds specifically to an antibody or T-cell receptor. Preferably said antigens are immunogenic.

The term "immunogenic" as used herein and in the 20 claims refers to the ability to induce an immune response, e.g., an antibody and/or a cellular immune response in a an animal, preferably a mammal or a bird.

The term "host" as used herein and in the claims refers to either *in vivo* in an animal or *in vitro* in 25 mammalian cell cultures.

An effective amount of the antigenic, immunogenic, pharmaceutical, including, but not limited to vaccine, composition of the invention should be administered, in which "effective amount" is defined as an amount that is sufficient

- 30 to produce a desired prophylactic, therapeutic or ameliorative response in a subject, including but not limited to an immune response. The amount needed will vary depending upon the immunogenicity of the HMW protein, fragment, nucleic acid or derivative used, and the species and weight of the
- 35 subject to be administered, but may be ascertained using standard techniques. The composition elicits an immune response in a subject which produces antibodies, including

PCT/US98/2073<sup>7</sup> WO 99/17741

anti-HMW protein antibodies and antibodies that are opsonizing or bactericidal. In preferred, non-limiting, embodiments of the invention, an effective amount of a composition of the invention produces an elevation of
5 antibody titer to at least three times the antibody titer prior to administration. In a preferred, specific, non-limiting embodiment of the invention, approximately 0.01 to 2000 μg and preferably 0.1 to 500 μg are administered to a host. Preferred are compositions additionally comprising an adjuvant.

Immunogenic, antigenic, pharmaceutical and vaccine compositions may be prepared as injectables, as liquid solutions or emulsions. The HMW protein may be mixed with one or more pharmaceutically acceptable excipient which is compatible with the HMW protein. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof.

Immunogenic, antigenic, pharmaceutical and vaccine compositions may further contain one or more auxiliary

20 substance, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness thereof. Immunogenic, antigenic, pharmaceutical and vaccine compositions may be administered parenterally, by injection, subcutaneously or intramuscularly.

pharmaceutical and vaccine compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces.

Thus, the immunogenic, antigenic, pharmaceutical and vaccine compositions may be administered to mucosal surfaces by, for example, the nasal, oral (intragastric), ocular, branchiolar, intravaginal or intrarectal routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients such as, for example, pharmaceutical

grades of saccharine, cellulose and magnesium carbonate.

These compositions can take the form of solutions,
suspensions, tablets, pills, capsules, sustained release
formulations or powders and contain about 0.001 to 95% of the

5 HMW protein. The immunogenic, antigenic, pharmaceutical and
vaccine compositions are administered in a manner compatible
with the dosage formulation, and in such amount as will be
therapeutically effective, protective or immunogenic.

Further, the immunogenic, antigenic, pharmaceutical

10 and vaccine compositions may be used in combination with or
conjugated to one or more targeting molecules for delivery to
specific cells of the immune system, such as the mucosal
surface. Some examples include but are not limited to
vitamin B12, bacterial toxins or fragments thereof,

15 monoclonal antibodies and other specific targeting lipids, proteins, nucleic acids or carbohydrates.

The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize antibodies,

- 20 and if needed, to produce a cell-mediated immune response.

  Precise amounts of active ingredient required to be
  administered depend on the judgment of the practitioner.

  However, suitable dosage ranges are readily determinable by
  one skilled in the art and may be of the order of 0.1 to 1000
- 25 micrograms of the HMW protein, fragment or analogue thereof. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dose may also depend on the route(s) of administration and will vary
  30 according to the size of the host.

The concentration of the HMW protein in an antigenic, immunogenic or pharmaceutical composition according to the invention is in general about 0.001 to 95%. A vaccine which contains antigenic material of only one

35 pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined

PCT/US98/2073<sup>7</sup> WO 99/17741

vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

The antigenic, immunogenic or pharmaceutical

5 preparations, including vaccines, may comprise as the immunostimulating material a nucleotide vector comprising at least a portion of the gene encoding the HMW protein, or the at least a portion of the gene may be used directly for immunization.

- To efficiently induce humoral immune responses

  (HIR) and cell-mediated immunity (CMI), immunogens are

  typically emulsified in adjuvants. Immunogenicity can be

  significantly improved if the immunogen is co-administered

  with an adjuvant. Adjuvants may act by retaining the
- 15 immunogen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an immunogen depot and stimulate such cells to elicit immune responses.
- Many adjuvants are toxic, inducing granulomas, acute and chronic inflammations (Freund's complete adjuvant, FCA), cytolysis (saponins and Pluronic polymers) and pyrogenicity, arthritis and anterior uveitis (LPS and MDP). Although FCA is an excellent adjuvant and widely used in
- 25 research, it is not licensed for use in human or veterinary vaccines because of its toxicity.

Desirable characteristics of ideal adjuvants include:

- (1) lack of toxicity;
- 30 (2) ability to stimulate a long-lasting immune response;
  - (3) simplicity of manufacture and stability in long-term storage;
- (4) ability to elicit either CMI or HIR or both to 35 antigens administered by various routes, if required;
  - (5) synergy with other adjuvants;

(6) capability of selectively interacting with populations of antigen presenting cells (APC);

- (7) ability to specifically elicit appropriate  $T_{H}\mathbf{1}$  or  $T_{H}\mathbf{2}$  cell-specific immune responses; and
- 5 (8) ability to selectively increase appropriate antibody isotype levels (for example, IgA) against antigens.

Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines. Intrinsic adjuvants, such as

- 10 lipopolysaccharides, normally are the components of the killed or attenuated bacteria used as vaccines. Extrinsic adjuvants are immunomodulators which are typically noncovalently linked to antigens and are formulated to enhance the host immune responses. Thus, adjuvants have been
- 15 identified that enhance the immune response to antigens delivered parenterally. Aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines. The efficacy of alum in increasing antibody responses to
- 20 diphtheria and tetanus toxoids is well established and a HBsAg vaccine has been adjuvanted with alum.

Other extrinsic adjuvants may include saponins complexed to membrane protein antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed

25 mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and liposomes.

International Patent Application, PCT/US95/09005 incorporated herein by reference describes mutated forms of 30 heat labile toxin of enterotoxigenic E. coli ("mLT"). U.S. Patent 5,057,540, incorporated herein by reference, describes the adjuvant, Qs21, an HPLC purified non-toxic fraction of a saponin from the bark of the South American tree Quiliaja saponaria molina 3D-MPL is described in great Britain Patent

U.S. Patent No. 4,855,283 granted to Lockhoff et al on August 8, 1989 which is incorporated herein by reference,

35 2,220,211, and is incorporated herein by reference.

teaches glycolipid analogues including N-glycosylamides, N-glycosylureas and N-glycosylcarbamates, each of which is substituted in the sugar residue by an amino acid, as immunomodulators or adjuvants. Lockhoff reported that N-

- 5 glycosphospholipids and glycoglycerolipids, are capable of eliciting strong immune responses in both herpes simplex virus vaccine and pseudorabies virus vaccine. Some glycolipids have been synthesized from long chain-alkylamines and fatty acids that are linked directly with the sugars
- 10 through the anomeric carbon atom, to mimic the functions of the naturally occurring lipid residues.

U.S. Patent No. 4,258,029 granted to Moloney, incorporated herein by reference thereto, teaches that octadecyl tyrosine hydrochloride (OTH) functioned as an adjuvant when complexed with tetanus toxoid and formalin inactivated type I, II and III poliomyelitis virus vaccine. Lipidation of synthetic peptides has also been used to increase their immunogenicity.

Therefore, according to the invention, the 20 immunogenic, antigenic, pharmaceutical, including vaccine, compositions comprising a HMW protein, or a fragment or derivative thereof or a HMW encoding nucleic acid or fragment thereof or vector expressing the same, may further comprise an adjuvant, such as, but not limited to alum, mLT, QS21 and 25 all those listed above. Preferably, the adjuvant is selected from alum, LT, 3D-mPL, or Bacille Calmette-Guerine (BCG) and mutated or modified forms of the above, particularly mLT and LTR192G. The compositions of the present invention may also further comprise a suitable pharmaceutical carrier, including 30 but not limited to saline, bicarbonate, dextrose or other aqueous solution. Other suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field, which is incorporated herein by reference in its entirety.

Immunogenic, antigenic and pharmaceutical, including vaccine, compositions may be administered in a suitable, nontoxic pharmaceutical carrier, may be comprised

in microcapsules, and/or may be comprised in a sustained release implant.

Immunogenic, antigenic and pharmaceutical, including vaccine, compositions may desirably be administered 5 at several intervals in order to sustain antibody levels, and/or may be used in conjunction with other bacteriocidal or bacteriostatic methods.

As used herein and in the claims, "antibodies" of the invention may be obtained by any conventional methods 10 known to those skilled in the art, such as but not limited to the methods described in Antibodies A Laboratory Manual (E. Harlow, D. Lane, Cold Spring Harbor Laboratory Press, 1989) which is incorporated herein by reference in its entirety. The term "antibodies" is intended to include all forms, such 15 as but not limited to polyclonal, monoclonal, purified IqG, IgM, IgA and fragments thereof, including but not limited to fragments such as Fv, single chain Fv (scFv), F(ab'), Fab fragments (Harlow and Leon, 1988, Antibody, Cold Spring Harbor); single chain antibodies (U.S. Patent No. 4,946,778) 20 chimeric or humanized antibodies (Morrison et al., 1984, Proc. Nat'l Acad. Sci. USA 81:6851); Neuberger et al., 1984, Nature 81:6851) and complementary determining regions (CDR), (see Verhoeyen and Windust, in Molecular Immunology 2ed., by B.D. Hames and D.M. Glover, IRL Press, Oxoford University 25 Press, 1996, at pp. 283-325), etc.

In general, an animal (a wide range of vertebrate species can be used, the most common being mice, rats, guinea pig, bovine, pig, hamsters, sheep, birds and rabbits) is immunized with the HMW protein or nucleic acid sequence or immunogenic fragment or derivative thereof of the present invention in the absence or presence of an adjuvant or any agent that enhances the immunogen's effectiveness and boosted at regular intervals. The animal serum is assayed for the presence of desired antibody by any convenient method. The serum or blood of said animal can be used as the source of polyclonal antibodies.

For monoclonal antibodies, animals are treated as described above. When an acceptable antibody titre is detected, the animal is euthanized and the spleen is aseptically removed for fusion. The spleen cells are mixed with a 5 specifically selected immortal myeloma cell line, and the mixture is then exposed to an agent, typically polyethylene glycol or the like, which promotes the fusion of cells. Under these circumstances fusion takes place in a random selection and a fused cell mixture together with unfused 10 cells of each type is the resulting product. The myeloma cell lines that are used for fusion are specifically chosen such that, by the use of selection media, such as HAT: hypoxanthine, aminopterin, and thymidine, the only cells to persist in culture from the fusion mixture are those that are 15 hybrids between cells derived from the immunized donor and the myeloma cells. After fusion, the cells are diluted and cultured in the selective media. The culture media is screened for the presence of antibody having desired specificity towards the chosen antigen. Those cultures 20 containing the antibody of choice are cloned by limiting dilution until it can be adduced that the cell culture is single cell in origin.

# Antigens, Immunogens and Immunoassays

fragments thereof are useful as an antigen or immunogen for the generation of anti-HMW protein antibodies or as an antigen in immunoassays including enzyme-linked immunosorbent assays (ELISA), radioimmmunoassays (RIA) and other non-enzyme linked antibody binding assays or procedures known in the art for the detection of anti-bacterial, anti-Chlamydia, and anti-HMW protein antibodies. In ELISA assays, the HMW protein is immobilized onto a selected surface, for example, a surface capable of binding proteins such as the wells of a polystyrene microtiter plate. After washing to remove incompletely absorbed HMW protein, a nonspecific protein solution that is known to be antigenically neutral with

regard to the test sample may be bound to the selected surface. This allows for blocking of nonspecific absorption sites on the immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto 5 the surface.

The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This may include diluting the 10 sample with diluents, such as solutions of bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from 2 to 4 hours, at temperatures such as of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed 15 to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound HMW protein, and subsequent washing, the occurrence, 20 and even amount, of immunocomplex formation may be determined by subjecting the immunocomplex to a second antibody having specificity for the first antibody. If the test sample is of

- human origin, the second antibody is an antibody having specificity for human immunoglobulins and in general IgG.

  To provide detecting means, the second antibody may have an associated activity such as an enzymatic activity that will generate, for example, a color development upon incubating with an appropriate chromogenic substrate.
- Detection may then be achieved by detecting color generation.
- 30 Quantification may then be achieved by measuring the degree of color generation using, for example, a visible spectrophotometer and comparing to an appropriate standard. Any other detecting means known to those skilled in the art are included.
- Another embodiment includes diagnostic kits comprising all of the essential reagents required to perform a desired immunoassay according to the present invention.

PCT/US98/2073<sup>7</sup> WO 99/17741

The diagnostic kit may be presented in a commercially packaged form as a combination of one or more containers holding the necessary reagents. Such a kit may comprise HMW protein or nucleic acid encoding same or fragment thereof, a monoclonal or polyclonal antibody of the present invention in combination with several conventional kit components. Conventional kit components will be readily apparent to those skilled in the art and are disclosed in numerous publications, including Antibodies A Laboratory Manual (E.

- 10 Harlow, D. Lane, Cold Spring Harbor Laboratory Press, 1989)
  which is incorporated herein by reference in its entirety.
  Conventional kit components may include such items as, for
  example, microtitre plates, buffers to maintain the pH of the
  assay mixture (such as, but not limited to Tris, HEPES,
- 15 etc.), conjugated second antibodies, such as peroxidase conjugated anti-mouse IgG (or any anti-IgG to the animal from which the first antibody was derived) and the like, and other standard reagents.

# 20 Nucleic Acids and Uses Thereof

The nucleotide sequences of the present invention, including DNA and RNA and comprising a sequence encoding the HMW protein or a fragment or analogue thereof, may be synthesized using methods known in the art, such as using

- 25 conventional chemical approaches or polymerase chain reaction (PCR) amplification using convenient pairs of oligonucleotide primers and ligase chain reaction using a battery of contiguous oligonucleotides. The sequences also allow for the identification and cloning of the HMW protein gene from
- 30 any species of *Chlamydia*, for instance for screening chlamydial genomic libraries or expression libraries.

The nucleotide sequences encoding the HMW protein of the present invention are useful for their ability to selectively form duplex molecules with complementary

35 stretches of other protein genes. Depending on the application, a variety of hybridization conditions may be employed to achieve varying sequence identities. In specific

aspects, nucleic acids are provided which comprise a sequence complementary to at least 10, 15, 25, 50, 100, 200 or 250 nucleotides of the HMW protein gene (Figure 2). In specific embodiments, nucleic acids which hybridize to an HMW protein nucleic acid (e.g. having sequence SEQ ID NO: 1, 23 or 24) under annealing conditions of low, moderate or high stringency conditions.

For a high degree of selectivity, relatively stringent conditions are used to form the duplexes, such as, 10 by way of example and not limitation, low salt and/or high temperature conditions, such as provided by 0.02 M to 0.15 M NaCl at temperatures of between about 50°C to 70°C. For some applications, less stringent hybridization conditions are required, by way of example and not limitation such a 0.15 M 15 to 0.9 M salt, at temperatures ranging from between about 20°C to 55°C. Hybridization conditions can also be rendered more stringent by the addition of increasing amounts of formamide, to destabilize the hybrid duplex. particular hybridization conditions can be readily 20 manipulated, and will generally be a method of choice depending on the desired results. By way of example and not limitation, in general, convenient hybridization temperatures in the presence of 50% formamide are: 42°C for a probe which is 95 to 100% homologous to the target fragment, 37°C for 90

Low, moderate and high stringency conditions are well known to those of skill in the art, and will vary predictably depending on the base composition and length of the particular nucleic acid sequence and on the specific organism from which the nucleic acid sequence is derived. For guidance regarding such conditions see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y., pp. 9.47-9.57; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley

25 to 95% homology and 32°C for 70 to 90% homology.

Interscience, N.Y. which is incorporate herein, by reference.

In the preparation of genomic libraries, DNA fragments are generated, some of which will encode parts or the whole of *Chlamydia* HMW protein. The DNA may be cleaved at specific sites using various restriction enzymes.

- 5 Alternatively, one may use DNase in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel
- 10 electrophoresis, column chromatography and sucrose gradient centrifugation. The DNA fragments can then be inserted into suitable vectors, including but not limited to plasmids, cosmids, bacteriophages lambda or  $T_4$ , bacmids and yeast artificial chromosome (YAC). (See, for example, Sambrook et
- 15 al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) The genomic library may be screened by nucleic acid hybridization
- 20 to labeled probe (Benton and Davis, 1977, Science 196:180; Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961).

The genomic libraries may be screened with labeled degenerate oligonucleotide probes corresponding to the amino

- 25 acid sequence of any peptide of HMW protein using optimal approaches well known in the art. In particular embodiments, the screening probe is a degenerate oligonucleotide that corresponds to the sequence of SEQ ID NO: 4. In another embodiment, the screening probe may be a degenerate
- 30 oligonucleotide that corresponds to the sequence of SEQ ID NO:5. In an additional embodiment, any one of the oligonucleotides of SEQ ID NOs: 6-9, 12-14 and 18-21 are used as the probe. In further embodiments, any one of the sequences of SEQ ID NOs: 1, 10-11, 22-24 or any fragments
- 35 thereof, or any complement of the sequence or fragments may be used as the probe. Any probe used preferably is 15 nucleotides or longer.

Clones in libraries with insert DNA encoding the HMW protein or fragments thereof will hybridize to one or more of the degenerate oligonucleotide probes. Hybridization of such oligonucleotide probes to genomic libraries are 5 carried out using methods known in the art. For example, hybridization with the two above-mentioned oligonucleotide probes may be carried out in 2X SSC, 1.0% SDS at 50°C and washed using the same conditions.

In yet another aspect, clones of nucleotide 10 sequences encoding a part or the entire HMW protein or HMWderived polypeptides may also be obtained by screening Chlamydia expression libraries. For example, Chlamydia DNA or Chlamydia cDNA generated from RNA is isolated and random fragments are prepared and ligated into an expression vector 15 (e.g., a bacteriophage, plasmid, phagemid or cosmid) such that the inserted sequence in the vector is capable of being expressed by the host cell into which the vector is then introduced. Various screening assays can then be used to select for the expressed HMW protein or HMW-derived 20 polypeptides. In one embodiment, the various anti-HMW antibodies of the invention can be used to identify the desired clones using methods known in the art. See, for example, Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring

25 Harbor, NY, Appendix IV. Clones or plaques from the library are brought into contact with the antibodies to identify those clones that bind.

In an embodiment, colonies or plaques containing
DNA that encodes HMW protein or HMW-derived polypeptide could
30 be detected using DYNA Beads according to Olsvick et al.,
29th ICAAC, Houston, Tex. 1989, incorporated herein by
reference. Anti-HMW antibodies are crosslinked to tosylated
DYNA Beads M280, and these antibody-containing beads would
then be used to adsorb to colonies or plaques expressing HMW
35 protein or HMW-derived polypeptide. Colonies or plaques
expressing HMW protein or HMW-derived polypeptide is
identified as any of those that bind the beads.

Alternatively, the anti-HMW antibodies can be nonspecifically immobilized to a suitable support, such as silica or Celite™ resin. This material would then be used to adsorb to bacterial colonies expressing HMW protein or HMW-5 derived polypeptide as described in the preceding paragraph.

In another aspect, PCR amplification may be used to produce substantially pure DNA encoding a part of or the whole of HMW protein from *Chlamydia* genomic DNA.
Oligonucleotide primers, degenerate or otherwise,

- 10 corresponding to known HMW protein sequences can be used as primers. In particular embodiments, an oligonucleotide, degenerate or otherwise, encoding the peptide having an amino acid sequence of SEQ ID NO: 2, 3 or 15-17 or any portion thereof may be used as the 5' primer. For fragment examples,
- 15 a 5' primer may be made from any one of the nucleotide sequences of SEQ ID NO: 4-7, 10, 12, 22-24 or any portion thereof. Nucleotide sequences, degenerate or otherwise, that are reverse complements of SEQ ID NO: 11, 13 or 14 may be used as the 3' primer.
- PCR can be carried out, e.g., by use of a Perkin-Elmer Cetus thermal cycler and Taq polymerase (Gene Amp). One can choose to synthesize several different degenerate primers, for use in the PCR reactions. It is also possible to vary the stringency of hybridization conditions used in
- 25 priming the PCR reactions, to allow for greater or lesser degrees of nucleotide sequence similarity between the degenerate primers and the corresponding sequences in Chlamydia DNA. After successful amplification of a segment of the sequence encoding HMW protein, that segment may be
- 30 molecularly cloned and sequenced, and utilized as a probe to isolate a complete genomic clone. This, in turn, will permit the determination of the gene's complete nucleotide sequence, the analysis of its expression, and the production of its protein product for functional analysis, as described infra.
- In a clinical diagnostic embodiment, the nucleic acid sequences of the HMW protein genes of the present invention may be used in combination with an appropriate

indicator means, such as a label, for determining hybridization. A wide variety of appropriate indicator means are known in the art, including radioactive, enzymatic or other ligands, such as avidin/biotin and digoxigenin-

- 5 labelling, which are capable of providing a detectable signal. In some diagnostic embodiments, an enzyme tag such as urease, alkaline phosphatase or peroxidase, instead of a radioactive tag may be used. In the case of enzyme tags, colorimetric indicator substrates are known which can be
- 10 employed to provide a means visible to the human eye or spectrophotometrically, to identify specific hybridization with samples containing HMW protein gene sequences.

The nucleic acid sequences of the HMW protein genes of the present invention are useful as hybridization probes

15 in solution hybridizations and in embodiments employing

- solid-phase procedures. In embodiments involving solid-phase procedures, the test DNA (or RNA) from samples, such as clinical samples, including exudates, body fluids (e.g., serum, amniotic fluid, middle ear effusion, sputum, semen,
- 20 urine, tears, mucus, bronchoalveolar lavage fluid) or even tissues, is absorbed or otherwise affixed to a selected matrix or surface. The fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes comprising the nucleic acid sequences of the HMW
- 25 protein encoding genes or fragments or analogues thereof of the present invention under desired conditions. The selected conditions will depend on the particular circumstances based on the particular criteria required depending on, for example, the G+C contents, type of target nucleic acid,
- 30 source of nucleic acid, size of hybridization probe etc. Following washing of the hybridization surface so as to remove non-specifically bound probe molecules, specific hybridization is detected, or even quantified, by means of the label. It is preferred to select nucleic acid sequence
- 35 portions which are conserved among species of *Chlamydia*. The selected probe may be at least 15 bp and may be in the range of about 30 to 90 bp.

Expression of the HMW protein Gene Plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell may be used for the expression of the genes 5 encoding the HMW protein or fragments thereof in expression systems. Expression vectors contain all the necessary elements for the transcription and translation of the inserted protein coding sequence. The vector ordinarily carries a replication site, as well as marking sequences 10 which are capable of providing phenotype selection in transformed cells. For example, E. coli may be transformed using pBR322 which contains genes for ampicillin and tetracycline resistance cells. Other commercially available vectors are useful, including but not limited to pZERO,

- 15 pTrc99A, pUC19, pUC18, pKK223-3, pEX1, pCAL, pET, pSPUTK, pTrxFus, pFastBac, pThioHis, pTrcHis, pTrcHis2, and pLEx. The plasmids or phage, must also contain, or be modified to contain, promoters which can be used by the host cell for expression of its own proteins.
- In addition, phage vectors containing replicon and 20 control sequences that are compatible with the host can be used as a transforming vector in connection with these hosts. For example, the phage in lambda  $GEM^{\text{\tiny{IM}}}-11$  may be utilized in making recombinant phage vectors which can be used to 25 transform host cells, such as E. coli LE392.

Promoters commonly used in recombinant DNA construction include the  $\beta$ -lactamase (penicillinase) and lactose promoter systems and other microbial promoters, such as the T7 promoter system as described in U.S. Patent No.

- 30 4,952,496. Details concerning the nucleotide sequences of promoters are known, enabling a skilled worker to ligate them functionally with genes. The particular promoter used will generally be matter of choice depending upon the desired results.
- In accordance with this invention, it is preferred 35 to make the HMW protein by recombinant methods, particularly when the naturally occurring HMW protein as isolated from a

culture of a species of *Chlamydia* may include trace amounts of toxic materials or other contaminants. This problem can be avoided by using recombinantly produced HMW protein in heterologous systems which can be isolated from the host in a manner to minimize contaminants in the isolated material. Particularly desirable hosts for expression in this regard include Gram positive bacteria which do not have LPS and are, therefore endotoxin free. Such hosts include species of *Bacillus* and may be particularly useful for the production of non-pyrogenic rHMW protein, fragments or analogues thereof.

A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA. Hosts that are appropriate for expression of the HMW protein genes, fragments, analogues or variants thereof, may include E.

20 coli, Bacillus species, Haemophilus, fungi, yeast, such as Saccharomyces pichia. Bordetella. or the baculovirus

- 20 coli, Bacillus species, Haemophilus, fungi, yeast, such as Saccharomyces pichia, Bordetella, or the baculovirus expression system may be used. Preferably, the host cell is a bacterium, and most preferably the bacterium is E. coli, B. subtilis or Salmonella.
- 25 The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used. In a preferred embodiment, a chimeric protein comprising HMW
- 30 protein or HMW-derived polypeptide sequence and a pre and/or pro sequence of the host cell is expressed. In other preferred embodiments, a chimeric protein comprising HMW protein or HMW-derived polypeptide sequence fused with, for example, an affinity purification peptide, is expressed. In
- 35 further preferred embodiments, a chimeric protein comprising HMW protein or HMW-derived polypeptide sequence and a useful immunogenic peptide or protein is expressed. In preferred

PCT/US98/20737 WO 99/17741

embodiments, HMW-derived protein expressed contains a sequence forming either an outer-surface epitope or the receptor-binding domain of native HMW protein.

Any method known in the art for inserting DNA

5 fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/ translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo

- 10 recombinants (genetic recombination). Expression of a nucleic acid sequence encoding HMW protein or HMW-derived polypeptide may be regulated by a second nucleic acid sequence so that the inserted sequence is expressed in a host transformed with the recombinant DNA molecule. For example,
- 15 expression of the inserted sequence may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control expression of inserted sequences include, but are not limited to the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the
- 20 promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982,
- Nature 296:39-42) for expression in animal cells; the promoters of β-lactamase (Villa-Kamaroff et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), tac (DeBoer et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25), P<sub>L</sub>, or trc for expression in bacterial cells (see also "Useful proteins from
- 30 recombinant bacteria" in Scientific American, 1980, 242:74-94); the nopaline synthetase promoter region or the cauliflower mosaic virus 35S RNA promoter (Gardner et al., 1981, Nucl. Acids Res. 9:2871), and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase
- 35 (Herrera-Estrella et al., 1984, <u>Nature</u> 310:115-120) for expression implant cells; promoter elements from yeast or other fungi such as the Gal4 promoter, the ADC (alcohol

dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter.

Expression vectors containing HMW protein or HMWderived polypeptide coding sequences can be identified by 5 three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences such as reactivity with anti-HMW antibody. In the first approach, the presence of a foreign gene inserted in an expression vector can be detected 10 by nucleic acid hybridization using probes comprising sequences that are homologous to the inserted HMW protein or HMW-derived polypeptide coding sequence. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of 15 certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. For example, if the HMW protein or HMW-derived polypeptide coding 20 sequence is inserted within the marker gene sequence of the vector, recombinants containing the insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the foreign gene product expressed by the 25 recombinant. Such assays can be based, for example, on the physical or functional properties of HMW protein or HMWderived polypeptide in in vitro assay systems, e.g., binding to an HMW ligand or receptor, or binding with anti-HMW antibodies of the invention, or the ability of the host cell 30 to hemagglutinate or the ability of the cell extract to

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and 35 growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As explained above, the expression vectors which can be used

interfere with hemagglutination by Chlamydia.

include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and 5 plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered HMW protein or HMW-derived HMW may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and

15 modification of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and

processing of the foreign protein expressed. The proteins, polypeptides, peptides, antibodies and nucleic acids of the invention are useful as reagents for 20 clinical or medical diagnosis of Chlamydia infections and for scientific research on the properties of pathogenicity, virulence, and infectivity of Chlamydia, as well as host defense mechanisms. For example, DNA and RNA of the invention can be used as probes to identify the presence of 25 Chlamydia in biological specimens by hybridization or PCR amplification. The DNA and RNA can also be used to identify other bacteria that might encode a polypeptide related to the Chlamydia HMW protein. The proteins of the invention may be used to prepare polyclonal and monoclonal antibodies that can 30 be used to further purify compositions containing the proteins of the invention by affinity chromatography. proteins can also be used in standard immunoassays to screen

#### 35 7. BIOLOGICAL DEPOSITS

Certain plasmids that contain portions of the gene having the open reading frame of the gene encoding the HMW

for the presence of antibodies to Chlamydia in a sample.

protein of *Chlamydia* that are described and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, Virginia 20110-2209, U.S.A., pursuant to the

5 Budapest Treaty and pursuant to 37 CFR 1.808 and prior to the filing of this application. The identifications of the respective portions of the genes present in these plasmids are shown below.

Samples of the deposited materials will become

10 available to the public upon grant of a patent based upon
this United Stated patent application. The invention
described and claimed herein is not to be limited by the
scope of the plasmids deposited, since the deposited
embodiment is intended only as an illustration of the

15 invention. Any equivalent or similar plasmids that encode
similar or equivalent proteins or fragments or analogues
thereof as described in this application are within the scope
of the invention.

20 Plasmid ATCC Accession No. Date Deposited
pAH342 ATCC 985538 September 8, 1997

#### 8. EXAMPLES

The above disclosure generally describes the

25 present invention. A more specific description is provided below in the following examples. The examples are described solely for the purpose of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances

30 suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitation.

Methods of molecular genetics, protein biochemistry and immunology used but not explicitly described in the

35 disclosure and examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

PCT/US98/20737 WO 99/17741

# 8.1. EXAMPLE 1: ISOLATION AND PURIFICATION OF MATURE CHLAMYDIA PROTEINS

McCoy cells were cultured either in standard 225 cm<sup>2</sup> tissue culture flasks or in Bellco spinner flasks (Cytodex 5 microcarrier, Pharmacia) at 37°C in 5% CO₂ using DMEM media supplemented with 10% Chlamydia-antibody free fetal bovine serum, glucose and nonessential amino acids. C. trachomatis  ${
m L_2}$  elementary bodies (ATCC VR-902B) were prepared from lysates of infected McCoy cells. Basically, McCoy cells infected 10 with C. trachomatis  $L_2$  (LGV) were sonicated and cellular debris was removed by centrifugation. The supernatant containing chlamydial elementary bodies (EBs) was then centrifuged and the pellet containing EBs was resuspended in Hanks' balanced salts solution (HBSS). RNase/DNase solution 15 was added and incubated at 37°C for 1 hour with occasional mixing. The EB containing solution was layered onto a discontinuous density gradient (40%, 44% and 54%) of Angiovist 370 (mixture of diatrizoate melgumine and diatrizoate sodium, Berlex Laboratories, Wayne, NJ) and 20 ultracentrifuged for separation of the EBs on the gradient. After centrifugation the EBs were harvested from the gradient between the interface of the 44% and 54% Angiovist 370 layers. The EBs were washed in phosphate buffered saline and

Purified EBs were sequentially extracted with 0.1%

OGP [high ionic strength] in HBSS to remove peripheral surface proteins and held on ice. The same EB preparation was then extracted with 1.0% OGP, 10 mM DTT, 1 mM PMSF, 10 mM EDTA, in a 50 mM Tris pH 7.4 buffer. Extracts were dialyzed

- 30 (3500 MWCO) to remove detergent and other reagents and concentrated by lyophilization. Protein containing extracts were diluted in HBSS and passed over commercially available heparin-sepharose columns (HiTrap Col., Pharmacia). After samples were applied to the heparin column nonadhered
- 35 proteins were removed by washing with excess HBSS. Bound proteins were batch eluted with PBS containing 2 M sodium chloride. Eluents were dialyzed extensively to remove salt

and then lyophilized. The heparin-binding proteins were size fractionated by SDS-PAGE and visualized by silver staining or analyzed by Western blotting. Protein(s) of about 105-115 KDa present in moderate amounts were detected as shown in 5 Figure 1. The isoelectric point of the native HMW protein was determined to be about 5.95.

To obtain one N-terminal amino acid sequence, sufficient quantities of the HMW protein (≥ 5 μg) were electroblotted onto a PVDF membrane (Applied Biosystems), and stained with Coomassie blue. Immobilized HMW protein was released from the membrane and treated in situ with low levels of endopeptidase Lys-C, endopeptidase Arg-C and/or endopeptidase Glu-C to fragment the native protein. The resulting peptide fragments were purified by HPLC and their N-terminal amino acid sequences determined using an ABI 430 Protein Sequenator and standard protein sequencing methodologies. The N-terminal amino acid sequence is:

$$E-I-M-V-P-Q-G-I-Y-D-G-E-T-L-T-V-S-F-X-Y$$

20

and is denoted SEQ ID No.: 3.

When a composite PDB+SwissProt+PIR+GenPept database (>145 K unique sequences) was searched with the HMW protein N-terminal sequence (20 residues) using rigorous match

25 parameters, no precise homologies were found. Thus the HMW protein is a novel chlamydial protein. Since this protein was isolated under conditions that should release only peripheral membrane proteins (e.g. Omp2), these data indicate that the HMW protein is a surface-associated protein.

30

## 8.2. EXAMPLE 2: PREPARATION OF ANTIBODIES TO WHOLE CHLAMYDIA EBS

To aid in the characterization of the HMW protein, hyperimmune rabbit antisera was raised against whole EBs from 35 C. trachomatis  $L_2$ . Each animal was given a total of three immunizations of about 250  $\mu g$  of Chlamydia EBs per injection (beginning with complete Freund's adjuvant and followed with

PCT/US98/2073<sup>7</sup> WO 99/17741

incomplete Freund's adjuvant) at approximately 21 day intervals. At each immunization, approximately half of the material was administered intramuscularly (i.m.) and half was injected intranodally. Fourteen days after the third
5 vaccination a fourth booster of about 100 μg of EBs was given i.m. and the animals exsanguinated 7-10 days later. A titre of 1:100,000 was obtained as determined by ELISA.

# 8.3. EXAMPLE 3: DETERMINATION OF POST-TRANSLATIONAL 10 MODIFICATIONS

Recently, several *C. trachomatis* membraneassociated proteins have been shown to be posttranslationally modified. The 18 kDa and 32 kDa cysteinerich EB proteins, which are lectin-binding proteins, have

15 been shown to carry specific carbohydrate moieties (Swanson,
A.F. and C.C. Kuo. 1990. <u>Infect. Immun.</u> 58:502-507).
Incorporation of radiolabelled palmitic acid has been used to
demonstrate that the about 27 kDa *C. trachomatis* Mip-like
protein is lipidated (Lundemose, A.G., D.A. Rouch, C.W. Penn,
and J.H. Pearce. 1993. <u>J. Bacteriol.</u> 175:3669-3671). Swanson
et al. have discovered that the MOMP from the L<sub>2</sub> serovar
contains N-acetylglucosamine and/or N-acetylgalactosamine and
these carbohydrate moieties mediate binding of MOMP to Hela

To ascertain whether the HMW protein is glycosylated, EBs are grown on McCoy cells in the presence of tritiated galactose or glucosamine, subjected to heparin affinity chromatography and the heparin binding proteins analyzed by SDS-PAGE and autoradiography. Briefly, McCoy cells are grown in T225 flasks under standard conditions (DMEM + 10% FCS, 35 ml per flask, 10% CO<sub>2</sub>) to about 90% confluency and inoculated with sufficient EBs to achieve 90%-100% infectivity. Following a 3 hour infection period at 37°C cycloheximide is added (1 μg/ml) to inhibit host cell protein synthesis and the cultures reincubated for an additional 4-6 hours. Approximately 0.5 mCi of tritiated galactose (D-[4,5-3H(N)]galactose, NEN) or glucosamine (D-

[1,6-3H(N)glucosamine, NEN) is then be added to each flask and the cultures allowed to incubate for an additional 30-40 hours. Cells are harvested by scraping and EBs purified by gradient centrifugation. HMW protein is isolated from 1.0% 5 OGP surface extracts by affinity chromatography, eluted with NaCl and analyzed by SDS-PAGE using 14C-labelled molecular weight markers (BRL) then subjected to autoradiography. Dried gels are exposed for 1-4 weeks to Kodak X-AR film at -70°C.

- To determine post synthesis lipid modification, C.trachomatis serovar L<sub>2</sub> is cultivated on monolayers of McCoy cells according to standard procedures. Approximately 24 hours postinfection, conventional culture media (DMEM + 10% FCS) is removed and replaced with a serum-free medium

  15 containing cycloheximide (1 μg/ml) and [U-14C]palmitic acid (0.5 mCi/T225 flask, NEN) and incubated for a further 16-24 hours to allow protein lipidation to occur. Surface EB extracts are prepared, heparin-binding proteins are isolated and analyzed by autoradiography as described above.
- The functionality of glycosylated or lipidated moieties is assessed by treating whole EBs or OGP surface extracts with appropriate glycosidases. Following carbohydrate removal, extracts are subjected to affinity chromatography and SDS-PAGE to determine whether the HMW protein retains the ability to bind to heparin sulfate.

# 8.4. EXAMPLE 4: Cloning of the N-terminal Segment of the HMW Protein Gene

Degenerate oligonucleotides were designed based on 30 the N-terminal amino acid sequence of the HMW protein and were synthesized. These oligonucleotides were then used to generate gene-specific PCR products that were employed as hybridization probes to screen a C. trachomatis  $L_2$   $\lambda ZAPII$  DNA library to isolate the gene for the HMW protein.

Briefly, appropriate low degeneracy peptide segments were identified from the N-terminal and internal amino acid sequence data by computer analysis (MacVector,

IBI) and used to guide the design of low degeneracy sequencespecific oligonucleotide PCR primer sets.

Using the N-terminal primary sequence as a guide, four degenerate oligonucleotide probes complementary to the 5 first six residues of the HMW peptide E-I-M-V-P-Q (residues 1-6 of SEQ ID No.: 3), and comprising all possible nucleotide combinations (total degeneracy = 192 individual sequences), have been designed and employed as forward amplification primers.

10

```
SEQ ID No.4 5'-GAA-ATH-ATG-GTN-CCN-CAA-3'.

SEQ ID No.5 5'-GAA-ATH-ATG-GTN-CCN-CAG-3'

SEQ ID No.6 5'-GAG-ATH-ATG-GTN-CCN-CAA-3'

SEQ ID No.7 5'-GAG-ATH-ATG-GTN-CCN-CAG-3'
```

15

Two additional oligonucleotide probes representing the reverse complement DNA sequence of the internal five residue peptide Y-D-G-E-T (residues 9-13 of SEQ ID No.: 3), and comprising all possible nucleotide combinations (total degeneracy = 128 individual sequences), have been designed and employed as reverse amplification primers.

```
SEQ ID No.8 5'-NGT-YTC-NCC-RTC-ATA-3'
SEQ ID No.9 5'-NGT-YTC-NCC-RTC-GTA-3'
```

25

Oligonucleotides were synthesized on an ABI Model 380B DNA synthesizer using a 0.2  $\mu$ mol scale column (tritylon, auto-cleavage) and standard phosphoramidite chemistry. Crude oligonucleotides were manually purified over C-18 syringe columns (OP Columns, ABI). Purity and yield were ascertained spectrophotometrically (230/260/280 ratios).

Standard PCR amplification reactions (2 mM Mg<sup>2+</sup>, 200 umol dNTPs, 0.75 units AmpliTaq, 50  $\mu$ l final volume) were programmed using about 0.2  $\mu$ g C. trachomatis L<sub>2</sub> DNA (about 35 3X10<sup>7</sup> copies of the HMW protein gene if single copy) and about 100 pmol of each forward (N-terminal oligo) and reverse (internal oligo) primer. Higher than normal concentrations

of primers (~20 pmol/50  $\mu$ l) were used for amplification, at least initially, in order to compensate for primer degeneracy. Amplification of target sequences was achieved using a standard 30-cycle, three-step thermal profile, i.e.

- 5 95°C, 30 sec; 60°C, 45 sec, 72°C, 1 min. Amplification was carried out in sealed 50  $\mu$ l glass capillary tubes using a Idaho Technologies thermal cycler. To verify that the PCR products generated during these amplification reactions were specific for the HMW protein coding sequence and were not
- 10 "primer-dimer" or other DNA amplification artifacts,
   amplimers were purified using silica-gel spin columns
   (QIAGEN), cloned into the PCR cloning vector pZERO
   (StrataGene), and subjected to direct DNA sequence analysis.
- The DNA sequence for the cloned PCR products were

  15 determined using conventional dideoxy-terminator sequencing chemistry and a modified T7 DNA polymerase (Sequenase, USB). Briefly, each double stranded plasmid template was denatured by a brief treatment with NaOH. Following neutralization, each denatured template was used to program 4 separate
- 20 sequencing reactions. Each reaction contained the M13 universal forward sequencing primer (21-mer) but a different ddNTP/dNTP termination mix (i.e. A,G,C, or T). Termination products were labelled by including  $[\alpha^{-35}S]$  dATP in the reaction (~50uCi/reaction, >3000Ci/mmol, Amersham).
- 25 Individual extension products were denatured (formamide, ~95°C) and subjected to high resolution denaturing polyacrylamide gel electrophoresis (6% acrylamide, 8M urea, TAE buffer, ~500V, ~90min). Sequencing gels were then transferred to filter paper (Whatmann 3MM), dried under
- 30 vacuum, and then autoradiographed at -70°C for 24-72 hours.

  Base ladders were read manually from each gel and a consensus sequence determined.

HMW protein-specific amplimers suitable for library screening and/or Southern blotting were produced by PCR and 35 uniformly radiolabelled during the amplification process by adding  $[\alpha^{-32}P]$  dNTPs (about 50  $\mu$ Ci each dNTP, Amersham, >5000 Ci/mmol) to the reaction mixture. Labelling reactions were

PCT/US98/20737 WO 99/17741

performed as above except reactions were performed in 0.5 ml microcentrifuge tubes using a Bellco Thermal Cycler.

Unincorporated label and amplification primers were removed from the reaction mixture using centrifugal size-exclusion 5 chromatography columns (BioSpin 6 columns, BioRad).

A highly redundant C.trachomatis serovar  $L_2$  DNA library (>50,000 primary clones) has been constructed by cloning size-fractionated fragments  $\geq 10$  Kbp produced from a partial EcoRI digest of genomic DNA into the lambda cloning 10 vector  $\lambda$ ZAPII (Stratagene). Radiolabelled HMW proteinspecific PCR products were used to screen this library for recombinant clones that carry all or part of the HMW protein coding sequence. Standard recombinant DNA procedures and methodologies were employed for these experiments. All phage 15 that hybridized with these probes were purified to homogeneity by sequential rounds of plating and hybridization screening. Once reactive phage were purified, insertcontaining phagmids (pBluescript SK- derivatives) were excision-rescued from the parental phage by coinfecting host 20 cells with an appropriate helper phage, e.g. R408 or VCSM13 Individual phagmids were further purified by (Stratagene). streak-plating on LB agar containing ampicillin (100  $\mu$ g/ml) and selecting for individual colonies.

To confirm purified phagemid derivatives carried

25 the HMW protein sequences, plasmid DNA was prepared and used to program amplification reactions containing the HMW protein-specific PCR primer sets. The presence of HMW protein-specific inserts was confirmed by the production of the appropriate sized PCR product.

Plasmid pAH306 is one HMW protein-containing derivative that was isolated by these methodologies.

### Physical Mapping of pAH306

The inserts from pAH306 were physically mapped and 35 the location of HMW protein gene determined using appropriate six-base restriction endonucleases (e.g. EcoRI, HindIII, BamHI, PstI, SmaI, KpnI, etc.) and HMW protein coding

sequences localized by Southern hybridization employing radiolabelled N-terminal-specific PCR products as probes. The orientation and extent of HMW protein-specific sequences were determined by PCR analysis using primer sets consisting of HMW protein-specific forward primers and reverse primers complementary to either the T3 or T7 promoter sequences located in the cloning vector.

Plasmid pAH306 was determined to contain a single ~6.6 Kbp EcoRI fragment of chlamydial origin. Directional 10 PCR analysis of pAH306 demonstrated this derivative encodes roughly 1.5Kbp of the N-terminal region of the HMW protein gene.

The DNA sequence for the HMW protein gene encoded on pAH306 was obtained for both strands via conventional

15 "sequence-walking" coupled with asymmetric PCR cycle sequencing methodologies (ABI Prism Dye-Terminator Cycle Sequencing, Perkin-Elmer). Sequencing reactions were programmed with undigested plasmid DNA (~0.5 µg/rxn) as a template and appropriate HMW protein-specific sequencing

20 primers (~3.5 pmol/rxn).

In addition to the template and sequencing primer, each sequencing reaction (~20 µl) contained the four different dNTPs (i.e. A,G,C, and T) and the four corresponding ddNTPs (i.e. ddA, ddG, ddC, and ddT) terminator nucleotides; with each terminator being conjugated to one of four different fluorescent dyes. Single strand sequencing elongation products were terminated at random positions along the template by the incorporation of the dye-labelled ddNTP terminators. Fluorescent dye-labelled termination products were purified using microcentrifuge size-exclusion chromatography columns (Princeton Genetics), dried under vacuum, suspended in a Template Resuspension Buffer (Perkin-Elmer), denatured at 95°C for ~5min, and resolved by high resolution capillary electrophoresis on an ABI 310 Automated 35 DNA Sequenator (Perkin-Elmer).

DNA sequence data produced from individual reactions were collected and the relative fluorescent peak

intensities analyzed automatically on a PowerMAC computer using ABI Sequence Analysis Software (Perkin-Elmer).

Individually autoanalyzed DNA sequences were edited manually for accuracy before being merged into a consensus sequence

5 "string" using AutoAssembler software (Perkin-Elmer). Both strands of the HMW protein gene segment encoded by pAH306 were sequenced and these data compiled to create a composite sequence for the HMW protein gene segment. The sequence encoding the segment of HMW protein is listed as SEQ ID No.:

10 and is represented by nucleotides 382 to 1979 in Figure 2. A map of pAH306 is shown in Figure 5.

Database analysis (e.g. primary amino acid homologies, hydropathy profiles, N-/O-glycosylation sites, functional/conformational domain analyses) of the DNA and 15 predicted amino acid sequences for the HMW protein was performed using GeneRunner and Intelligentics software, indicating the HMW protein is novel.

# 8.5. Example 5: CLONING OF THE C-TERMINAL SEGMENT OF THE 20 HMW PROTEIN GENE

Chromosome walking was employed to isolate the Cterminal portion of the HMW protein gene. A ~0.6 Kbp BamHIECORI fragment distal to the N-terminal sequence of the
mature HMW protein and proximal to the T3 promoter sequence
25 of the vector was chosen as the probe for the initial
chromosome walk. Briefly, pAH306 was digested to completion
with BamHI and ECORI and the digestion products size
fractionated by agarose gel electrophoresis (0.8% agarose in
TAE buffer). The desired ~0.6 Kbp BamHI/ECORI (B/E) band was
30 excised from the gel and purified using commercially
available silica gel microcentrifuge chromatography columns
and reagents (QIAGEN).

The purified 0.6 Kbp B/E fragment was radiolabelled with [α-dATP] (>3000Ci/mmol, Amersham) via random-priming
35 labelling methodologies employing commercially available reagents (Boehringer Mannheim) and used to probe Southern

blots of C. trachomatis  $L_2$  genomic DNA that had been digested to completion with HindIII.

The 0.6 Kbp B/E probe from pAH306 hybridized to a ~1.4Kbp HindIII genomic fragment. Based on the experimentally 5 derived restriction map of the HMW protein gene segment encoded on pAH306, this fragment encodes ~0.2Kbp of the C-terminal HMW protein sequence.

The radiolabelled 0.6 Kbp B/E fragment was used subsequently to probe a moderately redundant (~5,000 primary 10 clones) C. trachomatis L2 library to identify clones that contain the ~1.4 Kbp HindIII fragment. Briefly, C. trachomatis L2 genomic DNA was digested to completion using a ~10-fold excess of the restriction endonuclease HindIII (~10 units per 1 μg of genomic DNA, 37°C, 18-24 hours). Digestion 15 products were size fractionated by agarose gel electrophoresis (0.8% agarose, TAE) and DNA fragments ranging in size from ~1.0 Kbp to 2.0 Kbp were excised from the gel. Excised agarose strips contain the desired DNA fragment sizes were dissolved in a solubilization/binding solution
20 (QX1,QIAGEN) and purified using commercially available silica-gel spin columns (QIAGEN). Purified 1.0-2.0 Kbp

20 (QX1,QIAGEN) and purified using commercially available silica-gel spin columns (QIAGEN). Purified 1.0-2.0 Kbp genomic HindIII fragments were then cloned into the pBlueScript SK- plasmid which had been previously digested to completion with HindIII and treated with calf intestinal phosphatase to prevent vector religation.

Vector/insert ligations were performed in a ~50 μl final reaction volume (50 mM Tris-HCl, pH 7.00; 10 mM NaCl; 1 mM ATP; 0.5 mM DTT) at 25°C for ~16-24 hours using T4 DNA ligase (~10 units/reaction) and a vector:insert molar ratio of approximately 1:10. Following ligation, aliquots (~50 ng ligated DNA) were used to electroporate a competent *E.coli* host, *e.g. E.coli* TOP10. Electroporated cells were then plated onto LB agar containing ~100μg/ml ampicillin to select for plasmid-harboring clones. Approximately 1,000 plasmid-35 harboring Ap<sup>R</sup> transformants were transferred directly from LB Ap<sup>100</sup> agar plates onto nylon membranes (HyBond N+, Amersham)

by capillary action.

WO 99/17741

Following transfer, plates were re-incubated at 37°C to regenerate viable colonies for further manipulation. Colonies transferred to membranes were lysed and DNA liberated by treating the colony blots with a denaturing 5 SDS/NaOH solution. A Tris buffered NaCl solution was used to neutralize and stabilize lysis material. Released DNA was immobilized onto the membranes by UV irradiation. Standard recombinant DNA procedures and methodologies were employed to probe the colony blots with the radiolabelled 0.6 Kbp B/E 10 fragment and identify recombinant derivatives which carry the desired ~1.4Kbp HindIII fragment.

Plasmid pAH310 was one derivative isolated by these procedures and the coding segment of the HMW protein is represented by nucleotides 994-2401 in Figure 2.

15 Restriction analysis using HindIII and EcoRI, individually and in combination, together with DNA sequence analysis of purified plasmid DNA confirmed pAH310 encodes the expected ~1.4 Kbp HindIII fragment. These analyses also demonstrated that the ~1.4 Kbp insert consists of the same

20 ~1.2 Kbp HindIII-EcoRI fragment that is present in pAH306 and a unique ~0.2 Kbp EcoRI-HindIII fragment that encodes C-terminal HMW protein-specific DNA.

The ~0.2 Kbp EcoRI-HindIII (E/H) fragment was chosen as the probe for the second chromosome walk. Briefly, pAH310 was digested to completion with EcoRI and HindIII and the digestion products size fractionated by agarose gel electrophoresis (0.8% agarose in TAE buffer). The desired ~0.2 Kbp (E/H) band was excised from the gel, purified, radiolabelled with  $[\alpha-P^{32}]$  dATP, and used as a probe to identify clones in the original *C.trachomatis*  $L_2$   $\lambda ZAPII$  genomic library that encode the C-terminal segment of the HMW protein gene.

Plasmid pAH316 is one derivative isolated by these procedures. Restriction analysis of pAH316 demonstrated that 35 this derivative contains a *C. trachomatis* L<sub>2</sub> insert of ~4.5 Kbp which consists of two EcoRI fragments of ~2.5 Kbp and ~2.0 Kbp in size. Southern hybridization analysis using the

~0.2 Kbp E/H fragment as a probe localized this sequence to the ~2.5 Kbp EcoRI fragment of pAH316. Directional PCR analyses employing purified pAH316 plasmid DNA as a template and amplification primer sets specific for ~0.2 Kbp E/H

5 fragment and T3 and T7 vector sequences demonstrated pAH316 encodes the C-terminal segment of the HMW protein gene. The coding segment of the HMW protein is represented by nucleotides 1974 to 3420 in Figure 2, and is listed as SEQ ID No.:11.

10

## 8.6. Example 6: PRODUCTION OF TRUNCATED HMW RECOMBINANT PROTEIN

The N-terminal half of the HMW protein was PCR cloned as a ~1.5Kbp fragment into the commercially available

15 E.coli expression plasmid pTrcHisB (Invitrogen). The forward primer used in these reactions was designated 140FXHO (57-mer), listed as SEQ ID No. 18, and contains sequences complementary to the first 10 N-terminal residues of the mature HMW protein. In addition to the HMW proteincoding

20 sequences, this forward primer also carries a unique XhoI restriction site located optimally located upstream of the first residue of the mature HMW protein (Glu/E) for proper fusion to the (His)<sub>6</sub> affinity purification domain encoded on the vector plasmid, and 5' terminal 6 base G/C clamp for

25 effective amplification and a 12 base internal spacer for effective endonuclease recognition and digestion.

<u>SEQ ID No.18</u> 5' - AAG-GGC-CCA-ATT-ACG-CAG-AGC-TCG-AGA-GAA-ATT-ATG-GTT-CCT-CAA-GGA-ATT-TAC-GAT - 3'

30

SEO ID No.19 5' - CGC-TCT-AGA-ACT-AGT-GGA-TC - 3'

The commercially available reverse sequencing primer SK (20mer, StrataGene), <u>SEO ID No. 19</u>, which is complementary to 35 phagemid sequences downstream of the EcoRI site in pAH306, was used as the reverse amplification primer in these reactions. To obtain acceptable yields of the HMW protein ORF

product ( $\sim$ 1.5 Kbp), PCR amplification was performed using a mixture of thermostable DNA polymerases consisting of T. thermophilus DNA polymerase (Advantage Polymerase), as the primary amplification polymerase and a minor amount of a

- 5 second high fidelity thermostable DNA polymerase to provide additional 5' 3' proofreading activity (CloneTech). An anti-Tth DNA polymerase antibody was added to the reaction mixture to provide automatic "hot-start" conditions which foster the production of large >2Kbp amplimers. pAH306
- 10 plasmid DNA purified using a commercially available alkaline/SDS system (QIAGEN) and silica gel spin columns (QIAGEN) was used to program these amplification reactions (~0.2 ng/reaction).

The ~1.5 Kbp amplimer was purified from

- 15 unincorporated primers using silica gel spin columns and digested to completion using an excess of XhoI and EcoRI (~10 units per 1  $\mu$ g DNA). The purified and digested N-terminal truncated HMW protein ORF was then be cloned into the commercially available expression plasmid pTrcHisB that had
- 20 been previously digested with both XhoI and EcoRI (5:1, insert:vector ratio). Aliquots from the ligation reaction were then be used to electrotransform a suitable *E.coli* host (e.g. TOP10).

Mini-prep DNA from ampicillin-resistant

- 25 transformants picked at random were prepared, digested to completion with XhoI, EcoRI, or a combination of both and examined for the presence and orientation of the ~1.5 Kbp truncated HMW protein ORF insert by agarose gel electrophoresis. Mini-prep DNA from clones determined to
- 30 carry the ~1.5 Kbp XhoI/EcoRI insert was prepared and used to program asymmetric PCR DNA sequencing reactions to confirm the fidelity of the junction formed between the HMW protein fragment and the (His)<sub>6</sub> affinity purification domain of the expression vector. Plasmid pJJ36-J was one recombinant
- 35 derivative isolated by these procedures and is represented by nucleotides 446 to 1977 in figure 2. The deduced amino acid sequence of the truncated fragment of HMW protein is

represented by amino acids 29 to 532 in Figure 3 and is listed as SEQ ID No. 17.

#### 8.7. EXAMPLE 7: DETERMINATION OF PRESENCE IN OTHER SPECIES

- Polymerase chain reaction analyses were undertaken to establish the presence of the HMW gene in several clinically recognized *C. trachomatis* strains and as well as other chlamydial species, e.g., *C. pneumoniae*. *Chlamydia trachomatis* strains as frozen stocks from the ATCC
- 10 (Rockville, MD) were used to infect subconfluent monolayers (about 80%) of McCoy cells according to standard procedures. Infected monolayers were either centrifuged in a Sorvall RT6000B centrifuge (~1,300 rpm, 25°C, 30 min) and/or treated with dextran sulfate (~50  $\mu$ g/ml) at the time of infection to
- 15 enhance initial attachment of the low infectivity biovars (non-LGV) to host cells and thus increase the final EB yield. Roughly 48 hours later, infected monolayers were collected by scraping and host cells disrupted by sonication to release elementary bodies (EBs). Total DNA was extracted from
- 20 purified EBs (~10<sup>7</sup>-10<sup>8</sup>) of each strain using the proteinase K/
  Nonidet P40 method described by Denamur, et al., <u>J. Gen.</u>
  Microbiol. 137:2525-2530 (1991), incorporated herein by
  reference, and further purified by phenol/chloroform
  extraction and salt precipitation. Purified Chlamydia
- 25 pneumoniae (AR-139) genomic DNA was purchased from Advanced Biotechnologies Inc.

To determine the presence of the HMW protein gene in these strains, amplification reactions were programmed using total *Chlamydia* DNA as template and the HMW protein

30 segment-specific oligonucleotide primer (21mers) sets listed below.

SEO ID No.20 5' - ATG-GTT-CCT-CAA-GGA-ATT-TAC-G - 3'
SEO ID No.21 5' - GGT-CCC-CCA-TCA-GCG-GGA-G - 3'

Briefly, standard PCR amplification reactions (2 mM  $35~{\rm Mg^{2^{+}}},~100~\mu{\rm mol}$  dNTPs, 0.75 units AmpliTaq polymerase, 50  $\mu{\rm l}$  final volume) were programmed using approximately 15  $\mu{\rm l}$  of the crude C.trachomatis DNA extracts (~10  $\mu{\rm l}$  of the

commercially available C. pneumoniae DNA) and ~20 pmol of each forward and reverse HMW protein-specific amplification primers of SEQ ID No. 20 and 21. Amplification of small target sequences ( $\leq$  2 Kbp) was achieved using a 32-cycle,

- 5 three-step thermal profile, i.e. 95°C, 30 sec; 60°C, 30 sec, 72°C, 1 min. Amplification of longer target sequences for ORF-cloning and sequencing was carried out using the crude DNA extracts in an identical fashion except that a MAbinactivated Tth/Vent DNA polymerase enzyme combination was
- 10 employed (Advantage PCR, Clontech) and a 72°C extension time
  was used that matched the size of the desired PCR product
  plus 2 min (i.e. desired PCR product = 6Kbp, extension time =
  8 min).

Both conventional and long-distance PCRs were

- 15 carried out using 0.2 ml thin-walled polypropylene microcentrifuge tubes in an ABI 2400 Thermal Cycler (Perkin-Elmer). Following thermal cycling, aliquots (~20  $\mu$ l) of the reactions were analyzed and PCR products identified by standard agarose gel electrophoresis (0.8% agarose in TAE
- 20 buffer) and ethidium bromide staining. The results showed that the HMW protein is highly conserved in clinically relevant serovars; the HMW gene was present in all C hlamydia samples strains tested, including serovars B, Ba, D, E, F, G, H, I, J, K, L<sub>1</sub>, L<sub>2</sub> and MoPn and in C. pneumoniae.

25

### 8.8. EXAMPLE 8: DETERMINATION OF SEQUENCE VARIATION

To establish the degree of DNA and amino acid sequence variation among different *Chlamydia* strains, the gene for the HMW protein was PCR-cloned from both a *C*.

30 trachomatis B serovar (representing the trachoma group of organisms) and from a C. trachomatis F serovar (representing the low infectivity STD biovars) and compared to the HMW protein consensus C. trachomatis  $L_2$  sequence.

Briefly, LD-PCR was used to generate ~6Kbp HMW

35 protein-specific DNA fragments from C. trachomatis B and F
genomic DNA that contain the complete coding sequence for the
mature HMW protein. Amplification conditions for these LD-

PCR exercises were as described in Example 6. The reverse amplification primer employed in these reactions (p316Kpn-RC, 56mer), listed as SEQ ID No. 13, is complementary to a sequence located ~3 Kbp downstream of the predicted HMW

- 5 protein termination codon. As an aide to cloning the desired ~6 Kbp amplimer, a single KpnI restriction endonuclease site 5' to the chlamydial sequence was engineered into the p316Kpn-RC primer. The forward amplification primer used for these reactions (p306Kpn-F, 56mer), listed as SEQ ID No. 12,
- 10 contains the sequence complementary to the first 10 amino acid residues (30 nucleotides) specifying the mature HMW protein as well as a 5' sequence specifying a KpnI site.
  p306Kpn-F was designed such that the sequence encoding the N-terminus of the mature HMW protein could be linked in-frame
- 15 to a hexa-His affinity domain encoded downstream of the highly efficient trc promoter on the E.coli expression vector pTrcHisB (ClonTech) when the ~6 Kbp amplimer was inserted into the KpnI site of this vector.
- 20 SEQ ID No.12 5'-AAG-GGC-CCA-ATT-ACG-CAG-AGG-GTA-CCG-AAA-TTA-TGG-TTC-CTC-AAG-GAA-TTT-ACG-AT-3'
  - SEO ID No.13 5' -AAG-GGC-CCA-ATT-ACG-CAG-AGG-GTA-CCC-TAA-GAA-GAA-GGC-ATG-CCG-TGC-TAG-CGG-AG-3'

25

- The ~6 Kbp HMW protein products were purified using silicagel spin columns (QIAGEN) and the fragments subjected to two 8-10 hour cycles of KpnI digestion using a 10-fold excess of KpnI (~10 units per 1  $\mu$ g of purified fragment, 37°C).
- 30 Following the second digestion, residual restriction enzyme activity was removed using QIAGEN spin columns and the ~6 Kbp KpnI HMW protein fragments cloned into the pTrcHisB plasmid which had been previously digested to completion with KpnI and treated with calf intestinal phosphatase to prevent 35 vector religation.

Vector/insert ligations were performed in a ~50  $\mu l$  final reaction volume (50 mM Tris-HCl, pH 7.00; 10 mM NaCl; 1

PCT/US98/20737
WO 99/17741

mM ATP; 0.5 mM DTT) at 25°C for ~2 hours using T4 DNA ligase (~10 units/reaction) and a vector:insert molar ratio of approximately 1:5. Following ligation, aliquots (~50 ng ligated DNA) was used to electroporate a competent E.coli
5 host, e.g. E.coli TOP10. Plasmid-harboring transformants were selected by plating electrotransformed cells onto LB agar containing 100 μg/ml ampicillin. Ampicillin-resistant (Ap<sup>R</sup>) transformants appearing after a ~18-24 hour incubation period at 37°C were picked at random and restreaked onto the
10 same selective media for purification.

A single, purified Ap<sup>R</sup> colony from each initial transformant was used to inoculate ~5ml of LB broth and grown overnight at 37°C in a incubator shaker with mild aeration (~200 rpm). Cells from broth cultures were harvested by

15 centrifugation and used to prepare small quantities of plasmid DNA. Commercially available reagents (QIAGEN Plasmid Mini Kits) were employed for these plasmid extractions. Plasmid derivatives carrying inserts were presumptively identified by electrophoresing the non-digested plasmid DNA

20 in agarose gels (0.8% agarose in TAE buffer) and identifying derivatives greater in size than vector plasmid. Insert-containing derivatives were confirmed and the orientation of the HMW protein inserts relative to vector sequences were determined using appropriate restriction endonucleases (KpnI, EcoRI, HindIII, BamHI, etc.), either separately or together

The DNA sequence of the C. trachomatis B and F HMW protein genes were obtained for both strands using "sequence walking" the asymmetric dye-terminator PCR cycle sequencing methodology (ABI Prism Dye-Terminator Cycle Sequencing, Perkin-Elmer) described in Example 4. Reactions were programmed with plasmid mini-prep DNA and individual HMW protein sequence-specific primers that were employed in the sequencing of the HMW protein gene from the L2 type strain.

35 DNA sequence data were collected using the ABI 310 Sequenator and analyzed automatically on a PowerMAC computer and appropriate computer software as described in Example 4.

Individually autoanalyzed DNA sequences were edited manually for accuracy before being merged into a consensus sequence "string" using AutoAssembler software (Perkin-Elmer). Both strands of the HMW protein gene from the *C. trachomatis* B and 5 F serovars were sequenced and these data compiled to create composite consensus sequences for both the *C. trachomatis* B and F HMW protein genes. These sequences are listed as SEQ ID Nos.: 14 and 15. Sequence comparisons of the L<sub>2</sub>, F and B strains are presented in Figure 6.

10

5.

#### 8.9. EXAMPLE 9: PRODUCTION OF RECOMBINANT PROTEIN

To produce sufficient quantities of recombinant HMW protein for both immunogenicity and animal protection studies, the HMW gene has been PCR cloned into suitable

15 E.coli and baculovirus expression systems. Large quantities of rHMW protein are produced in an E.coli - based system as a chimeric fusion protein containing an N-terminal (His)<sub>6</sub> affinity purification domain. The complete HMW protein open reading frame (ORF) was PCR-cloned from the C. trachomatis L<sub>2</sub>

20 genome as a single KpnI fragment and fused in the proper orientation and in the correct reading frame to the (His)<sub>6</sub> affinity purification domain encoded on the high expression plasmid vector pTrcHisB (CloneTech) as described in Example

25 The (His)<sub>6</sub> affinity purification domain is part of a high expression locus consisting of the highly efficient tac promoter (IPTG-inducible) and consensus Shine and Delgarno ribosome binding site (RBS) located immediately upstream of the (His)<sub>6</sub> affinity purification domain. The HMW protein 30 genes from C. trachomatis LGV L<sub>2</sub>, C. trachomatis B, and C.trachomatis F were PCR cloned as ~3.0 Kbp fragments. The forward primer (56-mer) used in these reactions was designated p306Kpn-F and contains sequences complementary to the first 10 N-terminal amino acid residues of the mature HMW protein, listed as SEQ ID No 12. In addition to the HMW protein coding sequences, this forward primer also carries a

unique KpnI restriction site located optimally located

PCT/US98/20737 WO 99/17741

upstream of the first residue of the mature HMW protein(Glu) for proper fusion to the (His), affinity purification domain encoded on the vector plasmid, and 5' terminal 6 base G/C clamp for effective amplification and a 12 base internal 5 spacer for effective endonuclease recognition/digestion. The reverse PCR primer, designated p316Kpn-3RC, contains a reverse complement sequence to a C. trachomatis sequence located ~0.2Kbp downstream of the HMW protein termination codon, listed as SEQ ID No. 14. As with p306Kpn-F, the 10 reverse primer also contains a KpnI restriction site 5' to the C. trachomatis sequences, a 6 base G/C clamp, and a 12 base internal spacer.

To obtain acceptable yields of the HMW protein ORF product (about 3,500bp), PCR amplification was performed

15 using a mixture of thermostable DNA polymerases consisting of T. thermophilus DNA polymerase as the primary amplification polymerase and a minor amount of a second high fidelity thermostable DNA polymerase to provide additional 5'-3' proofreading activity (Advantage Polymerase, CloneTech). An anti-Tth DNA polymerase antibody was added to the reaction mixture to provide automatic 'hot-start' conditions which foster the production of large (>2 Kbp) amplimers.

Genomic DNA from the various *C.trachomatis* strains was isolated from EBs as described in the example above and 25 used to program these reactions. Following amplification, the desired reaction products were purified from excess primers using commercially available silica-gel spin columns and reagents (QIAGEN) and digested to completion with an excess of KpnI (~10 units per 1μg DNA). The purified and 30 digested KpnI HMW protein ORF was then be cloned into the KpnI predigested pTrcHisB expression plasmid (5:1, insert:vector ratio). Aliquots from the ligation reaction were then used to electrotransform a suitable *E.coli* host (e.g. TOP10).

Mini-prep DNA from ampicillin-resistant transformants picked at random were prepared, digested to completion with KpnI, HindIII, or a combination of both and

35

examined for the presence and orientation of the ~3.2 Kbp HMW protein ORF insert by agarose gel electrophoresis and ethidium bromide staining. Mini-prep DNA was used to program asymmetric PCR DNA sequencing reactions as described in 5 example(s) above to confirm the fidelity of the junction formed between the HMW protein fragment and the (His)<sub>6</sub> affinity purification domain of the vector. Plasmid pAH342 was one derivative isolated by these procedures, which contains the HMW protein gene ORF from C. trachomatis L<sub>2</sub> and 10 is represented by nucleotides 446 to 3421 in Figure 2.

Recombinants were grown in 2X-YT broth containing 100 μg/ml Ap to mid-log phase (~0.5 O.D.<sub>600</sub>) and induced with IPTG (1mM final) for an additional 4-5 hours to activate transcription from the vectors *trc* promoter. Cells were 15 harvested by centrifugation and crude cell lysates prepared by lysis using a French pressure cell.

Alternatively, expression of rHMW protein may be obtained by using a baculovirus expression system. Here, the HMW protein ORF from *C.trachomatis* L<sub>2</sub> and *C.trachomatis* F were 20 PCR-cloned as ~3 Kbp PCR products into a baculovirus transfer vector (e.g. pFastBacHTb) that had been previously digested to completion with KpnI and treated with CIP to minimize vector religation in essentially the same manner as described for pTrcHisB. The HMW protein expression cartridge generated 25 in this cloning exercise (i.e. the baculovirus polyhedron promoter, N-terminal (His)<sub>6</sub> affinity purification domain, HMW protein gene ORF) was then transferred to the baculovirus genome by site-specific transposition using a commercially available bacmid system (Bac-to-Bac, Gibco)

Briefly, the HMW protein baculovirus expression plasmid was used to transform competent *E. coli* DH10bac (Gibco) cells containing a bacmid (a hybrid baculovirus-plasmid replicon) to gentamicin resistance using standard transformation and selection methodologies. Transformants where the HMW protein expression cartridge had successfully transposed from the expression plasmid to the appropriate receptor site within the lacZ gene located on the bacmid

PCT/US98/20737 WO 99/17741

replicon were identified using a standard IPTG/X-gal blue-white selection.

White, Gm<sup>R</sup> transformants were picked at random and restreaked for purification. Bacmid DNA was prepared from 5 broth cultures by the method of Ish-Horowitz, N. A. R. 9:2989-2993 (1981) incorporated herein by reference, and is used to transfect Spodoptera frugiperda 9 cells. Following plaque purification, recombinant HMW protein baculovirus is used to infect large scale Spodoptera suspension cultures. A 10 yeast expression system is used to generate a glycosylated form of HMW protein.

## 8.10. EXAMPLE 10: PURIFICATION OF RECOMBINANT PROTEIN

Recombinant HMW protein was purified to homogeneity

15 using standard preparative immobilized metal affinity
chromatography (IMAC) procedures. Briefly, an E. coli strain
harboring an expression plasmid containing HMW protein gene
was grown in Luria broth in a 51 fermenter (New Brunswick) at
37°C with moderate aeration until mid-log phase (~0.5 O.D.600)

- 20 and induced with IPTG (1mM final) for 4-5 hours. Cell paste was collected, washed in PBS and stored at -20°C. Aliquots of frozen cell paste (~9-10 grams wet weight) were suspended in ~120 ml of D-PBS by mechanical agitation and lysed by passage through a French pressure cell (2X, 14,000psi, 4°C).
- 25 Soluble protein was then removed from rHMW protein inclusion bodies by high speed centrifugation (~10,000Xg, 4°C, 30min).

The insoluble pellet containing rHMW protein was suspended in ~20ml of ice cold D-PBS by homogenization and centrifuged as above. Washed rHMW protein inclusion bodies

- 30 were then denatured by suspension in a sodium phosphate buffer (0.1 M, pH 7.0) containing 6M guanidine hydrochloride and loaded onto a Ni<sup>2+</sup>-affinity column (1.5 cm X 25 cm, bed volume ~15 ml) prepared from Fast-Flow Chelating Sepharose (Pharmacia) and charged with Ni<sup>2+</sup>or Zn<sup>2+</sup> ions by standard
- 35 procedures. Unbound material was removed by washing the column with ~5-10 column volumes of a sodium phosphate buffer (0.1 M, pH 7.0) containing 8M urea.

Recombinant HMW protein bound to the affinity resin by virtue of the N-terminal (His), affinity purification domain was eluted using a pH 4.0 sodium phosphate/8M urea buffer (~20 ml). Eluted material was neutralized by the 5 addition of 1.0 M Tris-HCl (~2.5 ml, pH 7.5) and dialyzed against TE buffer containing SDS (0.5%) to remove the urea. Dialyzed material was concentrated using a Centricon-30 centrifugal concentrator (Amicon, 30,000 MWCO) and mixed with a 1/5 volume of 5X SDS gel sample buffer containing 1 mM 2-10 mercaptoethanol (Lammeli) and boiled at 100°C for 5 minutes.

- Samples were loaded onto Tris/glycine preparative acrylamide gels (4% stacking gel, 12% resolving gel, 30:0.8 acrylamide:bis solution, 3mm thickness). A prestained molecular weight standard (SeeBlue, Novex) was run in
- 15 parallel with the rHMW protein samples to identify size fractions on the gel. The area of the gel containing proteins having molecular masses of ~50-70 Kdal was excised and the proteins electroeluted using an Elu-Trap device and membranes (S&S) as specified by the manufacturer.
- 20 Electroeluted protein was dialyized to remove SDS. The protein concentration of the sample was determined using a Micro-BCA system (Pierce) and BSA as a concentration standard. The purity of rHMW protein was determined using conventional SDS-PAGE and commercially available silver
- 25 staining reagents (Silver Stain Plus, Novex) as shown in Figure 4.

The apparent molecular weight of the isolated mature rHMW is about 105-115 kDa as determined by SDS-PAGE.

#### 30 8.11. EXAMPLE 11: PREPARATION OF ANTIBODIES TO HMW PROTEIN

Polyvalent antisera directed against the HMW protein were generated by vaccinating rabbits with the purified HMW protein or fragments thereof. Each animal was given a total of three immunizations of about 250  $\mu g$  HMW

35 protein or fragment thereof per injection (beginning with complete Freund's adjuvant and followed with incomplete Freund's adjuvant) at approximately 21 day intervals. At

PCT/US98/2073<sup>7</sup> WO 99/17741

each immunization, approximately half of the material was administered intramuscullarly (i.m.) and half was injected intranodally. Fourteen days after the third vaccination a fourth booster of about 100 μg HMW protein was given i.m. and the animals exsanguinated 7-10 days later. Anti-HMW protein titers were measured by ELISA using purified HMW protein (1.0 μg/well) or C. trachomatis L<sub>2</sub> EBs (whole and crude protein extracts) as capture ligands. Immunogen specific IgG ELISA titres of 1/320,000 were observed using purified rHMW truncated protein and 1/2500 using either EBs or RBs.

Serial dilutions of antisera were made in PBS and tested by ELISA in duplicate. Goat HRP-conjugated anti-rabbit antibody diluted 1/1000 was used as the second reporter antibody in these assays. Titers are expressed as

- 15 the greatest dilution showing a positive ELISA reaction, i.e. an O.D.<sub>450</sub> value >2SD above the mean negative control value (prebleed rabbit sera). Hyperimmune antisera was then used to probe Western blots of crude EB or RB extracts as well as 1.0% OGP EB extract preparations to determine whether other
- 20 C. trachomatis serovars and Chlamydia species express the HMW protein. C. trachomatis serovars B, Ba, D, F, G, I, J, K,  $L_1$ ,  $L_2$ ,  $L_3$ , MoPn and Chlamydia pneumoniae were tested and found to have a protein of an apparent molecular weight of 105-115 KDa reactive with antisera generated against HMW protein.

### 25 8.12. EXAMPLE 12: SURFACE LOCALIZATION

Surface localization of the HMW protein on different Chlamydia strains and derivatives were examined by indirect fluorescence antibody (IFA). IFA was performed using the procedures generally known in the art using

30 hyperimmune anti-HMW protein as the primary antibody. Hak cells infected with whole EBs from one of  $\mathit{C. trachomatis}$  serovars  $L_2$ , B, and F,  $\mathit{C. pneumoniae}$  or  $\mathit{C. psittaci}$  are achieved by the following method.

McCoy or Hak cells were grown to confluence in D-35 MEM media on 12 mm plain coverslips inside 24 well tissue culture plates then centrifugally inoculated with ~5X10<sup>4</sup> inclusion forming units (IFU) of the *C. trachomatis* strain

N11 (serover F). After ~24 hours incubation, the culture media was removed and infected cells fixed inmethanol for 10 min. The fixed monoloayer was then washed with PBS (1X) to remove fixative and overlayer with >300 µl of anti-60Kdal

5 truncated HMWP rabbit antibody that had been diluted ~1/100 in PBS. After 1 hour incubation with the primary antibody, the cells were washed gently with PBS then incubated for ~30 min. with a 1/200 dilution of a mouse anti-rabbit IgG antibody conjugated with FITC. The second antibody was

10 diluted using a PBS solution containing 0.0091% Evans Blue as a counter stain to visualize the monolayer. Cells were washed 2X in PBS to remove the secondary antibody, the coverslips removed from the culture plates, and mounted onto

Identical cell samples stained with prebleed rabbit antibody or FITC-conjugated second antibody alone were processed in parallel and served as antibody specificity (negative) controls. Counterstained samples were examined at a 1000-X magnification with a Zeiss Axioskop photomicroscope equipped with plan-neoflur objectives. Results using C. trachomatis NII (F serovar) are shown in Figure 7. The results show that enhanced fluorescence of samples stained with HMW protein antibody compared to the controls confirmed the surface location of the HMW protein. Furthermore,

25 fluorescence of samples stained with HMW protein antibodies show binding to surface localized HMW protein from L2, B and

#### 9. **EXAMPLE:** IN VITRO NEUTRALIZATION MODEL

MoPn serovars and C. pneuomoniae.

30 The *in vitro* neutralization model has been used to show that protective antiserum inhibited chlamydial infection (neutralization) of various tissue culture cell lines.

Animal models are also essential for testing vaccine efficacy with both small animal (non-primate) and primate models

35 necessary for preclinical evaluation. The guinea-pig has been used for studying experimental ocular and genital

infection by the Guinea-pig inclusion conjunctivitis agent (GPIC), C. psittaci.

The mouse offers a consistent and reproducible model of genital tract infection using human genital tract 5 isolates. This mouse model is a generally accepted preclinical assay, and was used to evaluate MOMP as a subunit vaccine. Another model is known as the primate model of trachoma infection wherein the induction of secretory IgA was shown to be a prime component of protection. Vaccinogenic ability of new subunit antigen candidates is determined using the above-mentioned generally accepted in vitro neutralization and animal model systems.

As a preliminary exercise to the animal protection studies, hyperimmune anti-HMW antibody was evaluated for its ability to block the infectivity of various *C.trachomatis* serovars (e.g. L<sub>2</sub>,B,F) in vitro. Although McCoy cells were used to propagate *Chlamydia*, these cells also allow antibodymediated uptake via Fc receptors. Therefore, to evaluate anti-HMW antibody inhibition of infectivity, Hak cells, which do not display Fc receptors, were used in these analyses.

Cells were grown on coverslips in 24-well plates to a subconfluent monolayer (about 90% confluency =  $1\times10^5$  cells/ml) at 37°C in 5% CO<sub>2</sub>. Anti-HMW-antibody was diluted to about 100  $\mu$ g/ml (total protein) in sucrose-phosphate-

- 25 glutamate (SPG) buffer and then serially diluted in SPG buffer. Frozen aliquots of pretitered *Chlamydia* was diluted in SPG buffer to about  $2X10^4$  IFU/ml. EBs were premixed with the diluted anti-HMW-antibody to about 10-20 IFU/ $\mu$ l and incubated 30 minutes at  $37^{\circ}$ C on a rocking platform.
- Prepared Hak cells were washed in HBSS and then incubated with the anti-HMW-antibody/Chlamydia EB mixture in triplicate for each antibody using 500 IFU/ml. Plates were incubated for 2 hours at 37°C, then the inoculum removed and plates washed 3 times with HBSS. Tissue culture media
- 35 containing 1  $\mu$ g/ml of cyclohexamide was added and plates incubated for about 24-36 hours at 37°C in 5% CO<sub>2</sub> to allow inclusion bodies to develop. After incubation, the media was

removed and cell monolayers washed 3X in PBS. Plates were fixed in methanol for 20 minutes and re-washed in PBS.

Cells were stained to visualize inclusions by incubating with anti-Chlamydia LPS antibody (diluted about 5 1:500, ViroStat), cells washed 3 times in PBS, followed by incubation with FITC-conjugated goat secondary antibody for 30 minutes at 37°C. Coverslips were washed, air dried, and mounted in glycerol on glass coverslips. Inclusions were counted in five fields through the midline of the coverslip 10 on a Zeiss fluorescence photomicroscope. Results are reported as the percent reduction of inclusion-containing cells with respect to a heterogenous antibody control (rabbit prebleed sera).

# 15 10. EXAMPLE: VACCINE EFFICACY (Mouse Model of Salpingitis and Fertility)

#### 10.1. METHODS

#### 10.1.1. IMMUNIZATION AND CHALLENGE

The Tuffrey murine infertility model was employed 20 to evaluate the efficacy of rHMWP to protect animals against Chlamydia trachomatis-induced salpingitis and infertility. Three groups of 17 female C3H HeOuJ mice (~6 weeks of age, Jackson Labs) were employed for this evaluation. The test group of 17 animals was immunized at weeks 0, 2, and 3 by

- 25 intranasal administration of ~20  $\mu$ l of a vaccine formulation containing approximately 10-12  $\mu$ g of gel-purified rHMWP and ~5  $\mu$ g mLT (SmithKline Beecham) as adjuvant. Prior to immunization mice were sedated using an anesthesia cocktail consisting of 16% Ketaject and 16% Xylaject in 68% pyrogen-
- 30 free PBS (100  $\mu$ l i.p./animal). Sedated animals were placed on their backs and using a standard laboratory pipette administered the vaccine formulation; ~10  $\mu$ l of the vaccine solution per nostril with a 5-10 minute wait period between applications.
- Two groups of 17 female mice (per test group) were immunized similarly but with a preparation containing only 5  $\mu$ g mLT (i.e. adjuvant only, no antigen). One of these groups

was subsequently challenged with C.trachomatis ( sham immunized, infected) and served as the negative fertility control while the other group was not challenged (sham immunized, sham infected) and served as the positive fertility control.

5 fertility control. At week 4, all animals were administered a single i.p. dose of progesterone (2.5 mg in pyrogen-free PBS, Depo-Provera, Upjohn) to stabilize the uterine epithelium. At week 5, animals immunized with rHMWP and animals in the 10 negative control group were infected by bilateral intrauterine inoculation with ~5X10⁵ inclusion forming units (IFU) of C.trachomatis NI1 (serovar F) in 100  $\mu$ l of sucrose phosphate glutamate buffer (SPG). To mimic the manipulations to the reproductive tract experienced by the other two 15 groups, animals in the positive control were bilaterally inoculated with 100  $\mu l$  of a McCoy cell extract that contained no C.trachomatis. At week 7, 5-7 animals from each group were sacrificed by CO2 asphyxiation and the complete genital tract (both upper and lower reproductive tracts) removed for 20 histopathological analysis. At week 9, the remaining females from each group were caged with 8 - 10 week old male C3H mice for a 2 month breeding period to assess fertility (1 male for every 2 females per cage with weekly rotation of the males within each group, animals from different experimental groups

- 25 were not mixed). Palpation and periodic weighing were used
   to determine when animals in each pair became pregnant. The
   parameters used to estimate group fertility were: F, the
   number of mice which littered at least once during the mating
   period divided by the total number of mice in that study
  30 group; M, the number of newborn mice (born dead or alive)
- divided by the number of litters produced in that group during the mating period; and N, the number of newborn mice (born dead or alive) divided by the total number of mice in that group.

### 35 10.1.2. <u>HISTOPATHOLOGY</u>

Genital tracts were treated for  $\geq$  24 hrs in Bouin's fixative, progressively dehydrated in 50%, 70%, and 100%

methanol, soaked in toluol, and either paraffin embedded or
directly embedded in OCT compound (Tissue-TEK, Miles) and
subsequently snap frozen in liquid nitrogen. Tissue sections
(~6 μm) were stained with hematoxylin and eosin (after

5 deparaffinization of the Bouin fixed samples). Inflammatory
changes in the oviducts and ovaries were graded as follows:
0, no apparent inflammatory reaction; 1, a few mononuclear
cells infiltrating the periovarial space or the submucosa of
the oviduct; 2, same as 1 but to a greater extent; 3, same as
10 2 but with a thickened oviductal submucosa and the presence
of inflammatory cells in the oviductal lumen; 4, same as 3
but to a greater extent. Inflammation in the cervix/vagina
was scored based on the level of the intraepithelial
infiltrate observed.

# 15 10.1.3. <u>DETERMINATION OF rHMWP-SPECIFIC HUMORAL</u> RESPONSES

Blood samples were collected periodically during the immunization and challenge phases by retroorbital bleeding and serum prepared by centrifugation. Vaginal

20 secretions were collected by repeated injection of 50  $\mu$ l of sterile PBS into the vagina with a standard laboratory pipettor and immediately withdrawing the solution. Two-to-three injection/withdrawal cycles were performed.

Quantitation of antibody (Ab) responses by ELISA 25 were performed as described in Section 8.11. Microwell ELISA plates (Maxisorb, NUNC) for determining Ab levels were coated overnight at 4°C with ~0.5-1.0  $\mu g$  of gel-purified rHMWP per well in 10mM carbonate/bicarbonate buffer (pH 9.6), washed with PBS containing 0.1% Tween-20 (washing buffer) and

- 30 blocked for ~1hr at 37°C with a PBS solution containing 3% BSA. For the determination of antigen-specific serum IgG levels, test sera were serially diluted in washing buffer containing 0.5% BSA and aliquots (100 μl) incubated in the antigen-coated wells for ~2hr at 37°C. The plates were then
- 35 washed and incubated for ~1hr at 37°C with a horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG second antibody (Sigma). A HRP-conjugated goat anti-mouse IgA

PCT/US98/2073<sup>7</sup>
WO 99/17741

secondary antibody was used to detect the presence of rHMWP-specific IgA in vaginal secretions. After incubation with the appropriate secondary Ab, the plates were washed and incubated for ~20-30 minutes at room temperature with TMB substrate (Sigma). Reactions were stopped by the addition of 2M H<sub>2</sub>SO<sub>4</sub> and the absorbance determined at 450 nm on a Molecular Devices SpectroMax microplate reader. Titers were determined as the reciprocal of the sample dilution corresponding to an optical density of 1.0 at 450 nm.

# 10 10.1.4. <u>DETERMINATION OF rHMWP-SPECIFIC CELLULAR</u> RESPONSES

Groups of 6 female C3H HeOuJ mice (Jackson Labs) were sedated and immunized at weeks 0, 2, and 3 by intranasal administration with the rHMWP + mLT vaccine as described in

- 15 Section 10.1.3. At weeks 4 and 5 immediately prior to progesterone treatment and intrauterine challenge, respectively, 3 animals from each group were sacrificed by CO<sub>2</sub> asphyxiation and spleens aseptically removed and single cell suspensions prepared using conventional methodologies.
- 20 Spleen cells from immunized animals were analyzed separately. For both the positive control group (sham immunized and sham infected) and the negative control group (sham immunized, infected) spleen cells were pooled and tested for restimulation.
- For the measurement of spleen cell proliferation, spleens were ground (5 to 10 rounds) in 5ml of RPMI 1640 Glutamax I supplemented with 10% fetal calf serum, 25 mM HEPES, 50 U/ml penicillin, 50  $\mu$ g/ml streptomycin, 1 mm sodium pyruvate, nonessential amino acids, and 50  $\mu$ M 2-
- 30 mercaptoethanol (Gibco-BRL). Live cells were counted by Trypan Blue staining and diluted in the same media to reach a density of 1.0 2.0X10<sup>6</sup> cells/ml (Falcon 2063 polypropylene tubes). Triplicate cultures were set-up in round bottom 96-well culture plates (Nunclon, Nunc) using ~5X10<sup>5</sup> responder
- 35 cells per well in 200  $\mu l$  of media. Cells were stimulated with either 1.0  $\mu g/ml$  of rHMWP (antigen-specific proliferation) or with 4  $\mu g/ml$  concanavalin A (Boerhinger Mannheim) as a

positive stimulation control; unrestimulated cell cultures were used as a negative control of cellular activation.

After 72-96 hours of incubation at 37°C in 5% CO<sub>2</sub> cells were pulsed labelled for ~18hrs with 1.0 μCi ³H-thymidine

5 (Amersham) per well. Pulsed cells were harvested onto glassfiber sheets using a Tomtec Cell Harvester (Mk III) and counted for beta-emission in a 3-channel Wallac 1450 Trilux Liquid Scintillation Counter. The stimulation index (SI) for a sample (individual or pooled) was defined as the mean of the antigen or ConA-stimulated T-cell uptake of ³H-thymidine for triplicate wells divided by the mean of the unstimulated uptake for triplicate wells. SIs for both antigen-specific (rHMWP-specific) and ConA-specific proliferation were

15

#### 10.2. RESULTS

determined.

# 10.2.1. <u>EFFECT ON MOUSE FERTILITY AFTER A</u> HETEROTYPIC CHALLENGE

Evidence that mucosal immunization with rHMWP

20 combined with mLT can afford protection against infertility caused by a human clinical isolate of C.trachomatis (strain NI1, serovar F) is shown in Table 1. Animals immunized with the rHMWP displayed a significantly higher fertility rate (70%, i.e. number of fertile females in group/total number of animals in the group) than animals in the negative control group (30%, sham immunized and infected). Similarly, the rHMWP immunized group produced more offspring and exhibited a group fecundity greater than those observed in the negative control group (51 vs 24 offspring and 5.1 ± 4.7 vs 2.4 ± 30 4.6 fecundity scores, respectively). As a group, animals

30 4.6 fecundity scores, respectively). As a group, animals immunized with the rHMWP vaccine displayed a comparable fertility rate, total number of offspring, and a fecundity score to those observed in the sham infected positive control group (80% fertility rate, 56 total offspring, 4.9 ±2.7
35 fecundity).

The protection against C.trachomatis-induced infertility obtained in this experiment also demonstrates the

utility of the rHMWP to afford cross-biovar and cross-serovar protection against C.trachomatis disease. The recombinant HMWP antigen employed in this experiment was cloned from a strain belonging to the C.trachomatis lymphogranuloma

5 venereum (LGV) group (strain L2) which causes systemic as well as more localized mucosal infections of the eye and genital tract. The C.trachomatis challenge organism used in these experiments, strain NI1 is an F serovar organism that belongs to the trachoma biovar which causes numerous

10 urogenital tract infections.

Table 1. Fertility Assessments Observed After ~2 Breeding Cycles

5	Group	Number of Animals per Group	Percent Fertile Animals	Number of Off- spring	Group Fecundity¹ (Mean + SD)
	rHMWP- Immunized	10	$70$ $p = 0.089^{2}$	51	$5.10 \pm 4.68  p = 0.105^3$
10	Sham Immunized Sham Infected (Positive Control)	10	80 p = 0.035	56	$4.90 \pm 2.70$ p = 0.078
3.5	Sham Immunized Infected (Negative Control)	10	30	24	2.40 <u>+</u> 4.61
15					

Mean number of pups per group

20

### 10.2.2. EFFECT ON CELLULAR IMMUNE RESPONSE

immune system was demonstrated using a conventional spleen
cell proliferation assay. When spleen cells were tested
during week 4 (immediately prior to progesterone treatment)
(Table 2) and week 5 (~7 days after hormone treatment but
before intrauterine challenge) (Table 3), all samples
collected from rHMWP-immunized animals developed a strong
antigen-specific proliferative immune response. The antigenspecific Stimulation Indexes (SIs) obtained prior to
progesterone treatment from rHMWP-immunized animals were
equal to or greater than the SIs obtained via mitogenic
stimulation with ConA (mean values for antigen and ConA
stimulation obtained from 3 rHMWP-immunized animals: 26.2 vs
18.4, respectively). Spleen cells obtained from either sham

Fisher's exact test, one-sided, 95% confidence interval p-values are given relative to the negative control

Student's t-test, unpaired, Gausian distribution, 95% confidence interval p-values are given relative to the negative control

immunized animals or naive animals (i.e. animals that were
not exposed to either the rHMWP antigen or mLT) did not
respond to in vitro restimulation with the rHMWP material,
thus establishing the specificity of the proliferative

5 response observed in the immunized animals. Progesterone
treatment did not affect the antigen-specific proliferative
response observed in rHMWP immunized animals. Antigenspecific SIs obtained with spleen cells obtained after
hormone treatment were greater than obtained via mitogenic
10 stimulation (mean values for antigen and ConA stimulation
obtained from 3 rHMWP-immunized animals: 92.4 vs 37.8,
respectively). Again samples collected from sham immunized
or naive animals failed to demonstrate any antigen-specific
proliferative response.

Table 2. rHMWP-Specific Cell Proliferation Before Hormone Treatment

20	Group	Cell Proliferation (cpm) Untreated / ConA / rHMWP	Stimulation Index (Treated cpm/ Untreated cpm) ConA / rHMWP
-	rHMWP Immunized Animal #1	1557 / 20739 / 65741	13.3 / 42.2
25	rHMWP Immunized Animal #2	1508 / 26975 / 28361	17.9 / 18.8
	rHMWP Immunized Animal #3	1238 / 29991 / 23453	24.0 / 18.9
30	Sham-Immunized Animals (Pooled)	1687 / 30546 / 1292	18 / <1.0
	Naive Animals (Pooled)	335 / 23886 / 838	71 / 2.5

Table 3. rHMWP-Specific Cell Proliferation After Hormone Treatment

5	Group	Cell Proliferation (cpm) Untreated / ConA / rHMWP	Stimulation Index (Treated cpm/ Untreated cpm) ConA / rHMWP
	rHMWP Immunized Animal #1	767 / 15934 / 97458	20.8 / 127.0
10	rHMWP Immunized Animal #2	546 / 17212 / 28172	31.5 / <b>51.6</b>
	rHMWP Immunized Animal #3	297 / 18139 / 29300	61.1 / 98.6
15	Sham-Immunized Animal (Pooled)	273 / 18094 / 150	66.3 / <1.0
	Naive Animals (Pooled)	345 / 16740 / 1341	48.5 / 3.9

## 10.2.3. <u>EFFECT ON HUMORAL IMMUNE RESPONSE</u>

To demonstrate that immunization with the full length rHMWP produces a humoral immune response, IgG titers were measured by ELISA on sera collected at week 5 immediately prior to challenge (i.e. approximately 2 weeks after the third immunization). As shown in Table 4, immunization of C3H mice with three doses of ~10-12 μg rHMWP produced detectable levels of anti-rHMWP IgG in all animals. Vaginal secretions were also collected from these animals at the same time and tested for the presence of anti-rHMWP mucosal IgA. Antigen-specific vaginal IgA was detected in three animals (Table 4).

Table 4. rHMWP-Specific Humoral Response

-	rHMWP Immunized Animal	Anti-rHMWP Serum IgG ELISA Titer	Presence of Anti-rHMWP Vaginal IgA
5 -	4.4	5,000	
-	4.5	6,000	
-	4.6	12,000	+
-	4.7	130	
10	4.8	100	
-	4.9	54,000	+
•	4.10	670	
•	4.11	100	
•	4.12	570	
15	4.13	100,000	+
	4.14	4,500	
	4.15	400	
	4.16	1,600	
	4.17	2,500	
20	4.18	700	
	4.19	70,000	
	4.20	500	
	4.21	2,000	
25	4.22	18,000	
	4.23	3,000	
	Mean <u>+</u> S.D.	18.5 ± 29.6	

30

## 11. EXAMPLE: CONSTRUCTION OF PJJ701

A plasmid containing the entire  $C.trachomatis\ L_2$  HMWP gene was constructed by selectively removing the EcoRI site upstream to the HMWP N-terminus in pAH306 (Described in Section 8.4). This was accomplished by digesting pAH306 to completion with XhoI and then religating the plasmid to

create pAH306-Xhoa-1. The ~2.5 Kbp EcoRI fragment from pAH316 (described in Section 8.5) which contains the remaining HMWP C-terminus was isolated from preparative agarose gels that had been loaded with a complete EcoRI 5 digestion of pAH316. An agarose gel slice containing the appropriate ~2.5 Kbp fragment was then excised, dissolved with NaI buffer and purified from residual agarose by hydroxyapatite spin column chromatography (QiaGen). The purified C-terminal HMWP EcoRI fragment was then ligated into 10 the single EcoRI site of pAH306-Xhoa-1, located at the 3'-end of the HMWP N-terminal coding sequence, using T4 DNA ligase and standard molecular biology protocols. E.coli Top10 cells were transformed with an aliquot of the pAH306-Xhoa-1 (EcoRI digested and phosphatase treated vector) and the 2.5 Kbp 15 EcoRI C-terminal fragment ligation reaction and recombinants selected on 2X-YT agar containing 100  $\mu$ g/ml ampicillin. Ampicillin-resistant transformants were picked at random. Plasmid DNA was isolated from individual ApR transformants using a QiaGen Mini-Prep Plasmid DNA Isolation System and 20 screened for the presence of plasmids greater in size than pAH306-Xhoa-1 by conventional agarose gel electrophoresis and ethidium bromide staining. Derivatives of pAH306-Xhoa-1 carrying the 2.5 Kbp HMWP fragment in the proper orientation that would allow expression of the full length HMWP were 25 identified by restriction analyses using EcoRI and/or XhoI. Plasmid pAH374 was one derivative isolated from this experiment.

A PCR-based site-directed mutagenesis procedure
(Quik-Change Site-Directed Mutagenesis System, Stratagene)

30 was employed to effect a desired DNA change, namely to remove the NdeI site within the HMWP coding sequence of pAH374.

Mutagenic PCR primers, 41 bases in length and complementary to the sequencing containing the NdeI site and designated 140-Nde-FX and 140-NdeRCX, were designed so as to eliminate the NdeI recognition site but not change the corresponding protein coding sequence. The sequences of the two PCR

mutagenic primers employed to remove the NdeI site in pAH374 are given below.

140-Nde-FX (SEQ ID NO: 38)

5 5'- GGG TTT GGG AAT CAG CAC ATG AAA ACC TCA TAT ACA TTT GC - 3'

140-Nde-RCX(SEQ ID NO:39)

5'- GCA AAT GTA TAT GAG GTT TTC ATG TGC TGA TTC CCA AAC CC -

Following Pfu DNA polymerase (Stratagene) mutagenesis and DpnI digestion, to cleave any unaltered pAH374 parental plasmid, mutated plasmid DNA was then 15 transformed into E.coli XL1-Blue. Plasmid harboring transformants were selected on 2X-YT agar containing 100  $\mu$ g/ml ampicillin. Antibiotic resistant transformants were picked at random and screened for plasmids of the size as pAH374. The identity of plasmids isolated from transformants was determined by restriction enzyme digestion using EcoRI. The absence of the NdeI site in these plasmids was determined by digestion using NdeI. To verify the loss of the HMWP NdeI site and to ensure no unwanted DNA sequence changes had occurred in this region during the mutagenesis procedure, 25 mutagenized plasmids were further subjected to DNA sequence analysis using a sequence-specific sequencing primer located upstream of the NdeI site. Plasmid pAH374-Ndea-1 was one plasmid isolated from this experiment.

A DNA fragment encoding the *C. trachomatis* L<sub>2</sub> HMWP

without the internal NdeI site, plasmid pAH374-Ndea-1, was

PCR amplified from reactions programmed with plasmid pAH374
Ndea-1 (~50 ng) and primers 306-Nde-Metl and 312H6Xbal.

Primer 306NdeMetl was designed to contain a central NdeI site

for directed cloning onto pMG81. The NdeI site in 306NdeMetl

overlapped the ATG start codon for HMWP signal sequence and

was flanked by a 20 base G/C clamp on the 5' side and

sequences complementary to the first 15 residues of the HMWP signal sequence on the 3' side. Primer 312H6Xbal was designed to contain sequences complementary to the C-terminus of the HMWP followed by a (CAT)<sub>6</sub> motif specifying a hexa-

5 histidine affinity purification domain. This primer also contained two UAA termination codons, an XbaI recognition sequence, and a 20 base G/C clamp at the 3' end of the primer. The sequences of the 306NdeMet1 and 312H6Xba1 PCR primers are given below.

10

306NdeMet1(SEQ ID NO: 40)

5'- AAG GGC CCA ATT ACG CAG ACA TAT GGA AAC GTC TTT CCA TAA GTT CTT TCT TTC A - 3'

15 312H6Xba1 (SEQ ID NO: 41)

PCR amplification conditions described in Section 20 8.4 were used to generate the NdeI - XbaI HMWP gene cassette. Following amplification, the PCR product was purified using hydroxyapatite spin columns (QiaGen) and digested overnight at 37°C with a ~10-fold excess of NdeI and XbaI to generate the required 'overhangs' at the ends of the fragment. 25 digested fragment was again purified using spin columns and ~250 ng ligated to ~50 ng pMG81 plasmid DNA that had been previously digested to completion with NdeI and XbaI and subsequently treated with CIP to prevent vector religation. An aliquot of the ligation reaction was used to transform 30 E.coli strain AR58 which had been made competent by the method of Lederberg and Cohen. Transformants were selected on 2X-YT agar containing 40  $\mu$ g/ml kanamycin sulfate. Due to the temperature inducible promoter on pMG81, the transformed cells were grown at 30°C. Kanamycin-resistant transformants

35 were picked at random and screened for the presence of plasmids ~3.0 Kbp larger in size than pMG81. Insert containing derivatives of pMG81 were confirmed by restriction

enzyme analysis using NdeI, XbaI, EcoRI and NcoI. Plasmid pJJ701 was one plasmid isolated from this exercise.

# 12. Example 16: PRODUCTION OF FULL LENGTH rHMWP FROM AR58 5 (PJJ701)

One milliliter of a frozen stock of E. <u>coli</u> strain AR58 containing plasmid pJJ701 was used to inoculate ~100 ml of 2X-YT broth containing 40 µg/ml kanamycin and grown overnight at 30°C to prepare a fermentor seed culture.

10 Approximately 20 ml of the overnight seed culture was then used to inoculate a New Brunswick Bioflow 3000 fermentor loaded with ~2.0l of 2X-YT broth containing 40 µg/ml kanamycin. The AR58 (pJJ701) culture was grown at 30°C with vigorous aeration until an O.D.<sub>625</sub> value of 0.5 - 0.6 was attained. Expression of rHMWP was induced by increasing the temperature of the fermentor culture to ~39°C to 42°C. Incubation at the elevated temperature was continued for approximately 4 - 5 hours.

culture, with some cells displaying classic recombinant protein inclusion bodies, was harvested by continuous flow centrifugation using an Heraeus Contifuge 28RS centrifuge. Following centrifugation, cell mass was scraped from the centrifuge bowl and stored at -70°C until processed.

25 Approximately 15 gm of the AR58 (pJJ701) frozen cell paste was resuspended by vortexing and trituration in ~40 ml of ice cold 10mM sodium phosphate buffer, pH7.3. Once suspended, lysozyme (Chicken egg white, Sigma) and DNase I (Bovine pancreas, Sigma) were added to final concentrations of 1.0 mg/ml and 0.01 mg/ml, respectively, and the mixture incubated on ice for 30 - 45 minutes. Cells were disrupted by 2 sequential passes through a pre-cooled (~4°C) SLM Aminco French Pressure Cell (~14 Kpsi, 1" diameter bore). The cell lysate was then centrifuged for 5min at ~500Xg (4°C) in a Sorvall SS34 rotor to remove unbroken cells. Insoluble material containing the rHMWP was isolated (pelleted) by centrifugation for 45min at ~20,000Xg (4°C) in a Sorvall SS34

rotor. The supernatant from this centrifugation was discarded and the insoluble fraction stored at  $-20^{\circ}\text{C}$  in pellet form.

To selectively extract contaminating proteins and 5 remove endotoxin, the rHMWP-containing insoluble pellet was thawed on ice and washed twice with 10ml of PBS buffer containing 2.0% Triton X-100. Washing was performed at room temperature and suspension of the gelatinous rHMWP-containing pellet was accomplished by vortexing and homogenization in a 10 conventional glass tissue grinder. Insoluble material

- containing the rHMWP was recovered after washing by centrifugation at ~10,000Xg for 20 minutes (room temperature) in a Sorvall SS34 rotor. Insoluble material was then washed (again by vortexing and homogenization) 2-times with 10 ml of
- 15 a 4.0 M urea solution containing 2.0 M NaCl. Washed rHMWP material was recovered by centrifugation as above. The insoluble rHMWP fraction was further washed 2-times with 10 ml of a PBS solution containing 1.0% Zwittergent 3-14 (Sigma).
- The rHMWP pellet recovered after centrifugation of the final wash solution was then solubilized for 2 hours at room temperature in standard Laemelli SDS-PAGE sample buffer containing 4 M urea. Solubilized rHMWP was size fractionated into a single protein band of ~110 Kdal by electrophoresis
- 25 through a standard ~14 cm X ~20 cm X ~3 mm 10% polyacrylamide (36:1, acrylamide:bis-acrylamide) Tris/glycine/SDS preparative gel. A 4% polyacrylamide stacking gel formed using a 5-well, ~500  $\mu$ l/well preparative comb was polymerized on top of the resolving gel. Electrophoresis was carried out
- 30 on a BioRad Protean unit for ~12 hours at ~22°C (~80 85 volts, constant voltage) using a conventional Tris/glycine/SDS running buffer (BioRad). Prestained molecular weight standards (SeeBlue, Novex) were loaded into a parallel lane and were used to gauge the degree and
- 35 efficiency of separation of the protein species. Following electrophoresis, the gel sandwich was disassembled and a vertical slice was removed from the rHMWP sample lane

adjacent to the molecular weight markers and stained with coomassie blue R250 to visualize the rHMWP band. The stained section was then repositioned onto the remaining unstained preparative gel and the strip of acrylamide containing the 5 rHMWP identified and excised.

rHMWP was eluted from the gel slice using a Schleicher and Schuell EluTrap electroelution device. Electroelution was carried out according to the manufacturers recommendations except 1/4-strength SDS running buffer (Novex) was used as the elution buffer. Elution was carried

10 (Novex) was used as the elution buffer. Elution was carried out at ~40 mA for ~12-14 hours, at room temperature. At the end of the elution period the polarity of the cell was reversed for ~2-3 minutes to remove any protein absorbed to the BT1 membrane. The rHMWP-containing solution was removed from the collection chamber and stored in a polypropylene

conical tube at 4°C.

Excess SDS detergent was removed using an SDS precipitation system (SDS-OUT Precipitation kit, Pierce Chemical). Removal of excess detergent from the gel-eluted protein solution was accomplished following the manufacturer's protocol. Detergent extracted rHMWP was diluted approximately 15 fold with sterile, endotoxin-free 10m Molar sodium phosphate buffer (pH 7.4) and concentrated to approximately 1.0 mg/ml by ultrafiltration in an Amicon stirred concentration cell using a YM30 ultrafiltration

Residual endotoxin was removed from the concentrated rHMWP solution by polymyxin B Affi-Prep Polymyxin Matrix (BioRad) treatment. Affi-Prep treatment was performed overnight at 4°C in a batch mode according to the manufacturers recommendations.

The protein concentration of the concentrated, polymyxin B-treated rHMWP was determined using the Micro BCA method (Pierce Chem.) and BSA as a standard.

Purified rHMWP (~0.9-1.2 mg/ml protein concentration) was evaluated for purity, identity, and residual endotoxin burden by SDS-PAGE, Western blot, and a

colorimetric endotoxin assay (BioWhittaker), respectively. The gel-purified rHMWP material displayed a purity of >95% as a single band of the expected molecular size (~110 Kdal) by gel analysis and reacted vigorously with rHMWP-specific K196 5 antibody in Western blots. Residual endotoxin was calculated to be ≤ 0.05 EU/µg.

International Application No: PCT/

MICROORGANISMS  Still the still connection with the microorganism referred to on page 39, lines 20-21 of the description in the	
integral Sheet in connection with the microorganism referred to on page 39, lines 20-21 of the description '	- }
vional Sheet in connection with the misses	$\dashv$
	1
, IDENTIFICATION OF DEPOSIT	- {
Further deposits are identified on an additional sheet '	7
Name of depositary institution .	
American Type Culture Collection	1
A country) *	
Address of depositary institution (including postal code and country)	1
a cont. Hoiversity Blyd.	
Manasas, VA 201 10-2209	
Date of deposit ' September 8, 1997 Accession Number ' 985538	
B. ADDITIONAL INDICATIONS (Grave blank if not applicable). This information is continued on a separate areached about	
	Ì
•	1
C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE ' or the antidental and an indigenced account.	
C DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE THE	
C. DESIGNATURE	
D. SEPARATE FURNISHING OF INDICATIONS (Leave blank if and applicable)	
D. SEPARATE FURNISHING OF INDICATIONS  The indications listed below will be submitted to the international Burseu leter "(Specify the general nature of the indications e.g.,  The indications (Israel Deposit ")	
"Accession Number of Deposit")	
/.	
- continuous spatianting when filed (to be checked by the receiving	Office)
E. This sheet was received with the International application when filed (to be checked by the receiving	(Office)
E. This sheet was received with the International application when filed (to be checked by the receiving	(Office)
my ling S. Groden So.	Office)
E. This sheet was received with the International application when filed (to be checked by the receiving  (Authorized Officer)	Office)
my ling S. Groden So.	Office)
(Authorized Officer)	Office)
(Authorized Officer)	Office)
my ling S. Groden So.	Office)
(Authorized Officer)  The date of receipt (from the applicant) by the International Bureau.	, Office)
(Authorized Officer)	, Office)

### WHAT IS CLAIMED IS:

 An isolated Chlamydia species HMW protein wherein the apparent molecular weight is about 105-115 kDa,
 as determined by SDS-PAGE, or a fragment or analogue thereof.

- 2. The protein of claim 1 which is substantially purified.
- 3. The protein of claim 1 wherein the Chlamydia species is Chlamydia trachomatis, Chlamydia pecorum, Chlamydia psittaci or Chlamydia pneumoniae.
- 4. The protein of claim 1 having an amino acid
  15 sequence shown in SEQ ID No.: 2, 15 or 16 or a fragment or
  conservatively substituted analogue thereof.
  - 5. The fragment of claim 4, having an amino acid sequence shown in SEQ ID No.: 3, 17 or 25-37.

20

6. The protein of claim 1 recognizable by an antibody preparation that specifically binds to a peptide having an amino acid sequence of SEQ ID No.: 2, 15 or 16 or a fragment or conservatively substituted analogue thereof.

- 7. An isolated nucleic acid molecule encoding the HMW protein of claim 1 or a fragment or an analogue thereof.
- 8. The nucleic acid molecule of claim 7 wherein 30 the Chlamydia species is Chlamydia trachomatis, Chlamydia pecorum, Chlamydia psittaci or Chlamydia pneumoniae.
  - 9. The nucleic acid molecule of claim 7 wherein the encoded protein has the amino acid sequence of SEQ ID No:
- **35** 2, 15 or 16 or a fragment or conservatively substituted analogue thereof.

10. An isolated nucleic acid molecule having a sequence selected from the group consisting of:

- a) a DNA sequence of SEQ ID No.: 1, 23 or 24, or a complementary sequence or fragment thereof;
- b) a DNA sequence encoding a HMW protein having the amino acid sequence of SEQ ID No.: 2, 15 or 16 or fragment thereof;
- c) a DNA sequence encoding a deduced amino acid sequence of SEQ ID No.: 2, 15 or 16 or the complimentary or degenerate sequence thereto or fragment thereof; and
- d) a nucleic acid sequence which hybridizes under stringent conditions to any one of the sequences defined in a), b) or c).

15

5

10

- 11. A recombinant expression vector adapted for transformation of a host comprising the nucleic acid molecule of claim 7 or 10.
- 20 12. A recombinant expression vector adapted for transformation of a host comprising the nucleic acid molecule of claim 7 or 10 and expression means operatively coupled to the nucleic acid molecule for expression by the host of HMW protein or a fragment or analogue thereof.

25

13. The expression vector of claim 12, wherein the expression means includes a nucleic acid portion encoding a leader sequence for secretion from the host of the HMW protein or a fragment or analogue thereof.

- 14. A transformed host cell containing an expression vector of claim 12.
- 15. A transformed host cell containing an 35 expression vector of claim 13.

16. An isolated recombinant protein or fragment or analogue thereof producible by the transformed host of claim 14.

- 5 17. An isolated recombinant protein or fragment or analogue thereof producible by the transformed host of claim 15.
- 18. A recombinant vector for delivery of a HMW10 protein or fragment or analogue thereof to a host comprising the nucleic acid molecule of claim 7 or 10.
  - 19. An immunogenic composition, comprising at least one component selected from the group consisting of:
- a) an isolated HMW protein, wherein the apparent molecular weight is about 105-115 kDa, as determined by SDS-PAGE, or a fragment or conservatively substituted analogue thereof;

20

25

- b) an isolated nucleic acid molecule encoding a HMW protein of a) or a fragment or analogue thereof;
  - c) an isolated nucleic acid molecule having the sequence of SEQ ID No.: 1, 23 or 24, the complimentary sequence thereto or a nucleic acid sequence which hybridizes under stringent conditions thereto or fragment thereof;
  - d) an isolated recombinant protein or fragment or analogue thereof producible in a transformed host comprising an expression vector comprising a nucleic acid molecule as defined in b) or c) and expression means operatively coupled to the nucleic acid molecule for expression by the host of said HMW protein or the fragment or analogue thereof;
- e) a recombinant vector comprising a nucleic acid sequence of b) or c) encoding a HMW protein or fragment or analogue thereof; and

f) a transformed cell comprising the vector ofe),

and optionally an adjuvant, and a pharmaceutically acceptable
carrier or diluent therefor, said composition producing an
5 immune response when administered to a host.

- 20. An antigenic composition, comprising at least one component selected from the group consisting of:
- a) an isolated HMW protein, wherein the apparent molecular weight is about 105-115 kDa as determined by SDS-PAGE, or a fragment or analogue thereof;

15

20

25

30

- b) an isolated nucleic acid molecule encoding a HMW protein of a), or a fragment or analogue thereof;
- c) an isolated nucleic acid molecule having the sequence of SEQ ID No.: 1, 22, 23 or 24, the complimentary or degenerate sequence thereto or a nucleic acid sequence which hybridizes under stringent conditions thereto;
- an isolated recombinant protein or fragment or analogue thereof producible in a transformed host comprising an expression vector comprising a nucleic acid molecule as defined in b) or C) and expression means operatively coupled to the nucleic acid molecule for expression by the host of said HMW protein or the fragment or analogue thereof;
- e) a recombinant vector, comprising a nucleic acid sequence of b) or c) encoding a HMW protein or fragment or analogue thereof; and
- f) a transformed cell comprising the vector ofe),

and optionally an adjuvant, said composition producing an 35 immune response when administered to a host.

21. A method of producing an immune response in an animal comprising administering to said animal an effective amount of the antigenic composition of claim 20 or the immunogenic composition of claim 19.

5

30

- 22. The method of claim 21 wherein the animal is a mammal or a bird.
- 23. Antisera raised against the antigenic
  10 composition of claim 20 or the immunogenic composition of claim 19.
- 24. Antibodies present in the antisera of claim 23 that specifically bind a HMW protein or a fragment or 15 analogue thereof.
- 25. A diagnostic reagent selected from the group consisting of: the protein of claim 1, the nucleic acid molecule of claim 10, the immunogenic composition of claim 20, the antigenic composition of claim 19, the antisera of claim 23, the vector of claim 12, the transformed cell of claim 14, and the antibodies of claim 24.
- 26. A method for detecting anti-Chlamydia 25 antibodies in a test sample comprising the steps of:
  - contacting a sample with the HMW protein of claim 1, the antigenic composition of claim 20 or the immunogenic composition of claim 19 to form, in the presence of said antibodies, Chlamydia antigen: anti-Chlamydia antibody immunocomplexes, and further,
  - b) either detecting the presence of or measuring the amount of said immunocomplexes formed during step a) as an indication of the presence of said anti-Chlamydia antibodies in the test sample.

27. A diagnostic kit for detecting antibodies to Chlamydia, said kit comprising the HMW protein of claim 1, the antigenic composition of claim 20 or the immunogenic composition of claim 19, a container means for contacting said protein or composition with a test sample suspected of having said antibodies and reagent means for detecting or measuring Chlamydia antigen: anti-Chlamydia antibody immunocomplexes formed between said protein or composition and said antibodies.

10

15

20

- 28. A method for detecting the presence of Chlamydia in a test sample comprising the steps of:
  - a) contacting a test sample with the antibodies of claim 24 for a time sufficient to allow said antibodies to bind *Chlamydia*, if present, and to form a *Chlamydia*: anti-*Chlamydia* antibody immunocomplexes, and further,
  - b) either detecting the presence of or measuring the amount of said immunocomplexes formed during step a) as an indication of the presence of said Chlamydia in the test sample.
- 29. A diagnostic kit for detecting the presence of Chlamydia, said kit comprising the antibodies of claim 24, container means for contacting said antibodies with a test sample suspected of having said Chlamydia and reagent means for detecting or measuring Chlamydia: anti-Chlamydia antibody immunocomplexes formed between said antibodies and said Chlamydia.

- 30. A pharmaceutical composition comprising an effective amount of at least one component selected from the group consisting of:
- a) a HMW protein, wherein the apparent molecular weight is about 105-115 kDa, as determined by SDS-PAGE, or a fragment or analogue thereof;

5

10

15

20

b) an isolated nucleic acid molecule encoding a HMW protein of a), or a fragment or analogue thereof;

- c) an isolated nucleic acid molecule having the sequence of SEQ ID No.: 1, 23 or 24, the complimentary or degenerate sequence thereto or a nucleic acid sequence which hybridizes under stringent conditions thereto;
- d) an isolated recombinant HMW protein or fragment or analogue thereof producible in a transformed host comprising an expression vector comprising a nucleic acid molecule as defined in b) or c) and expression means operatively coupled to the nucleic acid molecule for expression by the host of said HMW protein or the fragment or analogue thereof:
- e) a recombinant vector, comprising a nucleic acid sequence of b) or c) encoding a HMW protein or fragment or analogue thereof;
- f) a transformed cell comprising the vector ofe), and
- g) antibodies that specifically bind the component of a), b), c), d), e) or f),
- 25 and optionally a pharmaceutically acceptable carrier or diluent therefor.
- 31. A vaccine composition comprising an effective amount of at least one component selected from the group 30 consisting of:
  - a) a HMW protein, wherein the apparent molecular weight is about 105-115 kDa, as determined by SDS-PAGE, or a fragment or analogue thereof;
- b) an isolated nucleic acid molecule encoding a HMW protein of a) or a fragment or analogue thereof;

c) an isolated nucleic acid molecule having the sequence of SEQ ID No.: 1, 23 or 24, the complimentary or degenerate sequence thereto or a nucleic acid sequence which hybridizes under stringent conditions thereto;

5

d) an isolated recombinant HMW protein or fragment or analogue thereof producible in a transformed host comprising an expression vector comprising a nucleic acid molecule as defined in b) or c) and expression means operatively coupled to the nucleic acid molecule for expression by the host of said HMW protein or the fragment or analogue thereof;

15

10

- a recombinant vector, comprising a nucleic acid sequence of b) or c) encoding a HMW protein or fragment or analogue thereof;
- f) a transformed cell comprising the vector ofe), and

20

g) antibodies that specifically bind the component of a), b), c), d), e), or f), and optionally an adjuvant, and a pharmaceutically acceptable carrier or diluent therefor, wherein the vaccine produces an

25

32. A method of preventing, treating or ameliorating a disorder related to *Chlamydia* in a host in need of such treatment comprising administering to a host, an effective amount of the pharmaceutical composition of claim 30 30 or the vaccine composition of claim 31.

immune response when administered to a host.

- 33. The method of claim 32, wherein the disorder is selected from the group consisting of a *Chlamydia* bacterial infection, conjunctivitis, urethritis,
- 35 lymphogranuloma venereum (LGV), cervicitis, epididymitis, endometritis, pelvic inflammatory disease (PID), salpingitis,

tubal occlusion, infertility, cervical cancer, arteriosclerosis and atherosclerosis.

34. The method of claim 33 wherein the host is a 5 bird or a mammal.

- 35. The composition of any one of claims 19, 20, 30 or 31 formulated for *in vivo* administration to a host to confer protection against disease caused by a species of **10** Chlamydia.
- 36. The composition of any one of claims 19, 20, 30, or 31 wherein the species is selected from the group consisting of Chlamydia trachomatis, Chlamydia pecorum, 15 Chlamydia psittaci and Chlamydia pneumoniae.
  - 37. The composition of any one of claims 19, 20, 30 or 31 formulated as a microparticle, capsule, or liposome preparation.

20

- 38. The protein of any one of claims 1, 4, 6, 16 and 17, wherein the protein binds to heparin or heparansulfate.
- 25 39. The protein of any one of claims 1, 4, 6, 16 or 17, wherein the protein is an outer membrane protein.
- 40. A method for determining the presence of nucleic acid encoding a HMW protein or a fragment or analogue 30 thereof in a sample, comprising the steps of:
  - a) contacting a sample with the nucleic acid molecule of claim 7 or 10 or any fragment thereof or complementary thereto to produce duplexes comprising the nucleic acid molecule and any said nucleic acid molecule encoding the HMW protein in the sample and specifically hybridizable therewith; and

b) determining the production of duplexes.

- 41. A diagnostic kit for determining the presence of nucleic acid encoding a HMW protein or fragment or 5 analogue thereof in a sample, comprising:
  - a) the nucleic acid molecule of claim 7 or 10 or any fragment thereof or complementary thereto;
    - b) means for contacting the nucleic acid with the sample to produce duplexes comprising the nucleic acid molecule and any said nucleic acid encoding the HMW protein in the sample and specifically hybridizable therewith; and
  - c) means for determining the production of duplexes.

15


10

20

25

30

Figure I



GGGCAAAACTCTTCCCCCGGGATTTATATGGGAAAGGGGAAACTTTGGC CCGTATTCAAGCGCCACGGGTTTTGGGGCGGAATGAATTTTTTCGTTCCG GAAAAAGTAATTCCCCGGGAACGTAGGGTATCGGTTTCATAGGCTCGCCA AATGGGATATAGGTGGAAAGGTAAAAAAAACTGAGCCAAGCAAAGGATAG AGAAGTCTTGTAATCATCGCAGGTTAAAGGGGGGGATGTTATTTTAGCCTG CAAATAGTGTAATTATTGGATCCTGTAAAGAGAAAAGGACGAATGCGCTG AAGATAAGAACATTTATTGATATTAAATTATTAATTTTTTATGAAGCGGA GTAATTAATTTTATCTCTCAGCTTTTGTGTGATGCAAACGTCTTTCCATA AGTICTITCTTCAATGATTCTAGCTTATTCTTGCTGCTCTTTAAATGGG GGGGGATATGCAGCAGAAATCATGGTTCCTCAAGGAATTTACGATGGGGA GACGTTAACTGTATCATTTCCCTATACTGTTATAGGAGATCCGAGTGGGA CTACTGTTTTTCTGCAGGAGAGTTAACATTAAAAAATCTTGACAATTCT ATTGCAGCTTTGCCTTTAAGTTGTTTTTGGGAACTTATTAGGGAGTTTTAC TGTTTTAGGGAGAGGACACTCGTTGACTTTCGAGAACATACGGACTTCTA CAAATGGGGCAGCTCTAAGTAATAGCGCTGCTGATGGACTGTTTACTATT CACCCTTTTAAAGAATTATCCTTTTCCAATTGCAATTCATTACTTGCCGT ACTGCCTGCTAACGACTAATAAGGGTAGCCAGACTCCGACGACAACAT CTACACCGTCTAATGGTACTATTTATTCTAAAACAGATCTTTTGTTACTC AATAATGAGAAGTTCTCATTCTATAGTAATTTAGTCTCTGGAGATGGGGG AGCTATAGATGCTAAGAGCTTAACGGTTCAAGGAATTAGCAAGCTTTGTG TCTTCCAAGAAATACTGCTCAAGCTGATGGGGGAGCTTGTCAAGTAGTC ACCAGTTTCTCTGCTATGGCTAACGAGGCTCCTATTGCCTTTGTAGCGAA TGTTGCAGGAGTAAGAGGGGGAGGGATTGCTGCTGTTCAGGATGGGCAGC AGGGAGTGTCATCATCTACTTCAACAGAAGATCCAGTAGTAAGTTTTTCC AGAAATACTGCCGTAGAGTTTGATGGGAACGTAGCCCGAGTAGCAGGAGG CATTTACTCCTACCGGAACGTTGCTTTCCTGAATAATGGAAAAACCTTGT ACTGGACAGGCTTCTAATACGAGTAATAATTACGGAGATGGAGGAGCTAT CTTCTGTAAGAATGGTGCGCAAGCAGGATCCAATAACTCTGGATCAGTTT CCTTTGATGGAGAGGGAGTAGTTTTCTTTAGTAGCAATGTAGCTGCTGGG AAAGGGGAGCTATTTATGCCAAAAAGCTCTCGGTTGCTAACTGTGGCCC GAGAATCTGGAGAGCTCAGTTTATCTGCTGATTATGGAGATATTATTTTC

FIG. 2A

SUBSTITUTE SHEET (RULE 26)

3/11

GATGGGAATCTTAAAAGAACAGCCAAAGAGAATGCTGCCGATGTTAATGG CGACATTAAGAGCTAAAGCAGGGCATCAGATTCTCTTTAATGATCCCATC GAGATGGCAAACGGAAATAACCAGCCAGCGCAGTCTTCCAAACTTCTAAA AATTAACGATGCTGAAGGATACACAGGGGATATTGTTTTTGCTAATGGAA CGTGAAAAGGCAAAATTATCAGTGAATTCTCTAAGTCAGACAGGTGGGAG TCTGTATATGGAAGCTGGGAGTACATGGGATTTTGTAACTCCACAACCAC CACAACAGCCTCCTGCCGCTAATCAGTTGATCACGCTTTCCAATCTGCAT TIGICICITICITICITIGITAGCAAACAATGCAGTTACGAATCCTCCTAC CAATCCTCCAGCGCAAGATTCTCATCCTGCAGTCATTGGTAGCACAACTG CTGGTTCTGTTACAATTAGTGGGCCTATCTTTTTTGAGGATTTGGATGAT ACAGCTTATGATAGGTATGATTGGCTAGGTTCTAATCAAAAAATCAATGT CCTGAAATTACAGTTAGGGACTAAGCCCCCAGCTAATGCCCCATCAGATT TGACTCTAGGGAATGAGATGCCTAAGTATGGCTATCAAGGAAGCTGGAAG CTTGCGTGGGATCCTAATACAGCAAATAATGGTCCTTATACTCTGAAAGC TACATGGACTAAAACTGGGTATAATCCTGGGCCTGAGCGAGTAGCTTCTT TGGTTCCAAATAGTTTATGGGGATCCATTTTAGATATACGATCTGCGCAT TCAGCAATTCAAGCAAGTGTGGATGGGCGCTCTTATTGTCGAGGATTATG CGTTTCTGGAGTTTCGAATTTCTTCTATCATGACCGCGATGCTTTAGGTC AGGGATATCGGTATATTAGTGGGGGTTATTCCTTAGGAGCAAACTCCTAC TTTGGATCATCGATGTTTGGTCTAGCATTTACCGAAGTATTTGGTAGATC TAAAGATTATGTAGTGTGTCGTTCCAATCATCATGCTTGCATAGGATCCG TTTATCTATCTACCCAACAAGCTTTATGTGGATCCTATTTGTTCGGAGAT GCGTTTATCCGTGCTAGCTACGGGTTTGGGAATCAGCATATGAAAACCTC ATATACATTTGCAGAGGAGAGCGATGTTCGTTGGGATAATAACTGTCTGG CTGGAGAGATTGGAGCGGGATTACCGATTGTGATTACTCCATCTAAGCTC TATTTGAATGAGTTGCGTCCTTTCGTGCAAGCTGAGTTTTCTTATGCCGA TCATGAATCTTTTACAGAGGAAGGCGATCAAGCTCGGGCATTCAAGAGCG GACATCTCCTAAATCTATCAGTTCCTGTTGGAGTGAAGTTTGATCGATGT TCTAGTACACATCCTAATAAATATAGCTTTATGGCGGCTTATATCTGTGA TGCTTATCGCACCATCTCTGGTACTGAGACAACGCTCCTATCCCATCAAG AGACATGGACAACAGATGCCTTTCATTTAGCAAGACATGGAGTTGTGGTT AGAGGATCTATGTATGCTTCTCTAACAAGTAATATAGAAGTATATGGCCA TGGAAGATATGAGTATCGAGATGCTTCTCGAGGCTATGGTTTGAGTGCAG

FIG. 2B

SUBSTITUTE SHEET (RULE 26)


GAAGTAGAGTCCGGTTCTAAAAATATTGGTTAGATAGTTAAGTGTTAGCG TTCCTATTCGTATGGATTCGCGAGCTCTCCTCAAGTGTTAACGCCTAATG TAACCACTCCTTTTAAGGGAGACGATGTTTACTTGAATGGAGACTGCGCT TTTGTCAATGTCTATGCAGGAGCTGAAGAAGGTTCGATTATCTCAGCTAA TGGCGACAATTTAACGATTACCGGACAAAACCATACATTATCATTTACAG ATTCTCAAGGGCCAGTTCTTCAAAATTATGCCTTCATTTCAGCAGGAGAG ACACTTACTCTGAGAGATTTTTCGAGTCTGATGTTCTCGAAAAATGTTTC TTGCGGAGAAAAGGGAATGATCTCCGGGAAAACCGTGAGTATTTCCGGAG CAGGCGAAGTGATTTTCTGGGATAACTCCGTGGGGTATTCTCCTTTATCT ACTGTGCCAACCTCATCATCAACTCCGCCTGCTCCAACAGTTAGTGATGC TCGGAAAGGGTCTATTTTTTCTGTAGAGACTAGTTTGGAGATCTCAGGCG TCAAAAAAGGGGTCATGTTCGATAATAATGCCGGGAATTTCGGAACAGTT TTTCGAGGTAAGAATAATAATAATGCTGGTGGTGGAGGCAGTGGGTTCCG CTACACCATCAAGTACGACTTTTACAGTTAAAAACTGTAAAGGGAAAGTT TCTTTCACAGATAACGTAGCCTCTTGCGGAGGCGGAGTGGTTTATAAAGG CATTGTGCTTTTCAAAGACAATGAAGGAGGCATATTCTTCCGAGGGAACA CAGCATACGATGATTTAAGGATTCTTGCTGCTACTAATCAGGATCAGAAT ACCGAGACACGCCGCTGGACGAGTTATTTGCTCTCCAGATGATTCTGT AAAGTTTGAAGGCAATAAAGGTTCTATTGTTTTTGATTACAACTTTGCAA AAGGCAGAGGCGGAAGCATCCTAACGAAAGAATTC

FIG. 2C

MQTSFHKFFLSMILAYSCCSLNGGGYAAE IMVPQGIYDGETLTVSFPYTV IGDPSGTTVFSAGFI TI KNLDNSTAALPLSCFGNLLGSFTVLGRGHSLTF ENTRESTNGAAL SNSAADGLETTEGEKELSESNCNSLLAVLPAATTNKGS QTPTTTSTPSNGT1YSKTDLLLLNNEKFSFYSNLVSGDGGA1DAKSLTVQ GISKLCVFQENTAQADGGACQVVTSFSAMANEAPIAFVANVAGVRGGGIA AVODGOOGVSSSTSTEDPVVSESRNTAVEEDGNVARVGGG LYSYGNVAFL NNGKTLFLNNVASPVYTAAKOPTSGOASNTSNNYGDGGATFCKNGAQAGS NNSGSVSFDGEGVVFFSSNVAAGKGGAIYAKKLSVANCGPVQFLRNIAND GGATYLGESGELSLSADYGDTTFDGNLKRTAKENAADVNGVTVSSQATSM GSGGKITTLRAKAGHQILFNDPIEMANGNNQPAQSSKLLKINDGEGYTGD IVFANGSSTI YONVT I EOGR I VLREKAKL SVNSL SOTGGSL YMEAGSTWD EVTPOPPOOPPAANOLITLSNLHLSLSSLLANNAVTNPPTNPPAODSHPA VIGSTTAGSVTISGPIFFEDLDDTAYDRYDWLGSNQKINVLKLQLGTKPP ANAPSDLTLGNEMPKYGYOGSWKLAWDPNTANNGPYTLKATWTKTGYNPG PFRVASI VPNSLWGSILDIRSAHSAIOASVDGRSYCRGLWVSGVSNFFYH DRDALGOGYRY I SGGYSLGANSYFGSSMFGLAFTE VFGRSKDYVVCRSNH HAC I GSVYLSTQQALCGSYLFGDAF I RASYGFGNQHMKTSYTFAEESDVR WDNNCLAGE IGAGLP I VI TPSKLYLNELRPF VQAEF SYADHESF TEEGDQ ARAFKSGHLLNLSVPVGVKFDRCSSTHPNKYSFMAAYICDAYRTISGTET TLLSHQETWTTDAFHLARHGVVVRGSMYASLTSNIEVYGHGRYEYRDASR GYGL SAGSRVRF

FIG.3

6/11 Figure 4



7/11




FIG.5
SUBSTITUTE SHEET (RULE 26)




FIG. 6A

SUBSTITUTE SHEET (RULE 26)





FIG. 6B

**SUBSTITUTE SHEET (RULE 26)** 

Figure 7A



Figure 7B



#### SEQUENCE LISTING

<110> ANTEXBIOLOGICS, INC.
<120> CHLAMYDIA PROTEIN, GENE SEQUENCE AND USES THEREOF
<130> 7969-076
<140>
<141>
<150> 08/942,596
<151> 1997-10-02
<160> 41
<170> PatentIn Ver. 2.0
<210> 1
<211> 4435
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:

recombinant expression vector

<400> 1

gggcaaaact cttccccccg ggatttatat gggaaagggg aaactttggc ccgtattcaa 60 gcgccacggg ttttggggcg gaatgaattt tttcgttccg gaaaaagtaa ttccccggga 120 acgtagggta tcggtttcat aggctcgcca aatgggatat aggtggaaag gtaaaaaaaa 180 ctgagccaag caaaggatag agaagtcttg taatcatcgc aggttaaagg ggggatgtta 240 ttttagcctg caaatagtgt aattattgga tcctgtaaag agaaaaggac gaatgcgctg 300 aagataagaa catttattga tattaaatta ttaattttt atgaagcgga gtaattaatt 360 ttatctctca gcttttgtgt gatgcaaacg tctttccata agttctttct ttcaatgatt 420 ctagettatt ettgetgete tttaaatggg gggggatatg cageagaaat catggtteet 480 caaggaattt acgatgggga gacgttaact gtatcatttc cctatactgt tataggagat 540 ccgagtggga ctactgtttt ttctgcagga gagttaacat taaaaaatct tgacaattct 600 attgcagctt tgcctttaag ttgttttggg aacttattag ggagttttac tgttttaggg 660 agaggacact cgttgacttt cgagaacata cggacttcta caaatggggc agctctaagt 720 aatagegetg etgatggaet gtttactatt gagggtttta aagaattate etttteeaat 780 tgcaattcat tacttgccgt actgcctgct gcaacgacta ataagggtag ccagactccg 840 acgacaacat ctacaccgtc taatggtact atttattcta aaacagatct tttgttactc 900 aataatgaga agttctcatt ctatagtaat ttagtctctg gagatggggg agctatagat 960 gctaagagct taacggttca aggaattagc aagctttgtg tcttccaaga aaatactgct 1020 caagetgatg ggggagettg teaagtagte accagtttet etgetatgge taacgagget 1080 cctattgcct ttgtagcgaa tgttgcagga gtaagagggg gagggattgc tgctgttcag 1140 gatgggcagc agggagtgtc atcatctact tcaacagaag atccagtagt aagtttttcc 1200

- 1 -

agaaatactg cggtagagtt tgatgggaac gtagcccgag taggaggagg gatttactcc 1260 tacgggaacg ttgctttcct gaataatgga aaaaccttgt ttctcaacaa tgttgcttct 1320 cctgtttaca ttgctgctaa gcaaccaaca agtggacagg cttctaatac gagtaataat 1380 tacggagatg gaggagctat cttctgtaag aatggtgcgc aagcaggatc caataactct 1440 ggatcagttt cctttgatgg agagggagta gttttcttta gtagcaatgt agctgctggg 1500 aaagggggag ctatttatgc caaaaagctc tcggttgcta actgtggccc tgtacaattt 1560 ttaaggaata tcgctaatga tggtggagcg atttatttag gagaatctgg agagctcagt 1620 ttatctgctg attatggaga tattattttc gatgggaatc ttaaaagaac agccaaagag 1680 aatgctgccg atgttaatgg cgtaactgtg tcctcacaag ccatttcgat gggatcggga 1740 gggaaaataa cgacattaag agctaaagca gggcatcaga ttctctttaa tgatcccatc 1800 gagatggcaa acggaaataa ccagccagcg cagtcttcca aacttctaaa aattaacgat 1860 ggtgaaggat acacagggga tattgttttt gctaatggaa gcagtacttt gtaccaaaat 1920 gttacgatag agcaaggaag gattgttctt cgtgaaaagg caaaattatc agtgaattct 1980 ctaagtcaga caggtgggag tctgtatatg gaagctggga gtacatggga ttttgtaact 2040 ccacaaccac cacaacagcc tectgeeget aatcagttga teaegettte caatetgeat 2100 ttgtctcttt cttctttgtt agcaaacaat gcagttacga atcctcctac caatcctcca 2160 gcgcaagatt ctcatcctgc agtcattggt agcacaactg ctggttctgt tacaattagt 2220 gggcctatct tttttgagga tttggatgat acagcttatg ataggtatga ttggctaggt 2280 tctaatcaaa aaatcaatgt cctgaaatta cagttaggga ctaagccccc agctaatgcc 2340 ccatcagatt tgactctagg gaatgagatg cctaagtatg gctatcaagg aagctggaag 2400 cttgcgtggg atcctaatac agcaaataat ggtccttata ctctgaaagc tacatggact 2460 aaaactgggt ataatcctgg gcctgagcga gtagcttctt tggttccaaa tagtttatgg 2520 ggatccattt tagatatacg atctgcgcat tcagcaattc aagcaagtgt ggatgggcgc 2580 tcttattgtc gaggattatg ggtttctgga gtttcgaatt tcttctatca tgaccgcgat 2640 gctttaggtc agggatatcg gtatattagt gggggttatt ccttaggagc aaactcctac 2700 tttggatcat cgatgtttgg tctagcattt accgaagtat ttggtagatc taaagattat 2760 gtagtgtgtc gttccaatca tcatgcttgc ataggatccg tttatctatc tacccaacaa 2820 gctttatgtg gatcctattt gttcggagat gcgtttatcc gtgctagcta cgggtttggg 2880 aatcagcata tgaaaacctc atatacattt gcagaggaga gcgatgttcg ttgggataat 2940 aactgtctgg ctggagagat tggagcggga ttaccgattg tgattactcc atctaagctc 3000 tatttgaatg agttgcgtcc tttcgtgcaa gctgagtttt cttatgccga tcatgaatct 3060 tttacagagg aaggcgatca agctcgggca ttcaagagcg gacatctcct aaatctatca 3120 gttcctgttg gagtgaagtt tgatcgatgt tctagtacac atcctaataa atatagcttt 3180 atggcggctt atatctgtga tgcttatcgc accatctctg gtactgagac aacgctccta 3240 tcccatcaag agacatggac aacagatgcc tttcatttag caagacatgg agttgtgggtt 3300 agaggateta tgtatgette tetaacaagt aatatagaag tatatggeea tggaagatat 3360 gagtatcgag atgcttctcg aggctatggt ttgagtgcag gaagtagagt ccggttctaa 3420 aaatattggt tagatagtta agtgttagcg atgccttttt ctttgagatc tacatcattt 3480 tgttttttag cttgtttgtg ttcctattcg tatggattcg cgagctctcc tcaagtgtta 3540 acgectaatg taaccaetee ttttaaggga gaegatgttt aettgaatgg agaetgeget 3600 tttgtcaatg tctatgcagg agctgaagaa ggttcgatta tctcagctaa tggcgacaat 3660 ttaacgatta ccggacaaaa ccatacatta tcatttacag attctcaagg gccagttctt 3720 caaaattatg ccttcatttc agcaggagag acacttactc tgagagattt ttcgagtctg 3780 atgttctcga aaaatgtttc ttgcggagaa aagggaatga tctccgggaa aaccgtgagt 3840 atttccggag caggcgaagt gattttctgg gataactccg tggggtattc tcctttatct 3900 actgtgccaa cctcatcatc aactccgcct gctccaacag ttagtgatgc tcggaaaggg 3960 tctatttttt ctgtagagac tagtttggag atctcaggcg tcaaaaaaagg ggtcatgttc 4020 gataataatq ccqqqaattt cggaacagtt tttcgaggta agaataataa taatqctqqt 4080

ggtggaggca gtgggttccg ctacaccatc aagtacgact tttacagtta aaaactgtaa 4140 agggaaagtt tctttcacag ataacgtagc ctcttgcgga ggcggagtgg tttataaagg 4200 cattgtgctt ttcaaagaca atgaaggagg catattcttc cgagggaaca cagcatacga 4260 tgatttaagg attcttgctg ctactaatca ggatcagaat acggagacag gaggcggtgg 4320 aggagttatt tgctcccag atgattctgt aaagtttgaa ggcaataaag gttctattgt 4380 ttttgattac aactttgcaa aaggcagagg cggaagcatc ctaacgaaag aattc 4435

<210> 2

<211> 1012

<212> PRT

<213> Chlamydia

<400> 2

Met Gln Thr Ser Phe His Lys Phe Phe Leu Ser Met Ile Leu Ala Tyr

1 5 10 15

Ser Cys Cys Ser Leu Asn Gly Gly Gly Tyr Ala Ala Glu Ile Met Val 20 25 30

Pro Gln Gly Ile Tyr Asp Gly Glu Thr Leu Thr Val Ser Phe Pro Tyr 35 40 45

Thr Val Ile Gly Asp Pro Ser Gly Thr Thr Val Phe Ser Ala Gly Glu 50 55 60

Leu Thr Leu Lys Asn Leu Asp Asn Ser Ile Ala Ala Leu Pro Leu Ser 65 70 75 80

Cys Phe Gly Asn Leu Leu Gly Ser Phe Thr Val Leu Gly Arg Gly His
85 90 95

Ser Leu Thr Phe Glu Asn Ile Arg Thr Ser Thr Asn Gly Ala Ala Leu 100 105 110

Ser Asn Ser Ala Ala Asp Gly Leu Phe Thr Ile Glu Gly Phe Lys Glu 115 120 125

Leu Ser Phe Ser Asn Cys Asn Ser Leu Leu Ala Val Leu Pro Ala Ala 130 135 140

Thr Thr Asn Lys Gly Ser Gln Thr Pro Thr Thr Ser Thr Pro Ser 145 150 155 160

Asn Gly Thr Ile Tyr Ser Lys Thr Asp Leu Leu Leu Leu Asn Asn Glu 165 170 175

Lys Phe Ser Phe Tyr Ser Asn Leu Val Ser Gly Asp Gly Gly Ala Ile 180 185 190

- 3 -

Asp	Ala	Lys 195	Ser	Leu	Thr	Val	Gln 200	Gly	Ile	Ser	Lys	Leu 205	Cys	Val	Phe
Gln	Glu 210	Asn	Thr	Ala	Gln	Ala 215	Asp	Gly	Gly	Ala	Cys 220	Gln	Val	Val	Thr
Ser 225	Phe	Ser	Ala	Met	Ala 230	Asn	Glu	Ala	Pro	Ile 235	Ala	Phe	Val	Ala	Asn 240
Val	Ala	Gly	Val	Arg 245	Gly	Gly	Gly	Ile	Ala 250	Ala	Val	Gln	Asp	Gly 255	Gln
Gln	Gly	Val	Ser 260	Ser	Ser	Thr	Ser	Thr 265	Glu	Asp	Pro	Val	Val 270	Ser	Phe
Ser	Arg	Asn 275	Thr	Ala	Val	Glu	Phe 280	Asp	Gly	Asn	Val	Ala 285	Arg	Val	Gly
Gly	Gly 290	Ile	Tyr	Ser	Tyr	Gly 295	Asn	Val	Ala	Phe	Leu 300	Asn	Asn	Gly	Lys
Thr 305	Leu	Phe	Leu	Asn	Asn 310	Val	Ala	Ser	Pro	Val 315	Tyr	Ile	Ala	Ala	Lys 320
Gln	Pro	Thr	Ser	Gly 325	Gln	Ala	Ser	Asn	Thr 330	Ser	Asn	Asn	Tyr	Gly 335	Asp
Gly	Gly	Ala	Ile 340	Phe	Cys	Lys	Asn	Gly 345	Ala	Gln	Ala	Gly	Ser 350	Asn	Asn
Ser	Gly	Ser 355	Val	Ser	Phe	Asp	Gly 360	Glu	Gly	Val	Val	Phe 365	Phe	Ser	Ser
Asn	Val 370	Ala	Ala	Gly	Lys	Gly 375	Gly	Ala	Ile	Tyr	Ala 380	Lys	Lys	Leu	Ser
Val 385	Ala	Asn	Cys	Gly	Pro 390	Val	Gln	Phe	Leu	Arg 395	Asn	Ile	Ala	Asn	Asp 400
Gly	G1y	Ala	Ile	Tyr 405	Leu	Gly	Glu	Ser	Gly 410	Glu	Leu	Ser	Leu	Ser 415	Ala
Asp	Tyr	Gly	Asp 420	Ile	Ile	Phe	Asp	Gly 425	Asn	Leu	Lys	Arg	Thr 430	Ala	Lys
Glu	Asn	Ala	Ala	Asp	Val	Asn	Gly	Val	Thr	Val	Ser	Ser	Gln	Ala	Ile

Ser Met Gly Ser Gly Gly Lys Ile Thr Thr Leu Arg Ala Lys Ala Gly 450 455 460

- His Gin Ile Leu Phe Asn Asp Pro Ile Glu Met Ala Asn Gly Asn Asn 465 470 475 480
- Gln Pro Ala Gln Ser Ser Lys Leu Leu Lys Ile Asn Asp Gly Glu Gly
  485 490 495
- Tyr Thr Gly Asp Ile Val Phe Ala Asn Gly Ser Ser Thr Leu Tyr Gln 500 505 510
- Asn Val Thr Ile Glu Gln Gly Arg Ile Val Leu Arg Glu Lys Ala Lys
  515 520 525
- Leu Ser Val Asn Ser Leu Ser Gln Thr Gly Gly Ser Leu Tyr Met Glu 530 535 540
- Ala Gly Ser Thr Trp Asp Phe Val Thr Pro Gln Pro Pro Gln Gln Pro 545 550 555 560
- Pro Ala Ala Asn Gln Leu Ile Thr Leu Ser Asn Leu His Leu Ser Leu 565 570 575
- Ser Ser Leu Leu Ala Asn Asn Ala Val Thr Asn Pro Pro Thr Asn Pro 580 585 590
- Pro Ala Gln Asp Ser His Pro Ala Val Ile Gly Ser Thr Thr Ala Gly 595 600 605
- Ser Val Thr Ile Ser Gly Pro Ile Phe Phe Glu Asp Leu Asp Asp Thr 610 615 620
- Ala Tyr Asp Arg Tyr Asp Trp Leu Gly Ser Asn Gln Lys Ile Asn Val 625 630 635 640
- Leu Lys Leu Gln Leu Gly Thr Lys Pro Pro Ala Asn Ala Pro Ser Asp 645 650 655
- Leu Thr Leu Gly Asn Glu Met Pro Lys Tyr Gly Tyr Gln Gly Ser Trp 660 665 670
- Lys Leu Ala Trp Asp Pro Asn Thr Ala Asn Asn Gly Pro Tyr Thr Leu 675 680 685
- Lys Ala Thr Trp Thr Lys Thr Gly Tyr Asn Pro Gly Pro Glu Arg Val 690 695 700

- 5 -

Ala 705	Ser	Leu	Val	Pro	Asn 710	Ser	Leu	Trp	Gly	Ser 715	Ile	Leu	Asp	Ile	Arg 720
Ser	AÌa	His	Ser	Ala 725	Ile	Gln	Ala	Ser	Val 730	Asp	Gly	Arg	Ser	Tyr 735	Cys
Arg	Gly	Leu	Trp 740	Val	Ser	Gly	Val	Ser 745	Asn	Phe	Phe	Tyr	His 750	Asp	Arg
Asp	Ala	Leu 755	Gly	Gln	Gly	Tyr	Arg 760	Tyr	Ile	Ser	Gly	Gly 765	Tyr	Ser	Leu
Gly	Ala 770	Asn	Ser	Tyr	Phe	Gly 775	Ser	Ser	Met	Phe	Gly 780	Leu	Ala	Phe	Thr
Glu 785	Val	Phe	Gly	Arg	Ser 790	Lys	Asp	Tyr	Val	Val 795	Cys	Arg	Ser	Asn	His 800
His	Ala	Cys	Ile	Gly 805	Ser	Val	Tyr	Leu	Ser 810	Thr	Gln	Gln	Ala	Leu 815	Cys
Gly	Ser	Tyr	Leu 820	Phe	Gly	Asp	Ala	Phe 825	Ile	Arg	Ala	Ser	Tyr 830	Gly	Phe
Gly	Asn	Gln 835	His	Met	Lys	Thr	Ser 840	Tyr	Thr	Phe	Ala	Glu 845	Glu	Ser	Asp
Val	Arg 850	Trp	Asp	Asn	Asn	Cys 855	Leu	Ala	Gly	Glu	Ile 8 <b>6</b> 0	Gly	Ala	Gly	Leu
Pro 865	Ile	Val	Ile	Thr	Pro 870	Ser	Lys	Leu	Tyr	Leu 875	Asn	Glu	Leu	Arg	Pro 880
Phe	Val	Gln	Ala	Glu 885	Phe	Ser	Tyr	Ala	Asp 890	His	Glu	Ser	Phe	Thr 895	Glu
Glu	Gly	Asp	Gln 900	Ala	Arg	Ala	Phe	Lys 905	Ser	Gly	His	Leu	Leu 910	Asn	Leu
Ser	Val	Pro 915	Val	Gly	Val	Lys	Phe 920	Asp	Arg	Cys	Ser	Ser 925	Thr	His	Pro
Asn	Lys 930	Tyr	Ser	Phe	Met	Ala 935	Ala	Tyr	Ile	Cys	Asp 940	Ala	Tyr	Arg	Thr
Ile 945	Ser	Gly	Thr	Glu	Thr 950	Thr	Leu	Leu	Ser	His 955	Gln	Glu	Thr	Trp	Thr 960

```
Thr Asp Ala Phe His Leu Ala Arg His Gly Val Val Arg Gly Ser
                                                         975
                                    970
                965
Met Tyr Ala Ser Leu Thr Ser Asn Ile Glu Val Tyr Gly His Gly Arg
                                985
            980
Tyr Glu Tyr Arg Asp Ala Ser Arg Gly Tyr Gly Leu Ser Ala Gly Ser
                                                1005
                           1000
        995
Arg Val Arg Phe
   1010
<210> 3
<211> 20
<212> PRT
<213> Chlamydia
<400> 3
Glu Ile Met Val Pro Gln Gly Ile Tyr Asp Gly Glu Thr Leu Thr Val
                                      10
                   5
Ser Phe Xaa Tyr
              20
 <210> 4
 <211> 18
 <212> DNA
 <213> Chlamydia
 <400> 4
                                                                    18
 gaaathatgg tnccncaa
 <210> 5
 <211> 18
 <212> DNA
 <213> Chlamydia
 <400> 5
                                                                    18
 gaaathatgg tnccncag
 <210> 6
 <211> 18
 <212> DNA
 <213> Chlamydia
```

- 7 -

WO 99/17741					PCT/US9	98/20737 <sup>¯</sup>
<400> 6						
gagathatgg	tnccncaa					18
<210> 7			•			
<211> 18						
<212> DNA						
<213> Chlam	nydia					
<400> 7						
gagathatgg	tneenese					18
gagacnacgg	checheag					10
<210> 8						
<211> 15						
<212> DNA						
<213> Chlam	nydia.					
<400> 8						
ngtytcnccr	tcata					15
.010						
<210> 9						
<211> 15 <212> DNA						
<212> DNA <213> Chlan	ovdi a					
VZ13/ Clifali	nyura					
<400> 9						
ngtytcnccr	tcgta					15
	•					
<210> 10						
<211> 1511						
<212> DNA						
<213> Chlan	nydia			,		
<100> 10						
<400> 10	ttaataaaa		aaaaaaaaa	taaatatata	2+++22++	60
		_		taactgtatc caggagagtt		
				ttgggaactt		
	_	-		acatacggac		
_				ctattgaggg		
				ctgctgcaac	-	
	-			gtactattta	-	
				gtaatttagt		
gggggagcta	tagatgctaa	gagcttaacg	gttcaaggaa	ttagcaagct	ttgtgtcttc	540
caagaaaata	ctgctcaagc	tgatggggga	gcttgtcaag	tagtcaccag	tttctctgct	600
atggctaacg	aggctcctat	tgcctttgta	gcgaatgttg	caggagtaag	agggggaggg	660
attgctgctg	ttcaggatgg	gcagcaggga	gtgtcatcat	ctacttcaac	agaagatcca	720
gtagtaagtt	tttccagaaa	tactgcggta	gagtttgatg	ggaacgtagc	ccgagtagga	780
ggagggattt	actcctacgg	gaacgttgct	ttcctgaata	atggaaaaac	cttgtttctc	840
aacaatgttg	cttctcctgt	ttacattgct	gctaagcaac	caacaagtgg	acaggcttct	900

- 8 -

aatacgagta ataattacgg agatggagga gctatcttct gtaagaatgg tgcgcaagca 960 ggatccaata actctggatc agtttccttt gatggagagg gagtagttt ctttagtagc 1020 aatgtagctg ctgggaaagg gggggctatt tatgccaaaa agctctcggt tgctaactgt 1080 ggccctgtac aattttaag gaatatcgct aatgatggtg gagcgattta tttaggagaa 1140 tctggagagc tcagtttatc tgctgattat ggaggatatta ttttcgatgg gaatcttaaa 1200 agaacagcca aagagaatgc tgccgatgtt aatggcgtaa ctgtgtcctc acaagccatt 1260 tcgatgggat cgggaggaa aataacgaca ttaagagcta aagcagggca tccagattt 1380 tttaatgatc ccatcgagat ggcaaaccga aataaccagc cagcgcagtc ttccaaactt 1380 ctaaaaatta acgatggtga aggatacaca ggggatattg tttttgctaa tggaagcagt 1440 actttgtacc aaaatgttac gatagagcaa ggaaggattg ttcttcgtga aaaggcaaaa 1500 ttatcaagtga a

<210> 11 <211> 1444 <212> DNA <213> Chlamydia

<400> 11

ttetetaagt cagacaggtg ggagtetgta tatggaaget gggagtacat gggattttgt 60 aactccacaa ccaccacaac agcctcctgc cgctaatcag ttgatcacgc tttccaatct 120 gcatttgtct ctttcttctt tgttagcaaa caatgcagtt acgaatcctc ctaccaatcc 180 tecagegeaa gatteteate etgeagteat tggtageaca actgetggtt etgttacaat 240 tagtgggcct atctttttg aggatttgga tgatacagct tatgataggt atgattggct 300 aggttctaat caaaaaatca atgtcctgaa attacagtta gggactaagc ccccagctaa 360 tgccccatca gatttgactc tagggaatga gatgcctaag tatggctatc aaggaagctg 420 gaagettgeg tgggateeta atacageaaa taatggteet tataetetga aagetacatg 480 gactaaaact gggtataatc ctgggcctga gcgagtagct tctttggttc caaatagttt 540 atggggatcc attttagata tacgatctgc gcattcagca attcaagcaa gtgtggatgg 600 gegetettat tgtcgaggat tatgggtttc tggagtttcg aatttettet atcatgaceg 660 cgatgcttta ggtcagggat atcggtatat tagtgggggt tattccttag gagcaaactc 720 ctactttgga tcatcgatgt ttggtctagc atttaccgaa gtatttggta gatctaaaga 780 ttatgtagtg tgtcgttcca atcatcatgc ttgcatagga tccgtttatc tatctaccca 840 acaagettta tgtggateet atttgttegg agatgegttt ateegtgeta getaegggtt 900 tgggaatcag catatgaaaa cctcatatac atttgcagag gagagcgatg ttcgttggga 960 taataactgt ctggctggag agattggagc gggattaccg attgtgatta ctccatctaa 1020 gctctatttg aatgagttgc gtcctttcgt gcaagctgag ttttcttatg ccgatcatga 1080 atcttttaca gaggaaggcg atcaagctcg ggcattcaag agcggacatc tectaaatct 1140 atcagtteet gttggagtga agtttgateg atgttetagt acacateeta ataaatatag 1200 ctttatggcg gcttatatct gtgatgctta tcgcaccatc tctggtactg agacaacgct 1260 cctatcccat caagagacat ggacaacaga tgcctttcat ttagcaagac atggagttgt 1320 ggttagagga tctatgtatg cttctctaac aagtaatata gaagtatatg gccatggaag 1380 atatgagtat cgagatgctt ctcgaggcta tggtttgagt gcaggaagta gagtccggtt 1440 1444 ctaa

<210> 12 <211> 56 <212> DNA <213> Chlamydia

- 9 -

<400> 12	
aagggcccaa ttacgcagag ggtaccgaaa ttatggttcc tcaaggaatt t	tacgat 56
<210>`13	
<211> 56	
<212> DNA	
<213> Chlamydia	
•	
<400> 13	
aagggcccaa ttacgcagag ggtaccctaa gaagaaggca tgccgtgcta g	gcggag 56
<210> 14	
<211> 57	
<212> DNA	
<213> Chlamydia	
<400> 14	
aagggcccaa ttacgcagag ggtaccggag agctcgcgaa tccatacgaa t	taggaac 57
<210> 15	
<211> 1013	
<212> PRT	
<213> Chlamydia	
<400> 15	•
Met Gln Thr Ser Phe His Lys Phe Phe Leu Ser Met Ile Leu	Ala Tyr
1 5 10	15
Ser Cys Cys Ser Leu Asn Gly Gly Gly Tyr Ala Ala Glu Ile	Met Val
20 25 30	
Pro Gln Gly Ile Tyr Asp Gly Glu Thr Leu Thr Val Ser Phe	Pro Tyr
35 40 45	
Thr Val Ile Gly Asp Pro Ser Gly Thr Thr Val Phe Ser Ala	Gly Glu
50 55 60	
Leu Thr Leu Lys Asn Leu Asp Asn Ser Ile Ala Ala Leu Pro	Leu Ser
65 70 75	80
Cys Phe Gly Asn Leu Leu Gly Ser Phe Thr Val Leu Gly Arg	Gly His
85 90	95
Ser Leu Thr Phe Glu Asn Ile Arg Thr Ser Thr Asn Gly Ala	Ala Leu
Ser Leu Thr Phe Glu Asn Ile Arg Thr Ser Thr Asn Gly Ala 100 105 110	Ala Leu
	Ala Leu

1	•	•
- 1	- 1	~

- Leu Ser Phe Ser Asn Cys Asn Pro Leu Leu Ala Val Leu Pro Ala Ala Thr Thr Asn Asn Gly Ser Gln Thr Pro Ser Thr Thr Ser Thr Pro Ser
- Asn Gly Thr Ile Tyr Ser Lys Thr Asp Leu Leu Leu Asn Asn Glu
- Lys Phe Ser Phe Tyr Ser Asn Ser Val Ser Gly Asp Gly Ala Ile
- Asp Ala Lys Ser Leu Thr Val Gln Gly Ile Ser Lys Leu Cys Val Phe
- Gln Glu Asn Thr Ala Gln Ala Asp Gly Gly Ala Cys Gln Val Val Thr
- Ser Phe Ser Ala Met Ala Asn Glu Ala Pro Ile Ala Phe Val Ala Asn
- Val Ala Gly Val Arg Gly Gly Gly Ile Ala Ala Val Gln Asp Gly Gln
- Gln Gly Val Ser Ser Ser Thr Ser Thr Glu Asp Pro Val Val Ser Phe
- Ser Arg Asn Thr Ala Val Glu Phe Asp Gly Asn Val Ala Arg Val Gly
- Gly Gly Ile Tyr Ser Tyr Gly Asn Val Ala Phe Leu Asn Asn Gly Lys
- Thr Leu Phe Leu Asn Asn Val Ala Ser Pro Val Tyr Ile Ala Ala Glu
- Gln Pro Thr Asn Gly Gln Ala Ser Asn Thr Ser Asp Asn Tyr Gly Asp
- Gly Gly Ala Ile Phe Cys Lys Asn Gly Ala Gln Ala Gly Ser Asn
- Asn Ser Gly Ser Val Ser Phe Asp Gly Glu Gly Val Val Phe Phe Ser
- Ser Asn Val Ala Ala Gly Lys Gly Gly Ala Ile Tyr Ala Lys Lys Leu

370 375 380

Ser Val Ala Asn Cys Gly Pro Val Gln Leu Leu Gly Asn Ile Ala Asn 385 390 395 400

- Asp Gly Gly Ala Ile Tyr Leu Gly Glu Ser Gly Glu Leu Ser Leu Ser 405 410 415
- Ala Asp Tyr Gly Asp Met Ile Phe Asp Gly Asn Leu Lys Arg Thr Ala 420 425 430
- Lys Glu Asn Ala Ala Asp Val Asn Gly Val Thr Val Ser Ser Gln Ala 435 440 445
- Ile Ser Met Gly Ser Gly Gly Lys Ile Thr Thr Leu Arg Ala Lys Ala 450 455 460
- Gly His Gln Ile Leu Phe Asn Asp Pro Ile Glu Met Ala Asn Gly Asn 465 470 475 480
- Asn Gln Pro Ala Gln Ser Ser Glu Pro Leu Lys Ile Asn Asp Gly Glu 485 490 495
- Gly Tyr Thr Gly Asp Ile Val Phe Ala Asn Gly Asn Ser Thr Leu Tyr 500 505 510
- Gln Asn Val Thr Ile Glu Gln Gly Arg Ile Val Leu Arg Glu Lys Ala 515 520 525
- Lys Leu Ser Val Asn Ser Leu Ser Gln Thr Gly Gly Ser Leu Tyr Met 530 540
- Glu Ala Gly Ser Thr Leu Asp Phe Val Thr Pro Gln Pro Pro Gln Gln 545 550 555 560
- Pro Pro Ala Ala Asn Gln Ser Ile Thr Leu Ser Asn Leu His Leu Ser 565 570 575
- Leu Ser Ser Leu Leu Ala Asn Asn Ala Val Thr Asn Pro Pro Thr Asn 580 585 590
- Pro Pro Ala Gln Asp Ser His Pro Ala Val Ile Gly Ser Thr Thr Ala 595 600 605
- Gly Ser Val Thr Ile Ser Gly Pro Ile Phe Phe Glu Asp Leu Asp Asp 610 615 620
- Thr Ala Tyr Asp Arg Tyr Asp Trp Leu Gly Ser Asn Gln Lys Ile Asp

625 630 635 640

Val Leu Lys Leu Gln Leu Gly Thr Gln Pro Pro Ala Asn Ala Pro Ser 645 650 655

Asp Leu Thr Leu Gly Asn Glu Met Pro Lys Tyr Gly Tyr Gln Gly Ser 660 665 670

Trp Lys Leu Ala Trp Asp Pro Asn Thr Ala Asn Asn Gly Pro Tyr Thr 675 680 685

Leu Lys Ala Thr Trp Thr Lys Thr Gly Tyr Asn Pro Gly Pro Glu Arg 690 695 700

Val Ala Ser Leu Val Pro Asn Ser Leu Trp Gly Ser Ile Leu Asp Ile 705 710 715 720

Arg Ser Ala His Ser Ala Ile Gln Ala Ser Val Asp Gly Arg Ser Tyr 725 730 735

Cys Arg Gly Leu Trp Val Ser Gly Val Ser Asn Phe Phe Tyr His Asp 740 745 750

Arg Asp Ala Leu Gly Gln Gly Tyr Arg Tyr Ile Ser Gly Gly Tyr Ser 755 760 765

Leu Gly Ala Asn Ser Tyr Phe Gly Ser Ser Met Phe Gly Leu Ala Phe 770 775 780

Thr Glu Val Phe Gly Arg Ser Lys Asp Tyr Val Val Cys Arg Ser Asn 785 790 795 800

His His Ala Cys Ile Gly Ser Val Tyr Leu Ser Thr Lys Gln Ala Leu 805 810 815

Cys Gly Ser Tyr Val Phe Gly Asp Ala Phe Ile Arg Ala Ser Tyr Gly 820 825 830

Phe Gly Asn Gln His Met Lys Thr Ser Tyr Thr Phe Ala Glu Glu Ser 835 840 845

Asp Val Cys Trp Asp Asn Asn Cys Leu Val Gly Glu Ile Gly Val Gly 850 855 860

Leu Pro Ile Val Ile Thr Pro Ser Lys Leu Tyr Leu Asn Glu Leu Arg 865 870 870 875 875 880

Pro Phe Val Gln Ala Glu Phe Ser Tyr Ala Asp His Glu Ser Phe Thr

885 890 895

Glu Glu Gly Asp Gln Ala Arg Ala Phe Arg Ser Gly His Leu Met Asn 900 905 910

Leu Ser Val Pro Val Gly Val Lys Phe Asp Arg Cys Ser Ser Thr His 915 920 925

Pro Asn Lys Tyr Ser Phe Met Gly Ala Tyr Ile Cys Asp Ala Tyr Arg 930 935 940

Thr Ile Ser Gly Thr Gln Thr Thr Leu Leu Ser His Gln Glu Thr Trp 945 950 955 960

Thr Thr Asp Ala Phe His Leu Ala Arg His Gly Val Ile Val Arg Gly 965 970 975

Ser Met Tyr Ala Ser Leu Thr Ser Asn Ile Glu Val Tyr Gly His Gly 980 985 990

Arg Tyr Glu Tyr Arg Asp Thr Ser Arg Gly Tyr Gly Leu Ser Ala Gly 995 1000 1005

Ser Lys Val Arg Phe 1010

<210> 16

<211> 1013

<212> PRT

<213> Chlamydia

<400> 16

Met Gln Thr Ser Phe His Lys Phe Phe Leu Ser Met Ile Leu Ala Tyr

1 5 10 15

Ser Cys Cys Ser Leu Thr Gly Gly Gly Tyr Ala Ala Glu Ile Met Val $20 \hspace{1.5cm} 25 \hspace{1.5cm} 30$ 

Pro Gln Gly Ile Tyr Asp Gly Glu Thr Leu Thr Val Ser Phe Pro Tyr 35 40 45

Thr Val Ile Gly Asp Pro Ser Gly Thr Thr Val Phe Ser Ala Gly Glu 50 55 60

Leu Thr Leu Lys Asn Leu Asp Asn Ser Ile Ala Ala Leu Pro Leu Ser 65 70 75 80

Cys Phe Gly Asn Leu Leu Gly Ser Phe Thr Val Leu Gly Arg Gly His 85 90 95

- Ser Leu Thr Phe Glu Asn Ile Arg Thr Ser Thr Asn Gly Ala Ala Leu 100 105 110
- Ser Asp Ser Ala Asn Ser Gly Leu Phe Thr Ile Glu Gly Phe Lys Glu 115 120 125
- Leu Ser Phe Ser Asn Cys Asn Ser Leu Leu Ala Val Leu Pro Ala Ala 130 135 140
- Thr Thr Asn Asn Gly Ser Gln Thr Pro Thr Thr Thr Ser Thr Pro Ser 145
- Asn Gly Thr Ile Tyr Ser Lys Thr Asp Leu Leu Leu Leu Asn Asn Glu 165 170 175
- Lys Phe Ser Phe Tyr Ser Asn Leu Val Ser Gly Asp Gly Gly Thr Ile 180 185 190
- Asp Ala Lys Ser Leu Thr Val Gln Gly Ile Ser Lys Leu Cys Val Phe 195 200 205
- Gln Glu Asn Thr Ala Gln Ala Asp Gly Gly Ala Cys Gln Val Val Thr 210 215 220
- Ser Phe Ser Ala Met Ala Asn Glu Ala Pro Ile Ala Phe Ile Ala Asn 225 230 235 240
- Val Ala Gly Val Arg Gly Gly Gly Ile Ala Ala Val Gln Asp Gly Gln 245 250 255
- Gln Gly Val Ser Ser Ser Thr Ser Thr Glu Asp Pro Val Val Ser Phe 260 265 270
- Ser Arg Asn Thr Ala Val Glu Phe Asp Gly Asn Val Ala Arg Val Gly 275 280 285
- Gly Gly Ile Tyr Ser Tyr Gly Asn Val Ala Phe Leu Asn Asn Gly Lys 290 295 300
- Thr Leu Phe Leu Asn Asn Val Ala Ser Pro Val Tyr Ile Ala Ala Glu 305 310 315 320
- Gln Pro Thr Asn Gly Gln Ala Ser Asn Thr Ser Asp Asn Tyr Gly Asp 325 330 335

- 15 -

Gly Gly Ala Ile Phe Cys Lys Asn Gly Ala Gln Ala Ala Gly Ser Asn 340 345 350

- Asn Ser Gly Ser Val Ser Phe Asp Gly Glu Gly Val Val Phe Phe Ser 355 360 365
- Ser Asn Val Ala Ala Gly Lys Gly Gly Ala Ile Tyr Ala Lys Lys Leu 370 375 380
- Ser Val Ala Asn Cys Gly Pro Val Gln Phe Leu Gly Asn Ile Ala Asn 385 390 395 400
- Asp Gly Gly Ala Ile Tyr Leu Gly Glu Ser Gly Glu Leu Ser Leu Ser 405 410 415
- Ala Asp Tyr Gly Asp Ile Ile Phe Asp Gly Asn Leu Lys Arg Thr Ala 420 425 430
- Lys Glu Asn Ala Ala Asp Val Asn Gly Val Thr Val Ser Ser Gln Ala 435 440 445
- Ile Ser Met Gly Ser Gly Gly Lys Ile Thr Thr Leu Arg Ala Lys Ala 450 455 460
- Gly His Gln Ile Leu Phe Asn Asp Pro Ile Glu Met Ala Asn Gly Asn 465 470 475 480
- Asn Gln Pro Ala Gln Ser Ser Glu Pro Leu Lys Ile Asn Asp Gly Glu
  485 490 495
- Gly Tyr Thr Gly Asp Ile Val Phe Ala Asn Gly Asn Ser Thr Leu Tyr
  500 505 510
- Gln Asn Val Thr Ile Glu Gln Gly Arg Ile Val Leu Arg Glu Lys Ala 515 520 525
- Lys Leu Ser Val Asn Ser Leu Ser Gln Thr Gly Gly Ser Leu Tyr Met 530 535 540
- Glu Ala Gly Ser Thr Leu Asp Phe Val Thr Pro Gln Pro Pro Gln Gln 545 550 555 560
- Pro Pro Ala Ala Asn Gln Leu Ile Thr Leu Ser Asn Leu His Leu Ser 565 570 575
- Leu Ser Ser Leu Leu Ala Asn Asn Ala Val Thr Asn Pro Pro Thr Asn 580 585 590

Pro Pro Ala Gln Asp Ser His Pro Ala Val Ile Gly Ser Thr Thr Ala 595 600 605

- Gly Pro Val Thr Ile Ser Gly Pro Phe Phe Phe Glu Asp Leu Asp Asp 610 615 620
- Thr Ala Tyr Asp Arg Tyr Asp Trp Leu Gly Ser Asn Gln Lys Ile Asp 625 630 630 635 640
- Val Leu Lys Leu Gln Leu Gly Thr Gln Pro Ser Ala Asn Ala Pro Ser 645 650 655
- Asp Leu Thr Leu Gly Asn Glu Met Pro Lys Tyr Gly Tyr Gln Gly Ser 660 665 670
- Trp Lys Leu Ala Trp Asp Pro Asn Thr Ala Asn Asn Gly Pro Tyr Thr 675 680 685
- Leu Lys Ala Thr Trp Thr Lys Thr Gly Tyr Asn Pro Gly Pro Glu Arg 690 695 700
- Val Ala Ser Leu Val Pro Asn Ser Leu Trp Gly Ser Ile Leu Asp Ile 705 710 715 720
- Arg Ser Ala His Ser Ala Ile Gln Ala Ser Val Asp Gly Arg Ser Tyr 725 730 735
- Cys Arg Gly Leu Trp Val Ser Gly Val Ser Asn Phe Ser Tyr His Asp 740 745 750
- Arg Asp Ala Leu Gly Gln Gly Tyr Arg Tyr Ile Ser Gly Gly Tyr Ser 755 760 765
- Leu Gly Ala Asn Ser Tyr Phe Gly Ser Ser Met Phe Gly Leu Ala Phe
  770 775 780
- Thr Glu Val Phe Gly Arg Ser Lys Asp Tyr Val Val Cys Arg Ser Asn 785 790 795 800
- His His Ala Cys Ile Gly Ser Val Tyr Leu Ser Thr Lys Gln Ala Leu 805 810 815
- Cys Gly Ser Tyr Leu Phe Gly Asp Ala Phe Ile Arg Ala Ser Tyr Gly 820 825 830
- Phe Gly Asn Gln His Met Lys Thr Ser Tyr Thr Phe Ala Glu Glu Ser 835

- 17 -

Asp Val Arg Trp Asp Asn Asn Cys Leu Val Gly Glu Ile Gly Val Gly 850 855 860

Leu Pro Ile Val Thr Thr Pro Ser Lys Leu Tyr Leu Asn Glu Leu Arg 865 870 875 880

Pro Phe Val Gln Ala Glu Phe Ser Tyr Ala Asp His Glu Ser Phe Thr 885 890 895

Glu Glu Gly Asp Gln Ala Arg Ala Phe Arg Ser Gly His Leu Met Asn 900 905 910

Leu Ser Val Pro Val Gly Val Lys Phe Asp Arg Cys Ser Ser Thr His 915 920 925

Pro Asn Lys Tyr Ser Phe Met Gly Ala Tyr Ile Cys Asp Ala Tyr Arg 930 935 940

Thr Ile Ser Gly Thr Gln Thr Thr Leu Leu Ser His Gln Glu Thr Trp 945 950 955 960

Thr Thr Asp Ala Phe His Leu Ala Arg His Gly Val Ile Val Arg Gly 965 970 975

Ser Met Tyr Ala Ser Leu Thr Ser Asn Ile Glu Val Tyr Gly His Gly 980 985 990

Arg Tyr Glu Tyr Arg Asp Thr Ser Arg Gly Tyr Gly Leu Ser Ala Gly 995 1000 1005

Ser Lys Val Arg Phe 1010

<210> 17

<211> 505

<212> PRT

<213> Chlamydia

<400> 17

Glu Ile Met Val Pro Gln Gly Ile Tyr Asp Gly Glu Thr Leu Thr Val 1 5 10 15

Ser Phe Pro Tyr Thr Val Ile Gly Asp Pro Ser Gly Thr Thr Val Phe 20 25 30

Ser Ala Gly Glu Leu Thr Leu Lys Asn Leu Asp Asn Ser Ile Ala Ala 35 40 45

PCT/US98/20737 WO 99/17741

Leu	Pro 50		eu	Ser	Cys	Pl	ne	Gly 55	As	n :	Leu	Le	ι G	Sly	Ser 60	Ph	ie '	Thr	Val	L€	eu
Gly 65	Arg	G	ly	His	Sei		eu 70	Thr	Ph	ie	Glu	As	n I	11e 75	Arg	Tì	ır	Ser	Thr	A	sn 80
Gly	Ala	ı F	Ala	Leu	Se:		.sn	Ser	A.	La	Ala	As 9	р ( 0	Gly	Leu	Pl	ne	Thr	Ile 95	G	lu
Gly	Phe	e 1	Ĺуs	Glu 100		u S	Ser	Phe	S	er	Asn 105	Су	s i	Asn	Ser	L	eu	Leu 110	Ala	ιV	al
Leu	Pr		Ala 115		a Th	r T	fhr	Asn		ys 20	Gly	Se	er	Gln	Thi	: P	ro 25	Thr	Thi	T	hr
Ser	Th		Pro	Se	r As	n (	Gly	Thr 135		le	Tyr	: Se	er	Lys	Th:	c A O	ds,	Leu	Le	ı I	eu
Lev 145		n	Asr	Gl	u Ly		Phe 150		r F	he	Туз	: Se	er	Asn 155	Le	u V	/al	Ser	: G1	y <i>1</i>	Asp 160
Gl	y G]	Lу	Ala	a Il		sp 65	Ala	Ly	s S	Ser	Le	1 T	hr 70	Val	. G1	n (	Gly	Ile	e Se 17	r 1 5	Lys
Le	u C	ys	Va	1 Ph		ln	Glı	ı As	n '	Thr	Al 18		ln	Ala	a As	p (	Gly	Gl;	y Al O	a	Cys
G1	n V	al	Va 19		nr S	er	Pho	e Se		Ala 200		t P	la	Ası	n Gl	u.	Ala 209	a Pr	o I]	.e	Ala
Ph		al 10		a A	sn V	al	Al	a G]		Va.	l Ar	g (	Sly	· G1	y G1 22	20 20	Ile	e Al	a A	La	Val
	ln A 25	sp	G]	.y G	ln (	iln	G1 23		al	Se	r Se	er :	Ser	Th 23	r Se	er	Th	r Gl	u A	sp	Pro 240
Va	al V	/al	L Se	er P		Ser 245		g A	sn	Th	r A	la	Va] 25(	G 1	.u P.	he	As	p G	Ly A 2	sn 55	Val
A	la i	Ard	g V		60	Gly	- G!	Ly I	le	Ту	r S	er 65	Ту	r G]	ly A	.sn	Va	1 A	la P 70	he	Leu

- 19 -

Asn Asn Gly Lys Thr Leu Phe Leu Asn Asn Val Ala Ser Pro Val Tyr

Ile Ala Ala Lys Gln Pro Thr Ser Gly Gln Ala Ser Asn Thr Ser Asn

280

295

275

290

285

300

Asn Tyr Gly Asp Gly Gly Ala Ile Phe Cys Lys Asn Gly Ala Gln Ala Gly Ser Asn Asn Ser Gly Ser Val Ser Phe Asp Gly Glu Gly Val Val Phe Phe Ser Ser Asn Val Ala Ala Gly Lys Gly Gly Ala Ile Tyr Ala Lys Lys Leu Ser Val Ala Asn Cys Gly Pro Val Gln Phe Leu Arg Asn Ile Ala Asn Asp Gly Gly Ala Ile Tyr Leu Gly Glu Ser Gly Glu Leu Ser Leu Ser Ala Asp Tyr Gly Asp Ile Ile Phe Asp Gly Asn Leu Lys Arg Thr Ala Lys Glu Asn Ala Ala Asp Val Asn Gly Val Thr Val Ser Ser Gln Ala Ile Ser Met Gly Ser Gly Gly Lys Ile Thr Thr Leu Arg Ala Lys Ala Gly His Gln Ile Leu Phe Asn Asp Pro Ile Glu Met Ala Asn Gly Asn Asn Gln Pro Ala Gln Ser Ser Lys Leu Leu Lys Ile Asn Asp Gly Glu Gly Tyr Thr Gly Asp Ile Val Phe Ala Asn Gly Ser Ser Thr Leu Tyr Gln Asn Val Thr Ile Glu Gln Gly Arg Ile Val Leu Arg Glu Lys Ala Lys Leu Ser Val Asp Ser <210> 18 <211> 57 <212> DNA <213> Chlamydia

<400> 18

aagggcccaa ttacgcaqaq ctcgagagaa attatggttc ctcaaggaat ttacqat

```
<210> 19
<211> 20
<212> DNA
<213> Chlamydia
<400> 19
                                                                   20
cgctctagaa ctagtggatc
<210> 20
<211> 22
<212> DNA
<213> Chlamydia
<400> 20
                                                                   22
atggttcctc aaggaattta cg
 <210> 21
 <211> 19
 <212> DNA
 <213> Chlamydia
 <400> 21
                                                                    19
 ggtccccat cagcgggag
 <210> 22
 <211> 1515
 <212> DNA
 <213> Chlamydia
 <400> 22
 gaaatcatgg ttcctcaagg aatttacgat ggggagacgt taactgtatc atttccctat 60
  actgttatag gagatccgag tgggactact gttttttctg caggagagtt aacattaaaa 120
  aatcttgaca attctattgc agctttgcct ttaagttgtt ttgggaactt attagggagt 180
  tttactgttt tagggagagg acactcgttg actttcgaga acatacggac ttctacaaat 240
  ggggcagctc taagtaatag cgctgctgat ggactgttta ctattgaggg ttttaaagaa 300
  ttateetttt ecaattgeaa tteattaett geegtaetge etgetgeaac gaetaataag 360
  ggtagccaga ctccgacgac aacatctaca ccgtctaatg gtactattta ttctaaaaca 420
  gatcttttgt tactcaataa tgagaagttc tcattctata gtaatttagt ctctggagat 480
  gggggagcta tagatgctaa gagcttaacg gttcaaggaa ttagcaagct ttgtgtcttc 540
  caagaaaata ctgctcaagc tgatggggga gcttgtcaag tagtcaccag tttctctgct 600
  atggctaacg aggctcctat tgcctttgta gcgaatgttg caggagtaag agggggaggg 660
  attgctgctg ttcaggatgg gcagcaggga gtgtcatcat ctacttcaac agaagatcca 720
  gtagtaagtt tttccagaaa tactgcggta gagtttgatg ggaacgtagc ccgagtagga 780
  ggagggattt actcctacgg gaacgttgct ttcctgaata atggaaaaac cttgtttctc 840
  aacaatgttg cttctcctgt ttacattgct gctaagcaac caacaagtgg acaggcttct 900
   aatacgagta ataattacgg agatggagga gctatcttct gtaagaatgg tgcgcaagca 960
   ggatccaata actctggatc agtttccttt gatggagagg gagtagtttt ctttagtagc 1020
```

- 21 -

```
aatgtagctg ctgggaaagg gggagctatt tatgccaaaa agctctcqqt tqctaactqt 1080
ggccctgtac aattittaag gaatatcgct aatgatggtg gagcgattta tttaggagaa 1140
totggagago toagtttato tgotgattat ggagatatta ttttcgatqq qaatottaaa 1200
agaacagcca aagagaatgc tgccgatgtt aatggcgtaa ctgtgtcctc acaagccatt 1260
tegatèggat egggagggaa aataaegaca ttaagageta aageagggea teagattete 1320
tttaatgatc ccatcgagat ggcaaacgga aataaccagc cagcgcagtc ttccaaactt 1380
ctaaaaatta acgatggtga aggatacaca ggggatattg tttttgctaa tggaagcagt 1440
actttgtacc aaaatgttac gatagagcaa ggaaggattg ttcttcgtqa aaaqqcaaaa 1500
ttatcagtga attct
                                                                  1515
<210> 23
<211> 3354
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
     recombinant expression vector
<400> 23
atgcaaacgt ctttccataa gttctttctt tcaatgattc tagcttattc ttgctqctct 60
ttaaatgggg gggggtatgc agaaatcatg gttcctcaag gaatttacga tggggagacg 120
ttaactgtat catttcccta tactgttata ggagatccga gtgggactac tgtttttct 180
gcaggagagt taacgttaaa aaatcttgac aattctattg cagctttgcc tttaagttgt 240
tttgggaact tattagggag ttttactgtt ttagggagag gacactcgtt gactttcgag 300
aacatacgga cttctacaaa tggagctgca ctaagtgaca gcgctaatag cgggttattt 360
actattgagg gttttaaaga attatctttt tccaattgca acccattact tqccqtactq 420
cctgctgcaa cgactaataa tqqtagccag actccgtcga caacatctac accgtctaat 480
ggtactattt attctaaaac agatcttttg ttactcaata atgagaagtt ctcattctat 540
agtaattcag tctctqqaga tggqggagct ataqatqcta agagcttaac qqttcaaqqa 600
attagcaage tttgtgtctt ccaagaaaat actgctcaag ctgatggggg agettgtcaa 660
gtagtcacca gtttctctgc tatggctaac gaggctccta ttgcctttgt agcqaatgtt 720
gcaggagtaa gagggggagg gattgctgct gttcaggatg ggcagcaggg aqtqtcatca 780
totacticaa cagaagatcc agtagtaagt tittccagaa atactqcqqt agaqtitqat 840
gggaacgtag cccgagtagg aggagggatt tactcctacg ggaacgttqc tttcctqaat 900
aatggaaaaa ccttgtttct caacaatgtt gcttctcctg tttacattqc tgctgagcaa 960
ccaacaaatg gacaggcttc taatacgagt gataattacg gagatggagg agctatcttc 1020
tgtaagaatg gtgcgcaagc agcaggatcc aataactctg gatcagtttc ctttgatgga 1080
gagggagtag ttttctttag tagcaatgta gctgctggga aagggggagc tatttatqcc 1140
aaaaagctct cggttgctaa ctgtggccct gtacaactct tagggaatat cqctaatqat 1200
ggtggagcga tttatttagg agaatctgga gagctcagtt tatctgctga ttatggagat 1260
atgattttcg atgggaatct taaaagaaca gccaaagaga atgctgccga tgttaatggc 1320
```

gtaactgtgt cctcacaagc catttcgatg ggatcgggag ggaaaataac gacattaaga 1380 gctaaagcag ggcatcagat tctctttaat gatcccatcg agatggcaaa cggaaataac 1440 cagccagcgc agtcttccqa acctctaaaa attaacgatg gtgaaggata cacaggggat 1500 attgtttttg ctaatggaaa cagtactttg taccaaaatg ttacgataga gcaaggaagg 1560 attgttcttc gtgaaaaggc aaaattatca gtgaattctc taagtcagac aggtgggagt 1620 ctgtatatgg aagctgggag tacattggat tttgtaactc cacaaccacc acaacagcct 1680

PCT/US98/20737 WO 99/17741

```
cctgccgcta atcagtcgat cacgctttcc aatctgcatt tgtctctttc ttctttgtta 1740
gcaaacaatg cagttacgaa teeteetace aateeteeag egcaagatte teateetgea 1800
gtcattggta gcacaactgc tggttctgtt acaattagtg ggcctatctt ttttgaggat 1860
ttggatgata cagcttatga taggtatgat tggctaggtt ctaatcaaaa aatcgatgtc 1920
ctgaaattac agttagggac tcagccccca gctaatgccc catcagattt gactctaggg 1980
aatgagatgc ctaagtatgg ctatcaagga agctggaagc ttgcgtggga tcctaataca 2040
gcaaataatg gteettatae tetgaaaget acatggaeta aaactgggta taateetggg 2100
cctgagcgag tagcttcttt ggttccaaat agtttatggg gatccatttt agatatacga 2160
tetgegeatt cagcaattca agcaagtgtg gatgggeget ettattgteg aggattatgg 2220
gtttctggag tttcgaattt cttctatcat gaccgcgatg ctttaggtca gggatatcgg 2280
tatattagtg ggggttattc cttaggagca aactcctact ttggatcatc gatgtttggt 2340
ctagcattta ctgaagtatt tggtagatct aaagattatg tagtgtgtcg ttccaatcat 2400
catgettgea taggateegt ttatetatet accaaacagg etttatgtgg atettatgtg 2460
tttggagatg cgtttattcg tgctagctac gggtttggga atcagcatat gaaaacctca 2520
tatacatttg cagaggagag cgatgtttgt tgggataata actgtctggt tggagagatt 2580
ggagtgggat taccgattgt gattactcca tctaagctct atttgaatga gttgcgtcct 2640
ttcgtgcaag ctgagttttc ttatgccgat catgaatctt ttacagagga aggcgatcaa 2700
 gctcgggcat tcaggagtgg acatctcatg aatctatcag ttcctgttgg agtaaaattt 2760
 gatcgatgtt ctagtacaca ccctaataaa tatagcttta tgggggctta tatctgtgat 2820
 gettategea ceatetetgg gaeteagaca acaeteetat eecateaaga gaeatggaca 2880
 acagatgeet tteatttgge aagacatgga gteatagtta gagggtetat gtatgettet 2940
 ctaacaagca atatagaagt atatggccat ggaagatatg agtatcgaga tacttctcga 3000
 ggttatggtt tgagtgcagg aagtaaagtc cggttctaaa aatattggtt agatagttaa 3060
 gtgttagcga tgcctttttc tttgagatct acatcatttt gttttttagc ttgtttgtgt 3120
 tectattegt atggattege gageteteet caagtgttaa caectaatgt aaccaeteet 3180
 tttaaggggg acgatgttta cttgaatgga gactgcgctt ttgtcaatgt ctatgcaggg 3240
 gcagagaacg gctcaattat ctcagctaat ggcgacaatt taacgattac cggacaaaac 3300
 catacattat catttacaca ttctcaaggg ccagttcttc aaaattagcc ttca
                                                                    3354
```

<210> 24

<211> 3324

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: recombinant expression vector

<400> 24

atgcaaacgt ctttccataa gttctttctt tcaatgattc tagcttattc ttgctgctct 60 ttaagtgggg gggggtatgc agcagaaatc atgattcctc aaggaattta cgatgggag 120 acgttaactg tatcatttcc ctatactgtt ataggagatc cgagtgggac tactgtttt 180 tctgcaggag agttaacgtt aaaaaatctt gacaattcta ttgcagcttt gcctttaagt 240 tgttttggga acttattagg gagttttact gttttaggga gaggacactc gttgactttc 300 gagaacatac ggacttctac aaatggagct gcactaagtg acagcgctaa tagcgggtta 360 tttactattg agggttttaa agaattatct ttttccaatt gcaactcatt acttgccgta 420 ctgcctgctg caacgactaa taatggtagc cagactccga cgacaacatc tacaccgtct 480 aatggtacta tttattctaa aacagatctt ttgttactca ataatgagaa gttctcattc 540

- 23 -

tatagtaatt tagtetetgg agatqqqqqa actatagatg etaagagett aacggtteaa 600 ggaattagca agctttgtgt cttccaagaa aatactgctc aagctgatgg gggagcttgt 660 caagtagtca ccagtttctc tgctatggct aacgaggctc ctattgcctt tatagcgaat 720 gttgcaggag taagaggggg agggattgct gctgttcagg atgggcagca gggagtqtca 780 tcatctactt caacagaaga tccagtagta agtttttcca gaaatactgc ggtagagttt 840 gatgggaacg tagcccgagt aggaggaggg atttactcct acgggaacgt tgctttcctg 900 aataatggaa aaaccttgtt tctcaacaat gttgcttctc ctgtttacat tgctgctgag 960 caaccaacaa atggacaggc ttctaatacg agtgataatt acggagatgq aggaqctatc 1020 ttctgtaaga atggtgcgca agcagcagga tccaataact ctggatcagt ttcctttgat 1080 ggagagggag tagttttctt tagtagcaat gtagctgctg ggaaaggggg aqctatttat 1140 gccaaaaagc tctcggttgc taactgtggc cctgtacaat tcttagggaa tatcgctaat 1200 gatggtggag cgatttattt aggagaatct ggagagctca gtttatctgc tgattatgga 1260 gatattattt tcgatgggaa tcttaaaaga acagccaaag agaatgctgc cqatgttaat 1320 ggcgtaactg tgtcctcaca agccatttcg atgggatcgg gagggaaaat aacgacatta 1380 agagctaaag cagggcatca gattctcttt aatgatccca tcgagatggc aaacggaaat 1440 aaccagccag cgcagtcttc cgaacctcta aaaattaacg atggtgaagg atacacaggg 1500 gatattgttt ttgctaatgg aaacagtact ttgtaccaaa atgttacgat agagcaagga 1560 aggattgttc ttcgtgaaaa ggcaaaatta tcagtgaatt ctctaagtca gacaggtggg 1620 agtctgtata tggaagctgg gagtacattg gattttgtaa ctccacaacc accacaacag 1680 cotcotgoog ctaatcagtt gatcacgctt tocaatctgc atttgtctct ttcttctttq 1740 ttagcaaaca atgcagttac gaatcctcct accaatcctc cagcgcaaga ttctcatcct 1800 gcagtcattg gtagcacaac tgctggtcct gtcacaatta gtgggccttt cttttttgag 1860 gatttggatg atacagctta tgataggtat gattggctag gttctaatca aaaaatcgat 1920 gtcctgaaat tacagttagg gactcagccc tcagctaatg ccccatcaga tttgactcta 1980 gggaatgaga tgcctaagta tggctatcaa ggaagctgga agcttgcgtg ggatcctaat 2040 acagcaaata atggtcctta tactctgaaa qctacatgga ctaaaactgg qtataatcct 2100 999cctgagc gagtagcttc tttggttcca aatagtttat ggggatccat tttagatata 2160 cgatctgcgc attcagcaat tcaagcaagt gtggatgggc gctcttattg tcgaggatta 2220 tgggtttctg gagtttcgaa tttctcctat catgaccgcg atgctttagg tcagggatat 2280 cggtatatta gtgggggtta ttccttagga gcaaactcct actttggatc atcgatgttt 2340 ggtctagcat ttaccgaagt atttggtaga tctaaagatt atgtagtgtg tcgttccaat 2400 catcatgctt gcataggatc cgtttatcta tctaccaaac aagctttatg tggatcctat 2460 ttgttcggag atgcgtttat ccgtgctagc tacgggtttg ggaaccagca tatgaaaacc 2520 tcatacacat ttgcagagga gagcgatgtt cgttgggata ataactgtct ggttggagag 2580 attggagtgg gattaccgat tgtgactact ccatctaagc tctatttgaa tgagttgcgt 2640 cctttcgtgc aagctgagtt ttcttatgcc gatcatgaat cttttacaga ggaaggcgat 2700 caageteggg catteaggag tggteatete atgaatetat cagtteetgt tggagtaaaa 2760 tttgatcgat gttctagtac acaccctaat aaatatagct ttatgggggc ttatatctgt 2820 gatgettate geaceatete tgggaeteag acaacactee tateceatea agagacatgg 2880 acaacagatg cctttcattt ggcaagacat ggagtcatag ttagagggtc tatgtatgct 2940 tctctaacaa gcaatataga agtatatggc catggaagat atgagtatcg agatacttct 3000 cgaggttatg gtttgagtgc aggaagtaaa gtccggttct aaaaatattg gttagatagt 3060 taagtgttag cgatgccttt ttctttgaga tctacatcat tttgtttttt agcttgtttg 3120 tgttcctatt cgtatggatt cgcgagctct cctcaagtgt taacacctaa tgtaaccact 3180 ccttttaagg gggacgatgt ttacttgaat ggagactgcg ctttagtcaa tgtctatgca 3240 ggggcagaga acggctcaat tatctcagct aatggcgaca atttaacgat taccggacaa 3300 aaccatgcat tatcatttac agat 3324

PCT/US98/20737

WO 99/17741 <210> 25 <211> 65 <212> PRT <213> Chlamydia <400> 25 20

Pro Tyr Thr Val Ile Gly Asp Pro Ser Gly Thr Thr Val Phe Ser Ala 5

Gly Glu Leu Thr Leu Lys Asn Leu Asp Asn Ser Ile Ala Ala Pro Leu 25

Ser Cys Phe Gly Asn Leu Leu Gly Ser Phe Thr Val Leu Gly Arg Gly 40 35

His Ser Leu Thr Phe Glu Asn Ile Arg Thr Ser Thr Asn Gly Ala Ala 55

Leu 65

<210> 26

<211> 24

<212> PRT

<213> Chlamydia

<400> 26

Ala Ala Asn Gln Leu Ile Thr Leu Ser Asn Leu His Leu Ser Leu Ser 15 10 5 1

Ser Leu Leu Ala Asn Asn Ala Val

20

<210> 27

<211> 8

<212> PRT

<213> Chlamydia

<400> 27

Gly Tyr Thr Gly Asp Ile Val Phe

<210> 28

<211> 7

<212> PRT

<213> Chlamydia <400> 28 Tyr Gly Asp Ile Ile Phe Asp 1 ` <210> 29 <211> 63 <212> PRT <213> Chlamydera cerviniventris <400> 29 Gly Tyr Ala Ala Glu Ile Met Val Pro Gln Gly Ile Tyr Asp Gly Glu Thr Leu Thr Val Ser Phe Pro Tyr Thr Val Ile Gly Asp Pro Ser Gly 25 Thr Thr Val Phe Ser Ala Gly Glu Leu Thr Leu Lys Asn Leu Asp Asn 40 Ser Ile Ala Ala Leu Pro Leu Ser Cys Phe Gly Asn Leu Leu Gly 50 55 <210> 30 <211> 22 <212> PRT <213> Chlamydia Met Ala Asn Gly Asn Asn Gln Pro Ala Gln Ser Ser Lys Leu Leu Lys 10 Ile Asn Asp Gly Glu Gly 20 <210> 31 <211> 14 <212> PRT <213> Chlamydia <400> 31

Ala Asn Gly Ser Ser Thr Leu Tyr Gln Asn Val Thr Ile Glu

1 5 10

WO 99/17741

<210> 32 <211> 10 <212> PRT <213> Chlamydia <400> 32 Lys Leu Ser Val Asn Ser Leu Ser Gln Thr 5 1 <210> 33 <211> 45 <212> PRT <213> Chlamydia <400> 33 Val Ile Gly Ser Thr Thr Ala Gly Ser Val Thr Ile Ser Gly Pro Ile 10 5 Phe Phe Glu Asp Leu Asp Asp Thr Ala Tyr Asp Arg Tyr Asp Trp Leu 25 20 Gly Ser Asn Gln Lys Ile Asn Val Leu Lys Leu Gln Leu 40 <210> 34 <211> 64 <212> PRT <213> Chlamydia Val Ile Gly Ser Thr Thr Ala Gly Ser Val Thr Ile Ser Gly Pro Ile 10 5 1 Phe Phe Glu Asp Leu Asp Asp Thr Ala Tyr Asp Arg Tyr Asp Trp Leu 25 20 Gly Ser Asn Gln Lys Ile Asn Val Leu Lys Leu Gln Leu Gly Thr Lys 40 35

Pro Pro Ala Asn Ala Pro Ser Asp Leu Thr Leu Gly Asn Glu Met Pro

55

<210> 35

<211> 10

<212> PRT

<213> Chlamydia

<400> 35

Asp Pro Asn Thr Ala Asn Asn Gly Pro Tyr

1 5 10

<210> 36

<211> 458

<212> PRT

<213> Chlamydia

<400> 36

Gly Gly Ala Cys Gln Val Val Thr Ser Phe Ser Ala Met Ala Asn Glu

1 5 10 15

Ala Pro Ile Ala Phe Val Ala Asn Val Ala Gly Val Arg Gly Gly
20 25 30

Ile Ala Ala Val Gln Asp Gly Gln Gln Gly Val Ser Ser Ser Thr Ser
35 40 45

Thr Glu Asp Pro Val Val Ser Phe Ser Arg Asn Thr Ala Val Glu Phe
50 55 60

Asp Gly Asn Val Ala Arg Val Gly Gly Gly Ile Tyr Ser Tyr Gly Asn 65 70 75 80

Val Ala Phe Leu Asn Asn Gly Lys Thr Leu Phe Leu Asn Asn Val Ala 85 90 95

Ser Pro Val Tyr Ile Ala Ala Lys Gln Pro Thr Ser Gly Gln Ala Ser 100 105 110

Asn Thr Ser Asn Asn Tyr Gly Asp Gly Gly Ala Ile Phe Cys Lys Asn 115 120 125

Gly Ala Gln Ala Gly Ser Asn Asn Ser Gly Ser Val Ser Phe Asp Gly
130 135 140

Glu Gly Val Val Phe Phe Ser Ser Asn Val Ala Ala Gly Lys Gly Gly 145 150 155 160

Ala Ile Tyr Ala Lys Lys Leu Ser Val Ala Asn Cys Gly Pro Val Gln

175

- Phe Leu Arg Asn Ile Ala Asn Asp Gly Gly Ala Ile Tyr Leu Gly Glu 180 185 190
- Ser Gly Glu Leu Ser Leu Ser Ala Asp Tyr Gly Asp Ile Ile Phe Asp 195 200 205
- Gly Asn Leu Lys Arg Thr Ala Lys Glu Asn Ala Ala Asp Val Asn Gly 210 215 220
- Val Thr Val Ser Ser Gln Ala Ile Ser Met Gly Ser Gly Gly Lys Ile 225 230 235 240
- Thr Thr Leu Arg Ala Lys Ala Gly His Gln Ile Leu Phe Asn Asp Pro 245 250 255
- Ile Glu Met Ala Asn Gly Asn Asn Gln Pro Ala Gln Ser Ser Lys Leu 260 265 270
- Leu Lys Ile Asn Asp Gly Glu Gly Tyr Thr Gly Asp Ile Val Phe Ala 275 280 285
- Asn Gly Ser Ser Thr Leu Tyr Gln Asn Val Thr Ile Glu Gln Gly Arg 290 295 300
- Ile Val Leu Arg Glu Lys Ala Lys Leu Ser Val Asn Ser Leu Ser Gln 305 310 315 320
- Thr Gly Gly Ser Leu Tyr Met Glu Ala Gly Ser Thr Trp Asp Phe Val 325 330 335
- Thr Pro Gln Pro Pro Gln Gln Pro Pro Ala Ala Asn Gln Leu Ile Thr 340 345 350
- Leu Ser Asn Leu His Leu Ser Leu Ser Ser Leu Leu Ala Asn Asn Ala 355 360 365
- Val Thr Asn Pro Pro Thr Asn Pro Pro Ala Gln Asp Ser His Pro Ala 370 375 380
- Val Ile Gly Ser Thr Thr Ala Gly Ser Val Thr Ile Ser Gly Pro Ile 385 390 395 400
- Phe Phe Glu Asp Leu Asp Asp Thr Ala Tyr Asp Arg Tyr Asp Trp Leu 405 410 415
- Gly Ser Asn Gln Lys Ile Asn Val Leu Lys Leu Gln Leu Gly Thr Lys

420 425 430

Pro Pro Ala Asn Ala Pro Ser Asp Leu Thr Leu Gly Asn Glu Met Pro
435 440 445

Lys Tyr Gly Tyr Gln Gly Ser Trp Lys Leu 450 455

<210> 37

<211> 325

<212> PRT

<213> Chlamydia

<400> 37

Leu Lys Ala Thr Trp Thr Lys Thr Gly Tyr Asn Pro Gly Pro Glu Arg

1 5 10 15

Val Ala Ser Leu Val Pro Asn Ser Leu Trp Gly Ser Ile Leu Asp Ile 20 25 30

Arg Ser Ala His Ser Ala Ile Gln Ala Ser Val Asp Gly Arg Ser Tyr 35 40 45

Cys Arg Gly Leu Trp Val Ser Gly Val Ser Asn Phe Phe Tyr His Asp 50 55 60

Arg Asp Ala Leu Gly Gln Gly Tyr Arg Tyr Ile Ser Gly Gly Tyr Ser 65 70 75 80

Leu Gly Ala Asn Ser Tyr Phe Gly Ser Ser Met Phe Gly Leu Ala Phe 85 90 95

Thr Glu Val Phe Gly Arg Ser Lys Asp Tyr Val Val Cys Arg Ser Asn 100 105 110

His His Ala Cys Ile Gly Ser Val Tyr Leu Ser Thr Gln Gln Ala Leu 115 120 125

Cys Gly Ser Tyr Leu Phe Gly Asp Ala Phe Ile Arg Ala Ser Tyr Gly
130 135 140

Phe Gly Asn Gln His Met Lys Thr Ser Tyr Thr Phe Ala Glu Glu Ser 145 150 155 160

Asp Val Arg Trp Asp Asn Asn Cys Leu Ala Gly Glu Ile Gly Ala Gly 165 170 175 PCT/US98/20737

WO 99/17741 Leu Pro Ile Val Ile Thr Pro Ser Lys Leu Tyr Leu Asn Glu Leu Arg 185 180 Pro Phe Val Gln Ala Glu Phe Ser Tyr Ala Asp His Glu Ser Phe Thr 200 Glu Glu Gly Asp Gln Ala Arg Ala Phe Lys Ser Gly His Leu Leu Asn 215 Leu Ser Val Pro Val Gly Val Lys Phe Asp Arg Cys Ser Ser Thr His 235 230 Pro Asn Lys Tyr Ser Phe Met Ala Ala Tyr Ile Cys Asp Ala Tyr Arg 250 245 Thr Ile Ser Gly Thr Glu Thr Thr Leu Leu Ser His Gln Glu Thr Trp 270 265 260 Thr Thr Asp Ala Phe His Leu Ala Arg His Gly Val Val Arg Gly 285 280 275 Ser Met Tyr Ala Ser Leu Thr Ser Asn Ile Glu Val Tyr Gly His Gly 300 295 290 Arg Tyr Glu Tyr Arg Asp Ala Ser Arg Gly Tyr Gly Leu Ser Ala Gly 320 315 310 Ser Arg Val Arg Phe 325 <210> 38 <211> 41 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: primer <400> 38 41 gggtttggga atcagcacat gaaaacctca tatacatttg c <210> 39 <211> 41 <212> DNA

<220>

<213> Artificial Sequence

PCT/US98/20737 WO 99/17741

<223> Description of Artificial Sequence: primer

<400> 39

gcaaatgtat atgaggtttt catgtgctga ttcccaaacc c 41

<210> 40

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 40

aagggcccaa ttacgcagac atatggaaac gtctttccat aagttctttc tttca 55

<210> 41

<211> 80

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

aagggcccaa ttacgcagag tctagattat taatgatgat gatgatgatg gaaccggact 60 ctacttcctg cactcaaacc 80

- 32 -

International application No. PCT/US98/20737

A. CLASS	SIFICATION OF SUBJECT MATTER			
IPC(6) :P	lease See Extra Sheet.			
US CL :P	lease See Extra Sheet. International Patent Classification (IPC) or to both natio	nal classification	and IPC	
p FIELD	S SEARCHED			
Minimum do	cumentation searched (classification system followed by	classification syr	nbols)	
U.S. : P	case See Extra Sheet.			
D -4-6	on searched other than minimum documentation to the ext	ent that such docu	ments are included i	n the fields searched
Documentation	, , , , , , , , , , , , , , , , , , ,			
		of data have and	where practicable,	search terms used)
Electronic da	ata base consulted during the international search (name	OTECHDS, CON	FSCI, LIFESCI	
APS, MEI	DLINE, SCISEARCH, EMBASE, BIOSIS, CAPLUS, BIO	0120122,	,	
c. Doc	UMENTS CONSIDERED TO BE RELEVANT			Relevant to claim No.
Category*	Citation of document, with indication, where appro	priate, of the rele	vant passages	Relevant to claim No.
V	US 4,427,782 A (CALDWELL et al.) 2	4 January 19	84, column 3,	1-6, 16-17, 19-24,
X	line 13 to column 7, line 68.			26-39
		D how 10	001 column 4	1-24, 26-41
X	US 5,071,962 A (MORRISON et al.) 10	December 13	791, Column 4,	12.,20
1	line 10 to column 8, line 51.			
x	US 5,516,638 A (URNOVITZ et al.) 14	May 1996,	column 2, line	23-24, 26-30, 32-
\^	6 to column 6, line 24.			34
	US 5,725,863 A (DANIELS et al.) 10 1	March 1998.	column 3, line	1-6, 16-17, 19 -
X,P	US 5,725,863 A (DANIELS et al.) 10 1 65 to column 4, line 47.	viaicii 1990,	,	24, 26-39
	65 to column 4, mic 47.			
	_			
	İ			
			1	
Fur	ther documents are listed in the continuation of Box C.		eatent family annex.	
<u> </u>	Special categories of cited documents:		and in conflict with the s	international filing date or priority pplication but cited to understand
-A-	document defining the general state of the art which is not considered to be of particular relevance	the princi	iple or theory underlying	the claimed invention cannot be
•B•	earlier document published on or after the international filing date	considere	d novel or cannot be come document is taken alone	IGGLGG TO MADIA & TO BLACKER A SOLL
1	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other			the claimed invention cannot be live step when the document is
1	special reason (es specified) document referring to an oral disclosure, use, exhibition or other		ed to involve an inven- d with one or more other wious to a person skilled	ETCD COCKED STATE ACTE ACTE ATTACK
	document published prior to the international filing date but later than		nt member of the same p	
•P•	the priority date claimed		of the international	
Date of t	he actual completion of the international search		AR 1999	
01 MA	RCH 1999	& I III		
Name an	d mailing address of the ISA/US	Authorized offi	Lunea	a Fer
Box PC		STEPHEN	OUCKER	Her
	gton, D.C. 20231 c No. (703) 305-3230	Telephone No.	(703) 308-0196	

International application No. PCT/US98/20737

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.:  because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. X Claims Nos.: 25 because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
Please See Extra Sheet.
1. X As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

International application No. PCT/US98/20737

A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

A61K 9/14, 9/48, 9/127, 38/16, 39/00, 39/02, 39/118, 39/395, 39/40; CO7H 21/04; CO7K 14/00, 14/195, 14/295, 16/00, 16/12; C12N 5/00, 15/63; C12Q 1/68; GO1N 33/53, 33/561, 33/571

A. CLASSIFICATION OF SUBJECT MATTER:

US CL:

424/139.1, 164.1, 184.1, 185.1, 190.1, 263.1, 450, 451, 489; 435/6, 7.36, 320.1, 325, 975; 436/513; 514/2, 12, 824, 931, 962; 530/300, 350, 387.1, 389.1, 389.5; 536/23.7

B. FIELDS SEARCHED
Minimum documentation searched
Classification System: U.S.

424/139.1, 164.1, 184.1, 185.1, 190.1, 263.1, 450, 451, 489; 435/6, 7.36, 320.1, 325, 975; 436/513; 514/2, 12, 824, 931, 962; 530/300, 350, 387.1, 389.1, 389.5; 536/23.7

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-6, 16-17, 19-20, 25, 30-31, and 35-39, drawn to protein or protein compositions.

Group II, claims 7-15 and 18, drawn to nucleic acid, vectors, and host cells.

Group III, claims 21-22, drawn to a method of producing an immune response.

Group IV, claims 23-24, drawn to antisera and antibodies.

Group V, claims 26-27, drawn to methods of detecting antibodies and a kit.

Group VI, claims 28-29, drawn to methods of detecting Chlamydia and a kit.

Group VII, claims 32-34, drawn to methods of treatment.

Group VIII, claims 40-41, drawn to methods of detecting nucleic acid and a kit.

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking Groups I-VIII appears to be that they all relate to a Chlamydia protein, fragment, or analogue thereof. However, Caldwell et al. (US 4,427,782, 1984) teach isolation of principal outer membrane protein and antigen of Chlamydia which appears to be encompassed by the scope of claim 1 ("fragment or analogue thereof"). Therefore, the technical feature linking the inventions of Groups I-VIII does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

The special technical feature of Group I is considered to be a HMW protein from Chlamydia.

The special technical feature of Group II is considered to be a nucleic acid encoding a HMW protein from Chlamydia.

The special technical feature of Group III is considered to be a method of producing an immune response against a HMW protein from Chlamydia.

The special technical feature of Group IV is considered to be antibodies against a HMW protein from Chlamydia.

The special technical feature of Group V is considered to be methods of detecting antibodies against a HMW protein

International application No. PCT/US98/20737

	_
from Chlamydia.	
The special technical feature of Group VI is considered to be methods of detecting Chlamydia by detecting a HMW protein from Chlamydia.	
The special technical feature of Group VII is considered to be methods of treating Chlamydia infection by using a HMW protein from Chlamydia.	
. The special technical feature of Group VIII is considered to be methods of detecting Chlamydia by detecting a nucleic acid encoding a HMW protein from Chlamydia.	
Accordingly, Groups I-VIII are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept.	
•	
·	

THIS PAGE BLANK (USPTO)

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

# **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

D	efects in the images include but are not limited to the items checked:
	☐ BLACK BORDERS
	☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
	☐ FADED TEXT OR DRAWING
	☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
	☐ SKEWED/SLANTED IMAGES
	☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
	☐ GRAY SCALE DOCUMENTS
	☐ LINES OR MARKS ON ORIGINAL DOCUMENT
	REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
	_

# IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)